Quotient (QTNTQ) 10-K/A 15 Nov 21 2021 FY Annual report (amended) Financial data

Document and Entity Information

Document and Entity Information - USD ($) $ in Millions	12 Months Ended
	Mar. 31, 2021	May 28, 2021	Sep. 30, 2020
Cover [Abstract]
Document Type	10-K/A
Amendment Flag	true
Amendment Description	Quotient Limited. (the “Company”) is filing this Amendment No. 1 to its Annual Report on Form 10-K/A for the fiscal year ended March 31, 2021 (this “Amendment No. 1”), as originally filed with the U.S. Securities and Exchange Commission (the “SEC”) on June 3, 2021 (the “Original Form 10-K” or the “Original Filing”) to amend and restate the Company’s Annual Report on Form 10-K, as further described below. This amended and restated report on Form 10-K/A is presented as of the filing date of the Original Form 10-K and does not reflect events occurring after that date, or modify or update disclosures in any way other than as required to reflect the restatement described below. Accordingly, this Amendment No. 1 on Form 10-K/A should be read in conjunction with our filings with the SEC subsequent to the date on which we filed the Original Form 10-K.   The Company is filing this Amendment No. 1 on Form 10-K/A to reflect restatements to the Company’s audited consolidated financial statements as of and for the fiscal year ended March 31, 2021, 2020, and 2019 and relevant unaudited condensed consolidated financial information for the fiscal year 2021 quarterly periods to correct errors in the Company’s accounting for its 12% Senior Secured Notes due 2024 (“Secured Notes“) and related royalty rights agreements. Subsequent to the issuance of the Original Form 10-K, management of the Company determined that it did not identify the correct accounting treatment at the time of entering into these transactions, and accounted for these instruments on a combined basis instead of treating these as separate freestanding financial instruments. This non-cash error resulted in an understatement of interest expense and total liabilities associated with these instruments. This Amendment No. 1 on Form 10-K/A sets forth the Original Form 10-K in its entirety, as amended to reflect the restatement. Among other things, forward-looking statements made in the Original Form 10-K have not been revised to reflect events that occurred or facts that became known to the Company after the filing of the Original Form 10-K, and such forward-looking statements should be read in their historical context.   For reasons discussed above, we are filing this Amendment in order to amend the following items in our Original Filing to the extent necessary to reflect the adjustments discussed above and make corresponding revisions to our financial data cited elsewhere in this Amendment. The following items have been amended as a result of the restatement:   • Item 1A of Part I, “Risk Factors”,   • Item 7 of Part II, “Management’s Discussion and Analysis of Financial Condition and Results of Operations”   • Item 8 of Part II, “Financial Statements and Supplementary Data”,   • Item 9A of Part II, “Controls and procedures”; and   • Item 15 of Part IV, “Exhibits and Financial Statement Schedules.” However, for the convenience of the reader, this Amendment sets forth the Original Filing in its entirety, as amended to reflect the restatement. In accordance with applicable SEC rules, this Amendment No. 1 on Form 10-K/A includes an updated signature page, certifications of our Chief Executive Officer and Chief Financial Officer in Exhibits 31.1, 31.2 and 32.1 as required by Rule 12b-15, and a Consent of Independent Registered Public Accounting Firm as Exhibit 23.1. The Company is also filing an amended Quarterly Report on Form 10-Q/A for the quarterly period ended June 30, 2021 to restate the previously issued interim condensed consolidated financial statements due to the accounting matter described above. In connection with the restatement, the Company has also corrected certain errors that the Company previously determined to be immaterial. Refer to Note 2, Restatement of Previously Reported Consolidated Financial Statements, of Notes to Consolidated Financial Statements of this Form 10-K/A for additional information and for the summary of the accounting impacts of these adjustments to the Company’s consolidated financial statements. As a result of the restatement, the Company has concluded its disclosure controls and procedures and internal control over financial reporting were not effective as of March 31, 2021 due to a material weakness in the Company's internal control over financial reporting as of March 31, 2021. See additional discussion included in Part II, Item 9A of this Amended Annual Report.
Document Period End Date	Mar. 31, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	FY
Trading Symbol	QTNT
Title of 12(b) Security	Ordinary Shares, nil par value
Security Exchange Name	NASDAQ
Entity Registrant Name	QUOTIENT LIMITED
Entity Central Index Key	0001596946
Current Fiscal Year End Date	--03-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Public Float			$ 391.1
Entity Common Stock, Shares Outstanding		101,527,304
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Shell Company	false
Document Annual Report	true
Document Transition Report	false
Entity File Number	001-36415
Entity Tax Identification Number	00-0000000
Entity Incorporation, State or Country Code	Y9
Entity Address, Address Line One	B1, Business Park Terre Bonne
Entity Address, Address Line Two	Route de Crassier 13
Entity Address, City or Town	Eysins
Entity Address, Country	CH
Entity Address, Postal Zip Code	1262
City Area Code	011-41
Local Phone Number	22-716-9800
ICFR Auditor Attestation Flag	false
Documents Incorporated by Reference	DOCUMENTS INCORPORATED BY REFERENCE Portions of the registrant’s definitive proxy statement for the 2021 annual meeting of shareholders are incorporated by reference into Part III of this Report.

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2018
Current assets:
Cash and cash equivalents	$ 45,673	$ 3,401	$ 18,125	$ 7,325	$ 3,923	$ 4,096
Short-term investments	65,999	131,062	144,618	87,152	116,871
Trade accounts receivable, net	5,323	4,539	4,518	5,972	5,402
Inventories	22,011	23,709	22,798	21,291	20,501
Prepaid expenses and other current assets	4,870	4,928	5,851	4,091	3,775
Total current assets	143,876	167,639	195,910	125,831	150,472
Restricted cash	9,024	9,046	9,031	9,021	9,017	7,507
Property and equipment, net	39,071	41,299	40,182	39,563	40,440
Operating lease right-of-use assets	22,011	22,364	21,557	21,124	21,493
Intangible assets, net	619	632	614	606	625
Deferred income taxes	255	741	573	405	237
Other non-current assets	4,956	4,914	4,634	4,438	4,454
Total assets	219,812	246,635	272,501	200,988	226,738
Current liabilities:
Accounts payable	4,659	5,860	5,138	5,621	4,826
Accrued compensation and benefits	12,343	4,844	5,191	5,190	7,210
Accrued expenses and other current liabilities	14,009	11,351	17,410	13,317	15,490
Current portion of long-term debt	24,167	24,167	12,083	12,083
Current portion of operating lease liability	3,446	3,309	3,138	3,045	3,033
Current portion of finance lease obligation	835	878	577	573	598
Total current liabilities	59,459	50,409	43,537	39,829	31,157
Long-term debt, less current portion	145,059	141,822	149,007	147,260	156,261
Operating lease liability, less current portion	20,907	21,203	20,282	19,695	19,914
Finance lease obligation, less current portion	445	582	921	1,017	1,117
Deferred income taxes	1,152	1,455
Defined benefit pension plan obligation	6,896	7,707	7,169	6,623	6,353
7% Cumulative redeemable preference shares	21,475	21,213	20,950	20,688	20,425
Total liabilities	255,393	244,391	241,866	235,112	235,227
Commitments and contingencies
Shareholders' equity (deficit):
Ordinary shares (nil par value) 101,264,412 and 80,398,326 issued and outstanding at March 31, 2021 and March 31, 2020 respectively	540,813	540,819	540,769	459,990	459,931
Additional paid in capital	38,116	36,630	35,416	34,092	33,132
Accumulated other comprehensive loss	(14,598)	(14,634)	(16,659)	(13,070)	(12,672)
Accumulated deficit	(599,912)	(560,571)	(528,891)	(515,136)	(488,880)
Total shareholders' equity (deficit)	(35,581)	2,244	30,635	(34,124)	(8,489)	$ 709	$ (15,185)
Total liabilities and shareholders' equity (deficit)	$ 219,812	$ 246,635	$ 272,501	$ 200,988	$ 226,738

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	3 Months Ended	6 Months Ended	9 Months Ended	12 Months Ended
	Jun. 30, 2020	Sep. 30, 2020	Dec. 31, 2020	Mar. 31, 2021	Mar. 31, 2020
Statement Of Financial Position [Abstract]
Preference share dividend percentage	7.00%	7.00%	7.00%	7.00%	7.00%
Common stock, par value
Common stock, shares issued	80,593,440	100,965,451	101,075,845	101,264,412	80,398,326
Common stock, shares outstanding	80,593,440	100,965,451	101,075,845	101,264,412	80,398,326

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended			6 Months Ended	9 Months Ended	12 Months Ended
	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Sep. 30, 2020	Dec. 31, 2020	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Revenue:
Total revenue	$ 8,751	$ 16,066	$ 8,924	$ 24,990	$ 33,741	$ 43,379	$ 32,656	$ 29,134
Cost of revenue	(4,970)	(4,499)	(5,414)	(9,913)	(14,883)	(20,074)	(17,800)	(17,230)
Gross profit	3,781	11,567	3,510	15,077	18,858	23,305	14,856	11,904
Operating expenses:
Sales and marketing	(2,283)	(2,231)	(2,243)	(4,474)	(6,757)	(9,849)	(9,853)	(8,637)
Research and development, net of government grants	(14,350)	(12,743)	(11,415)	(24,158)	(38,508)	(53,727)	(53,438)	(50,883)
General and administrative expense:
Compensation expense in respect of share options and management equity incentives	(1,214)	(1,324)	(960)	(2,284)	(3,498)	(4,984)	(4,467)	(4,957)
Other general and administrative expenses	(7,524)	(8,232)	(8,578)	(16,810)	(24,334)	(37,442)	(27,483)	(26,588)
Total general and administrative expense	(8,738)	(9,556)	(9,538)	(19,094)	(27,832)	(42,426)	(31,950)	(31,545)
Total operating expense	(25,371)	(24,530)	(23,196)	(47,726)	(73,097)	(106,002)	(95,241)	(91,065)
Operating loss	(21,590)	(12,963)	(19,686)	(32,649)	(54,239)	(82,697)	(80,385)	(79,161)
Other income (expense):
Interest expense, net	(9,404)	(6,297)	(6,931)	(13,228)	(22,632)	(29,804)	(26,900)	(20,277)
Other, net	617	5,354	208	5,562	6,179	2,723	2,205	(6,943)
Other income (expense), net	(8,787)	(943)	(6,723)	(7,666)	(16,453)	(27,081)	(24,695)	(27,220)
Loss before income taxes	(30,377)	(13,906)	(26,409)	(40,315)	(70,692)	(109,778)	(105,080)	(106,381)
Provision for income taxes	(1,303)	151	153	304	(999)	(1,254)	(58)	(30)
Net loss	(31,680)	(13,755)	(26,256)	(40,011)	(71,691)	(111,032)	(105,138)	(106,411)
Other comprehensive income (loss):
Change in fair value of effective portion of foreign currency cash flow hedges	295	279	(3)	276	571	582	(157)	(123)
Unrealized gain (loss) on short-term investments	111	(79)	(404)	(483)	(372)	(898)	554	796
Foreign currency gain (loss)	1,606	(3,803)	171	(3,632)	(2,026)	(2,057)	(2,469)	2,538
Provision for pension benefit obligation	13	14	(162)	(148)	(135)	447	2,209	(887)
Other comprehensive loss, net	2,025	(3,589)	(398)	(3,987)	(1,962)	(1,926)	137	2,324
Comprehensive loss	(29,655)	(17,344)	(26,654)	(43,998)	(73,652)	(112,958)	(105,001)	(104,087)
Net loss available to ordinary shareholders - basic and diluted	$ (31,680)	$ (13,755)	$ (26,256)	$ (40,011)	$ (71,691)	$ (111,032)	$ (105,138)	$ (106,411)
Loss per share - basic and diluted	$ (0.31)	$ (0.16)	$ (0.33)	$ (0.49)	$ (0.81)	$ (1.21)	$ (1.47)	$ (1.94)
Weighted-average shares outstanding - basic and diluted	101,016,040	83,949,195	80,485,985	82,227,052	88,512,823	91,637,966	71,610,035	54,874,391
Product Sales [Member]
Revenue:
Total revenue	$ 8,740	$ 8,543	$ 8,924	$ 17,467	$ 26,207	$ 35,787	$ 31,601	$ 28,665
Other Revenues [Member]
Revenue:
Total revenue	$ 11	$ 7,523		$ 7,523	$ 7,534	$ 7,592	$ 1,055	$ 469

CONSOLIDATED STATEMENTS OF CHAN

CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (DEFICIT) - USD ($) $ in Thousands	Total	Cumulative Effect of Accounting Changes [Member]	Ordinary Shares [Member]	Additional paid in Capital [Member]	Accumulated Other Comprehensive Loss [Member]	Accumulated Deficit [Member]	Accumulated Deficit [Member]Cumulative Effect of Accounting Changes [Member]
Beginning balance at Mar. 31, 2018	$ (15,185)		$ 253,934	$ 23,708	$ (15,133)	$ (277,694)
Beginning balance, Shares at Mar. 31, 2018			45,646,424
Issue of shares, net of issue costs, Amount	113,724		$ 113,724
Issue of shares, net of issue costs, Shares			19,635,068
Issue of shares upon exercise of incentive share options and vesting of RSU's, Amount	1,300		$ 1,300
Issue of shares upon exercise of incentive share options and vesting of RSU's, Shares			618,955
Net loss	(106,411)					(106,411)
Change in the fair value of the effective portion of foreign currency cash flow hedges	(123)				(123)
Change in unrealized gain on short-term investments	796				796
Foreign currency gain (loss) on:
Long-term investment nature intra-entity balances	5,074				5,074
Retranslation of foreign entities	(2,536)				(2,536)
Provision for pension benefit obligation	(887)				(887)
Other comprehensive loss	2,324				2,324
Stock-based compensation	4,957			4,957
Ending balance at Mar. 31, 2019	709		$ 368,958	28,665	(12,809)	(384,105)
Ending balance, Shares at Mar. 31, 2019			65,900,447
Issue of shares, net of issue costs, Amount	90,528		$ 90,528
Issue of shares, net of issue costs, Shares			13,800,000
Issue of shares upon exercise of incentive share options and vesting of RSU's, Amount	445		$ 445
Issue of shares upon exercise of incentive share options and vesting of RSU's, Shares			697,879
Net loss	(105,138)					(105,138)
Change in the fair value of the effective portion of foreign currency cash flow hedges	(157)				(157)
Change in unrealized gain on short-term investments	554				554
Foreign currency gain (loss) on:
Long-term investment nature intra-entity balances	18,394				18,394
Retranslation of foreign entities	(20,863)				(20,863)
Provision for pension benefit obligation	2,209				2,209
Other comprehensive loss	137				137
Stock-based compensation	4,467			4,467
Ending balance at Mar. 31, 2020	$ (8,489)	$ 363	$ 459,931	33,132	(12,672)	(488,880)	$ 363
Ending balance, Shares at Mar. 31, 2020	80,398,326		80,398,326
Issue of shares upon exercise of incentive share options and vesting of RSU's, Amount	$ 59		$ 59
Issue of shares upon exercise of incentive share options and vesting of RSU's, Shares			195,114
Net loss	(26,256)					(26,256)
Change in the fair value of the effective portion of foreign currency cash flow hedges	(3)				(3)
Change in unrealized gain on short-term investments	(404)				(404)
Foreign currency gain (loss) on:
Long-term investment nature intra-entity balances	4,685				4,685
Retranslation of foreign entities	(4,514)				(4,514)
Provision for pension benefit obligation	(162)				(162)
Other comprehensive loss	(398)				(398)
Stock-based compensation	960			960
Ending balance at Jun. 30, 2020	$ (34,124)		$ 459,990	34,092	(13,070)	(515,136)
Ending balance, Shares at Jun. 30, 2020	80,593,440		80,593,440
Beginning balance at Mar. 31, 2020	$ (8,489)	363	$ 459,931	33,132	(12,672)	(488,880)	363
Beginning balance, Shares at Mar. 31, 2020	80,398,326		80,398,326
Issue of shares, net of issue costs, Amount	$ 80,685		$ 80,685
Issue of shares, net of issue costs, Shares			20,294,117
Issue of shares upon exercise of incentive share options and vesting of RSU's, Amount	153		$ 153
Issue of shares upon exercise of incentive share options and vesting of RSU's, Shares			273,008
Net loss	(40,011)					(40,011)
Change in the fair value of the effective portion of foreign currency cash flow hedges	276				276
Change in unrealized gain on short-term investments	(483)				(483)
Foreign currency gain (loss) on:
Long-term investment nature intra-entity balances	844				844
Retranslation of foreign entities	(4,476)				(4,476)
Provision for pension benefit obligation	(148)				(148)
Other comprehensive loss	(3,987)				(3,987)
Stock-based compensation	2,284			2,284
Ending balance at Sep. 30, 2020	$ 30,635		$ 540,769	35,416	(16,659)	(528,891)
Ending balance, Shares at Sep. 30, 2020	100,965,451		100,965,451
Beginning balance at Mar. 31, 2020	$ (8,489)	363	$ 459,931	33,132	(12,672)	(488,880)	363
Beginning balance, Shares at Mar. 31, 2020	80,398,326		80,398,326
Issue of shares, net of issue costs, Amount	$ 80,685		$ 80,685
Issue of shares, net of issue costs, Shares			20,294,117
Issue of shares upon exercise of incentive share options and vesting of RSU's, Amount	203		$ 203
Issue of shares upon exercise of incentive share options and vesting of RSU's, Shares			383,402
Net loss	(71,691)					(71,691)
Change in the fair value of the effective portion of foreign currency cash flow hedges	571				571
Change in unrealized gain on short-term investments	(372)				(372)
Foreign currency gain (loss) on:
Long-term investment nature intra-entity balances	(3,848)				(3,848)
Retranslation of foreign entities	1,822				1,822
Provision for pension benefit obligation	(135)				(135)
Other comprehensive loss	(1,962)				(1,962)
Stock-based compensation	3,498			3,498
Ending balance at Dec. 31, 2020	$ 2,244		$ 540,819	36,630	(14,634)	(560,571)
Ending balance, Shares at Dec. 31, 2020	101,075,845		101,075,845
Beginning balance at Mar. 31, 2020	$ (8,489)	$ 363	$ 459,931	33,132	(12,672)	(488,880)	$ 363
Beginning balance, Shares at Mar. 31, 2020	80,398,326		80,398,326
Issue of shares, net of issue costs, Amount	$ 80,685		$ 80,685
Issue of shares, net of issue costs, Shares			20,294,117
Issue of shares upon exercise of incentive share options and vesting of RSU's, Amount	197		$ 197
Issue of shares upon exercise of incentive share options and vesting of RSU's, Shares			571,969
Net loss	(111,032)					(111,032)
Change in the fair value of the effective portion of foreign currency cash flow hedges	582				582
Change in unrealized gain on short-term investments	(898)				(898)
Foreign currency gain (loss) on:
Long-term investment nature intra-entity balances	(27,251)				(27,251)
Retranslation of foreign entities	25,194				25,194
Provision for pension benefit obligation	447				447
Other comprehensive loss	(1,926)				(1,926)
Stock-based compensation	4,984			4,984
Ending balance at Mar. 31, 2021	$ (35,581)		$ 540,813	38,116	(14,598)	(599,912)
Ending balance, Shares at Mar. 31, 2021	101,264,412		101,264,412
Beginning balance at Jun. 30, 2020	$ (34,124)		$ 459,990	34,092	(13,070)	(515,136)
Beginning balance, Shares at Jun. 30, 2020	80,593,440		80,593,440
Issue of shares, net of issue costs, Amount	$ 80,685		$ 80,685
Issue of shares, net of issue costs, Shares			20,294,117
Issue of shares upon exercise of incentive share options and vesting of RSU's, Amount	94		$ 94
Issue of shares upon exercise of incentive share options and vesting of RSU's, Shares			77,894
Net loss	(13,755)					(13,755)
Change in the fair value of the effective portion of foreign currency cash flow hedges	279				279
Change in unrealized gain on short-term investments	(79)				(79)
Foreign currency gain (loss) on:
Long-term investment nature intra-entity balances	(3,841)				(3,841)
Retranslation of foreign entities	38				38
Provision for pension benefit obligation	14				14
Other comprehensive loss	(3,589)				(3,589)
Stock-based compensation	1,324			1,324
Ending balance at Sep. 30, 2020	$ 30,635		$ 540,769	35,416	(16,659)	(528,891)
Ending balance, Shares at Sep. 30, 2020	100,965,451		100,965,451
Issue of shares upon exercise of incentive share options and vesting of RSU's, Amount	$ 50		$ 50
Issue of shares upon exercise of incentive share options and vesting of RSU's, Shares			110,394
Net loss	(31,680)					(31,680)
Change in the fair value of the effective portion of foreign currency cash flow hedges	295				295
Change in unrealized gain on short-term investments	111				111
Foreign currency gain (loss) on:
Long-term investment nature intra-entity balances	(4,692)				(4,692)
Retranslation of foreign entities	6,298				6,298
Provision for pension benefit obligation	13				13
Other comprehensive loss	2,025				2,025
Stock-based compensation	1,214			1,214
Ending balance at Dec. 31, 2020	$ 2,244		$ 540,819	$ 36,630	$ (14,634)	$ (560,571)
Ending balance, Shares at Dec. 31, 2020	101,075,845		101,075,845

CONSOLIDATED STATEMENTS OF CH_2

CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (DEFICIT) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended	9 Months Ended	12 Months Ended
	Sep. 30, 2020	Sep. 30, 2020	Dec. 31, 2020	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Statement Of Stockholders Equity [Abstract]
Issue of shares, issue costs	$ 5,565	$ 5,565	$ 5,565	$ 5,565	$ 6,072	$ 4,052

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS $ in Thousands	12 Months Ended
	Mar. 31, 2021USD ($)	Mar. 31, 2020USD ($)	Mar. 31, 2019USD ($)
OPERATING ACTIVITIES:
Net loss	$ (111,032)	$ (105,138)	$ (106,411)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation, amortization and loss on disposal of fixed assets	8,354	12,001	12,767
Share-based compensation	4,984	4,467	4,957
Increase in deferred lease rentals	726	293	372
Swiss pension obligation	1,054	756	575
Amortization of deferred debt issue costs	12,965	10,084	6,167
Impairment of short term investments	2,285
Accrued preference share dividends	1,050	1,050	1,050
Income taxes	1,254	(169)	(61)
Net change in assets and liabilities:
Trade accounts receivable, net	568	(2,177)	(637)
Inventories	(475)	(5,173)	113
Accounts payable and accrued liabilities	(3,410)	2,798	1,035
Accrued compensation and benefits	4,549	1,218	1,121
Other assets	(454)	(656)	3,297
Net cash used in operating activities	(77,582)	(80,646)	(75,655)
INVESTING ACTIVITIES:
Increase in short-term investments	(87,247)	(95,000)	(119,000)
Realization of short-term investments	134,936	69,412	34,735
Purchase of property and equipment	(4,240)	(4,598)	(4,791)
Purchase of intangible assets		(2)	(3)
Net cash from (used in) investing activities	43,449	(30,188)	(89,059)
FINANCING ACTIVITIES:
Repayment of finance leases	(633)	(524)	(486)
Proceeds from drawdown of new debt		25,000	36,000
Debt issue costs		(874)	(1,216)
Fee paid to noteholders			(3,900)
Proceeds from issuance of ordinary shares and warrants	80,881	90,973	115,024
Net cash generated from financing activities	80,248	114,575	145,422
Effect of exchange rate fluctuations on cash and cash equivalents	(4,358)	(2,404)	5,690
Change in cash and cash equivalents	41,757	1,337	(13,602)
Beginning cash and cash equivalents	12,940	11,603	25,205
Ending cash and cash equivalents	54,697	12,940	11,603
Supplemental cash flow disclosures:
Interest paid	17,529	15,776	11,838
Reconciliation of cash, cash equivalents and restricted cash:
Cash and cash equivalents	45,673	3,923	4,096
Restricted cash	9,024	9,017	7,507
Ending cash and cash equivalents	$ 54,697	$ 12,940	$ 11,603

Organization and Summary of Sig

Organization and Summary of Significant Accounting Policies	12 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Organization and Summary of Significant Accounting Policies	Note 1. Organization and Summary of Significant Accounting Policies Organization and Business The principal activity of Quotient Limited and its subsidiaries (the “Group” and or the “Company”) is the development, manufacture and sale of products for the global transfusion diagnostics market. Products manufactured by the Group are sold to hospitals, blood banking operations and other diagnostics companies worldwide. The Company has incurred net losses and negative cash flows from operations in each year since it commenced operations in 2007 and had an accumulated deficit of $599.9 million at March 31, 2021. At March 31, 2021, the Company had available cash holdings and short-term investments of $111.7 million. These holdings include $53.2 million of investments held in two short-term investment funds with CSAM that are currently in the process of being liquidated. The remaining short-term investments to be liquidated are subject to significant valuation uncertainty. The Company has recognized an impairment of $2.3 million related to one of the funds invested with CSAM during March of 2021. During April of 2021, payments from these funds of $18.5 million were received. While the timing and amount of further payments are not clear at present (see Note 5), the Company believes that it will receive the remaining distributions over the year. On May 26, 2021, the Company completed a private offering of $95 million aggregate principal amount of new 4.75% Convertible Notes due 2026 to certain investors. The additional net cash generated from the Convertible Notes issuance combined with t Thereafter, the Company expects to fund its operations in the near-term, including the ongoing development of MosaiQ through successful field trial completion, achievement of required regulatory authorizations and commercialization from a combination of funding sources. These expected funding sources include the use of existing available cash and short-term investment balances, the sale of rights and other assets, and the issuance of new equity and debt. Summary of Significant Accounting Policies Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries after elimination of intercompany transactions and balances. All gains and losses realized from foreign currency transactions denominated in currencies other than the foreign subsidiary’s functional currency are included in foreign currency exchange gain (loss) as part of other income or expenses in the Consolidated Statements of Comprehensive Loss. Adjustments resulting from translating the financial statements of all foreign subsidiaries into U.S. dollars are reported as a separate component of accumulated other comprehensive loss and changes in shareholders’ equity (deficit). The assets and liabilities of the Company’s foreign subsidiaries are translated from their respective functional currencies into U.S. dollars at the rates in effect at the balance sheet date, and revenue and expense amounts are translated at rates approximating the weighted average rates during the period. The translation effects of inter-company loans designated as long term net investments in subsidiaries are included in accumulated other comprehensive loss. Use of Estimates The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from these estimates. On March 11, 2020, the World Health Organization declared the outbreak of a strain of novel coronavirus disease, COVID-19, a global pandemic. The extent to which the COVID-19 pandemic will impact the Company’s business, operations and financial results will depend on future developments and numerous evolving factors, which are highly uncertain and difficult to predict. Fair Value of Financial Instruments The Company defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company’s valuation techniques used to measure fair value maximized the use of observable inputs and minimized the use of unobservable inputs. The fair value hierarchy is based on the following three levels of inputs: Level 1—Quoted prices in active markets for identical assets or liabilities. Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. See Note 5, “Fair Value Measurements,” for information and related disclosures regarding our fair value measurements. Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. As of March 31, 2021 and 2020, all cash and cash equivalents comprised cash balances and highly liquid investments having an original maturity of three months or less held with the banks used by the Company and its subsidiaries. Restricted cash comprised $8.7 million at both March 31, 2021 and March 31, 2020 , held in a cash reserve account pursuant to the indenture governing the Company’s 12% Senior Secured Notes (the “Secured Notes”) and $324 and $317, respectively, held in a restricted account as security for the property rental obligations of the Company’s Swiss subsidiary. Short-term Investments Short-term investments comprise investments in money-market funds which are valued daily and have minimal notice periods for withdrawals. The money market funds are invested in a portfolio of holdings and the creditworthiness requirement for individual investment holdings is a minimum of an A rating from a leading credit-rating agency. The Company records the value of its investments in the funds based on the quoted value of the funds at the balance sheet date (Note 5) . Unrealized gains or losses are recorded in accumulated other comprehensive loss and are transferred to the statement of comprehensive loss when they are realized. Trade Accounts Receivable Trade accounts receivable are recorded at the invoiced amount and are not interest bearing. The Company maintains an allowance for doubtful accounts to reserve for potentially uncollectible trade receivables. Movements in the allowance for doubtful accounts are recorded as general and administrative expenses. The Company reviews its trade receivables to identify specific customers with known disputes or collectability issues. In addition, the Company maintains an allowance for all other receivables not included in the specific reserve by applying specific rates of projected uncollectible receivables to the various aging categories. In determining these percentages, the Company analyzes its historical collection experience, customer credit-worthiness, current economic trends and changes in customer payment terms. The allowance for doubtful accounts at March 31, 2021 and 2020 was $48 and $111, respectively. Concentration of Credit Risks and Other Uncertainties The carrying amounts for financial instruments consisting of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate fair value due to their short maturities. Derivative instruments, consisting of foreign exchange contracts and short-term investments are stated at their estimated fair values, based on quoted market prices for the same or similar instruments. The counterparties to the foreign exchange contracts consist of large financial institutions of high credit standing. The short-term investments are invested in funds which is invested in a portfolio of holdings and the creditworthiness requirement for individual investment holdings is a minimum of an A rating from a leading credit-rating agency. On March 12, 2021, the Company announced that two funds managed by CSAM in which the Company had invested an aggregate of approximately $110.35 million had suspended redemptions. The investments into these funds were made in accordance with the Company’s investment policy of making individual investments with a minimum of an A rating from a leading credit-rating agency. Each fund holds short-term credit obligations of various obligors. According to a press release issued by CSAM, redemptions in the funds were suspended because “certain part of the Subfunds’ assets is currently subject to considerable uncertainties with respect to their accurate valuation.” CSAM subsequently began a liquidation of the funds. Pursuant to the liquidation, the Company has already received cash distributions of approximately $75.6 million. Based on information provided by Credit Suisse, the Company expects to receive further cash distributions from the funds in the next several months; however, there can be no assurance as to the timing or amount of any such distributions. While Credit Suisse has advised that the credit assets held by the funds are covered by insurance that potentially will be available to cover losses the funds would incur if any of the obligors on the funds’ credit assets were to default, the Company does not know if the funds will incur losses (net of insurance) on the credit assets held by the funds. Additionally, on April 22, 2021, Credit Suisse published its FY 2021 Q1 press release with commentary related to the supply chain financing funds. Notably, Credit Suisse indicated that the investors in the funds should assume losses will be incurred. The Company evaluated the investments in the CSAM managed funds for impairment, in accordance with ASC 321-10-35, Investments – Equity Securities The Company views the liquidation of the supply chain finance funds as a fluid situation with a significant amount of valuation uncertainty. The Company will closely monitor the situation and in the event that new information is released that provides valuation clarity, it will evaluate the accounting implications accordingly. The Company believes, and has advised Credit Suisse, that any losses on the supply chain funds should be borne by Credit Suisse. The Company will pursue all available options to recoup the full amount of its investment in the supply chain funds prior to liquidation. The Company’s main financial institutions for banking operation held all of the Company’s cash and cash equivalents as of March 31, 2021 and March 31, 2020. The Company’s accounts receivable are derived from net revenue to customers and distributors located in the United States and other countries. The Company performs credit evaluations of its customers’ financial condition. The Company provides reserves for potential credit losses but has not experienced significant losses to date. There was one customer whose accounts receivable balance represented 10% or more of total accounts receivable, net, as of March 31, 2021 and March 31, 2020. This customer represented 74% and 70% of the accounts receivable balances, as of March 31, 2021 and March 31, 2020, respectively. The Company currently sells products through its direct sales force and through third-party distributors. There was one direct customer that accounted for 10% or more of total product sales for the fiscal years ended March 31, 2021, 2020 and 2019. This customer represented 60%, 61% and 60% of total product sales for the fiscal years March 31, 2021, 2020 and 2019, respectively. Inventory Inventory is stated at the lower of standard cost or market, net of reserves. Cost is determined at standard cost, approximating average cost. Allocation of fixed production overheads to conversion costs is based on normal capacity of production. Abnormal amounts of idle facility expense, freight, handling costs and spoilage are expensed as incurred and not included in overhead. Variances between standard cost and actual cost, arising in the production process, are analyzed to determine whether they reflect part of the normal cost of production, and should therefore be reflected as inventory value, or whether they are a period cost and should thus not be included in inventory. Inventory reserves are recorded based upon historic usage, expected future demand and shelf life of the products held in inventory. No stock-based compensation cost was included in inventory as of March 31, 2021 and 2020. Property and Equipment Property, equipment and leasehold improvements are stated at cost, net of accumulated depreciation and amortization. Depreciation and amortization are computed on a straight-line basis over the estimated useful lives of the related assets as follows: Land—not depreciated. Plant, machinery and equipment—4 to 25 years. Leasehold improvements—the shorter of the lease term or the estimated useful life of the asset. Repairs and maintenance expenditures, which are not considered improvements and do not extend the useful life of property and equipment, are expensed as incurred. Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by comparing the carrying amount of the assets to the future undiscounted cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. During the fiscal years ended March 31, 2021, 2020 and 2019, no impairment losses have been recorded. Intangible Assets Intangible assets related to product licenses are recorded at cost, less accumulated amortization. Intangible assets related to technology and other intangible assets acquired in acquisitions are recorded at fair value at the date of acquisition, less accumulated amortization. Intangible assets are amortized over their estimated useful lives, on a straight-line basis as follows: Customer relationships—5 years Brands associated with acquired cell lines—40 years Product licenses—10 years Other intangibles—7 years The Company reviews its intangible assets for impairment and conducts the impairment review when events or circumstances indicate the carrying value of a long-lived asset may be impaired by estimating the future undiscounted cash flows to be derived from an asset to assess whether or not a potential impairment exists. If the carrying value exceeds the Company’s estimate of future undiscounted cash flows, an impairment value is calculated as the excess of the carrying value of the asset over the Company’s estimate of its fair market value. Events or circumstances which could trigger an impairment review include a significant adverse change in the business climate, an adverse action or assessment by a regulator, unanticipated competition, significant changes in the Company’s use of acquired assets, the Company’s overall business strategy, or significant negative industry or economic trends. No impairment losses have been recorded in any of the years ended March 31, 2021, 2020 or 2019. Revenue Recognition Revenue is recognized in accordance with ASU 2014-09, Revenue from Contracts with Customers. Product revenue is recognized at a point in time upon transfer of control of a product to a customer, which is generally at the time of delivery at an amount based on the transaction price. Customers have no right of return except in the case of damaged or ineffective goods and the Company has not experienced any significant returns of its products. Shipping and handling costs are expensed as incurred and included in cost of product sales. Revenue is also earned from the provision of development services to a small number of original equipment manufacturer (“OEM”) customers. These development service contracts are reviewed individually to determine the nature of the performance obligations and the associated transaction prices. In recent years, product development revenues have been commensurate with achieving milestones specified in the respective development agreements relating to those products. These milestones may include the approval of new products by the European or U.S. regulatory authorities, which are not within the Company’s control. While there can be no assurance that this will continue to be the case, the milestones have been such that they effectively represent completion of the Company’s performance obligations under a particular part of a development program. Should the Company fail to achieve these milestones the Company would not be entitled under the terms of the development agreements to any compensation for the work undertaken to date. As a result, the milestone-related revenues have been recognized as the contractual milestones are achieved. Pursuant to an Umbrella Supply Agreement with Ortho-Clinical Diagnostics, Inc. (“Ortho”), the Company executed a product attachment relating to the development of a range of rare antisera products. During the year ended March 31, 2020, the Company recognized milestones totaling $1,050 related to the approval by the FDA of an application submitted during the year ended March 31, 2019, and a further FDA submission and approval related to the use of the products on another of Ortho’s automation platforms. There are no further milestone revenues due under this agreement. In January 2015, t he Company’s subsidiaries, Quotient Suisse and QBD (QS-IP) Limited, Ortho initiated an arbitration proceeding as result of the Company's termination of the Prior Ortho Agreement. See Note 7, "Commitments and Contingencies—Ortho Arbitration and Settlement," for details. On September 4, 2020, the Company and Ortho entered into a binding letter agreement (the “Letter Agreement”) pursuant to which the Company and Ortho agreed: • to confirm the termination of the Prior Ortho Agreement and various related contracts; • to end the parties’ disputes regarding the Prior Ortho Agreement by executing mutual releases and terminating their pending arbitration proceeding related to the Prior Ortho Agreement (see Note 7); and • to negotiate in good faith, and use their respective reasonable best efforts to execute, a new distribution agreement (the “New Distribution Agreement”) based on the terms set forth in the Letter Agreement, but if for any reason no such definitive agreement is reached, the Letter Agreement will govern the parties’ respective rights and obligations as a binding contract. Pursuant to the Letter Agreement, Ortho made an initial, non-refundable milestone payment of $7.5 million to the Company on the date of the Letter Agreement. In the Letter Agreement, the Company and Ortho have agreed that Ortho has the right to distribute, market and sell a dedicated MosaiQ microarray optimized for the patient transfusion diagnostics market (the “MosaiQ IH3 Microarray”) in the European Territory (defined as the European Economic Area plus the United Kingdom and Switzerland) and in the United States, solely for use in testing the immuno-hematological profile of the blood of medical patients in the course of their care or treatment. Ortho’s rights in the two territories each are for one ten-year In addition to the initial $7.5 million milestone payment, Ortho is required to make up to another $60 million of additional milestone payments upon achievement of certain regulatory milestones and commercial sales benchmarks, including up to $25 million upon the achievement by Ortho of certain cumulative gross revenue hurdles. The Company has concluded that the initial $7.5 million milestone represents a payment in respect of development work undertaken to date in respect of the MosaiQ IH3 Microarray and accordingly has recognized the revenue in the year ended March 31, 2021. The Company has also concluded that each of the remaining milestones under the Letter Agreement require significant levels of development work to be undertaken and there is no certainty at the start of the projects that the development work will be successful, these milestones are substantive and, accordingly, the revenue will be recognized when the milestones are achieved. In the year ended March 31, 2021, revenue recognized from performance obligations related to prior periods was not material. At March 31, 2021 revenues expected to be recognized in future periods related to remaining performance obligations under the Ortho Letter Agreement were as described above. There were no other material revenues to be recognized in future periods related to remaining performance obligations at March 31, 2021. Research and Development Research and development expenses consist of costs incurred for company-sponsored and collaborative research and development activities. These costs include direct and research-related overhead expenses. Other than materials assessed as having alternative future uses and which are recognized as prepaid expenses, the Company expenses research and development costs, including products manufactured for research and development purposes and the expenses for research under collaborative agreements, as such costs are incurred. Where government grants are available for the sponsorship of such research, the grant receipt is included as a credit against the related expense. Stock-Based Compensation Stock-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as an expense on a straight-line basis over the requisite service period, which is generally the vesting period. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in the Company’s Consolidated Statements of Comprehensive Loss. In determining fair value of the stock-based compensation payments, the Company uses the Black–Scholes model and a single option award approach for share options , which require s the input of subjective assumptions. These assumptions include: the fair value of the underlying share, estimating the length of time employees will retain their awards before exercising them (expected term), the estimated volatility of the Company’s ordinary share price over the expected term (expected volatility), risk-free interest rate (interest rate), expected dividends and the number of shares subject to awards that will ultimately not complete their vesting requirements (forfeitures). Where modifications are made to vesting conditions, the Company considers the nature of the change and accounts for the change in accordance with ASC 718 Compensation – Stock Compensation Share Warrants As of March 31, 2021, the Company had one class of warrants to purchase ordinary shares outstanding which comprised warrants that were issued in December 2013 and August 2015 in connection with the establishment and subsequent increase of the Company’s then existing secured term loan facility. None of these warrants contain any obligation to transfer value and, as such, the issuance of these warrants has been recorded in additional paid in capital as part of shareholders’ (deficit) equity. Leases At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. A lease is a contract, or part of a contract, that conveys the right to control the use of identified property, plant or equipment (an identified asset) for a period of time, in exchange for consideration. The Company determines if the contract conveys the right to control the use of an identified asset for a period of time. The Company assesses throughout the period of use whether the Company has both of the following: (1) the right to obtain substantially all of the economic benefits for use of the identified asset, and (2) the right to direct the use of the identified asset. This determination is reassessed if the terms of the contract are changed. The Company also reviews the terms of the lease in accordance with Accounting Standard Update, or ASU, 2016-02 in order to determine whether the lease concerned is a finance or an operating lease. Most leases with a term greater than one year are recognized on the balance sheet as right-of-use assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize on the balance sheet leases with terms of one year or less. For finance leases, an asset is included within property and equipment and a lease liability equal to the present value of the minimum lease payments is included in current or long-term liabilities. Interest expense is recorded over the life of the lease at a constant rate. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected remaining lease term. The operating lease right-of-use assets also include any lease payments made prior to the commencement date and any initial direct costs incurred, less any lease incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rates, which are the rates incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. The incremental borrowing rate is determined at lease commencement, or as of April 1, 2019 for operating leases existing upon adoption of ASU 2016-02. The incremental borrowing rate is subsequently reassessed upon modification to the lease arrangement. Operating lease expense is recognized on a straight-line basis over the lease term. In accordance with the guidance in ASU 2016-02, components of a lease should be split into three categories: lease components (e.g., land, building, etc.), non-lease components (e.g., common area maintenance, maintenance, consumables, etc.), and non-components (e.g., property taxes, insurance, etc.). Although separation of lease and non-lease components is required, certain practical expedients are available. In particular, entities may elect a practical expedient to not separate lease and non-lease components and instead account for each lease component and the related non-lease component together as a single component. The Company has elected to account for the lease and non-lease components of each of its operating leases as a single lease component and allocate all of the contract consideration to the lease component only. The lease component results in an operating lease right-of-use asset being recorded on the balance sheet and amortized on a straight-line basis as lease expense. The finance lease assets and operating lease right-of-use assets are assessed for impairment in accordance with the Company’s accounting policy for long-lived assets. Derivative Financial Instruments In the normal course of business, the Company’s financial position is routinely subjected to market risk associated with foreign currency exchange rate fluctuations. The Company’s policy is to mitigate the effect of these exchange rate fluctuations on certain foreign currency denominated business exposures. The Company has a policy that allows the use of derivative financial instruments to hedge foreign currency exchange rate fluctuations on forecasted revenue denominated in foreign currencies. The Company carries derivative financial instruments (derivatives) on the balance sheet at their fair values. The Company does not use derivatives for trading or speculative purposes. The Company does not believe that it is exposed to more than a nominal amount of credit risk in its foreign currency hedges, as counterparties are large, global and well-capitalized financial institutions. To hedge foreign currency risks, the Company uses foreign currency exchange forward contracts, where possible and prudent. These forward contracts are valued using standard valuation formulas with assumptions about future foreign currency exchange rates derived from existing exchange rates, interest rates, and other market factors. The Company considers its most current forecast in determining the level of foreign currency denominated revenue to hedge as cash flow hedges. The Company combines these forecasts with historical trends to establish the portion of its expected volume to be hedged. The revenue and expenses are hedged and designated as cash flow hedges to protect the Company from exposures to fluctuations in foreign currency exchange rates. If the underlying forecasted transaction does not occur, or it becomes probable that it will not occur, the related hedge gains and losses on the cash flow hedge are reclassified from accumulated other comprehensive loss to the consolidated statement of comprehensive loss at that time. Income Taxes The Company accounts for income taxes using an asset and liability approach, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements, but have not been reflected in taxable income. A valuation allowance is established to reduce deferred tax assets to their estimated realizable value. Therefore, the Company provides a valuation allowance to the extent that is more likely than not that it will generate sufficient taxable income in future periods to realize the benefit of its deferred tax assets. Deferred tax assets and liabilities are classified as noncurrent on the balance sheet. The Company accounts for uncertain tax positions using a “more-likely-than-not” threshold for recognizing and resolving uncertain tax positions. The Company evaluates uncertain tax positions on a quarterly basis and considers various factors, including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit and changes in facts or circumstances related to the tax position. Pension Obligation The Company maintains a pension plan covering employees in Switzerland pursuant to the requirements of Swiss pension law. Certain aspects of the plan require that it be accounted for as a defined benefit plan pursuant to ASC 715 Compensation – Retirement Benefits The Company uses an actuarial valuation to determine its pension benefit costs and credits. The amounts calculated depend on a variety of key assumptions, including discount rates and expected return on plan assets. Details of the assumptions used to determine the net funded status are set out in Note 12. The Company’s pension plan assets are assigned to their respective levels in the fair value hierarchy in accordance with the valuation principles described in the ‘‘Fair Value of Financial Instruments’’ section above. Termination and Transition Charges Termination charges are recognized as a result of actions to restructure operations. Transition charges are recognized as a result of the retirement of senior employees. Such charges are recognized upon meeting certain criteria, including the finalization of committed plans or agreements and discussions with the impacted employees. Loss Contingencies Loss contingencies from legal proceedings and claims may occur from contractual and other related matters. Accruals are recognized when it is probable that a liability will be incurred and the amount of the loss can be reasonably estimated. Gain contingencies are not recognized until realized. Legal fees are expensed as incurred. Debt Issuance Costs and Royalty Rights The Company follows the requirements of Accounting Standards Update 2015-03, Interest — Imputation of Interest (Subtopic 835-30) — Simplifying the Presentation of Debt Issuance Costs, which requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the debt liability rather than as an asset. On October 14, 2016, June 29, 2018 and May 15, 2019, the Company issued Secured Notes, and, on December 4, 2018, the Company amended the indenture governing the Secured Notes, which amendments became effective on D

Restatement of Previously Repor

Restatement of Previously Reported Consolidated Financial Statements	12 Months Ended
	Mar. 31, 2021
Prior Period Adjustment [Abstract]
Restatement of Previously Reported Consolidated Financial Statements	Note 2. Restatement of Previously Reported Consolidated Financial Statements Restatement In connection with the preparation of the Company’s unaudited consolidated financial statements for the fiscal quarter ended September 30, 2021 , management of the Company identified an error related to the accounting of the Senior Secured Notes and royalty rights agreements originating in October 2016, August 2018, and June 2019. Specifically, management of the Company determined that it did not identify the correct accounting treatment at the time of entering into these transactions, and accounted for these instruments on a combined basis instead of treating these as separate freestanding financial instruments. Description of Misstatements (A) The Company historically accounted for its term debt and royalty rights agreements on a combined basis instead of separately recognizing them as standalone financial instruments. Over time, the subsequent accounting on a standalone basis differed from the combined accounting treatment and resulted in an increase to Interest expense, increase to long-term debt, and increase or decrease to foreign exchange gains/(losses) over the impacted periods. (B) Over recognition of depreciation expense related to specific property and equipment. The Company has recorded adjustments to recognize these amounts in the appropriate period(s). (C) Under-accrual for fringe benefits and taxes associated with employee compensation arrangements. The Company has recorded adjustments to recognize these amounts in the appropriate period(s). (D) Adjustment to recognize the foreign currency impact of certain immaterial monetary items within Other, net previously recognized in Foreign currency gain (loss) (E) The Company recognized an out of period adjustment for deferred tax assets related to certain research and development initiatives. (F) Correction of other immaterial errors. March 31, 2021 As previously Reported Restatement Impacts Restatement Reference As Restated ASSETS Current assets: Cash and cash equivalents $ 45,673 $ — $ 45,673 Short-term investments 65,999 — 65,999 Trade accounts receivable, net 5,323 — 5,323 Inventories 22,011 — 22,011 Prepaid expenses and other current assets 4,870 — 4,870 Total current assets 143,876 — 143,876 Restricted cash 9,024 — 9,024 Property and equipment, net 38,530 541 (B) 39,071 Operating lease right-of-use assets 22,011 — 22,011 Intangible assets, net 619 — 619 Deferred income taxes 255 — 255 Other non-current assets 4,956 — 4,956 Total assets $ 219,271 $ 541 $ 219,812 LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIT) Current liabilities: Accounts payable $ 4,659 $ — $ 4,659 Accrued compensation and benefits 11,833 510 (C) 12,343 Accrued expenses and other current liabilities 13,889 120 (F) 14,009 Current portion of long-term debt 24,167 — 24,167 Current portion of operating lease liability 3,446 — 3,446 Current portion of finance lease obligation 835 — 835 Total current liabilities 58,829 630 59,459 Long-term debt, less current portion 137,936 7,123 (A) 145,059 Operating lease liability, less current portion 20,907 — 20,907 Finance lease obligation, less current portion 445 — 445 Deferred income taxes 1,824 (672 ) (E) 1,152 Defined benefit pension plan obligation 6,896 — 6,896 7% Cumulative redeemable preference shares 21,475 — 21,475 Total liabilities 248,312 7,081 255,393 Commitments and contingencies — — — Shareholders' equity (deficit): Ordinary shares ( nil 540,813 — 540,813 Additional paid in capital 38,116 — 38,116 Accumulated other comprehensive loss (16,065 ) 1,467 (D) (14,598 ) Accumulated deficit (591,905 ) (8,007 ) (A)(B)(C)(D)(E)(F) (599,912 ) Total shareholders' equity (deficit) (29,041 ) (6,540 ) (35,581 ) Total liabilities and shareholders' equity (deficit) $ 219,271 $ 541 $ 219,812 March 31, 2020 As previously Reported Restatement Impacts Restatement Reference As Restated ASSETS Current assets: Cash and cash equivalents $ 3,923 $ — $ 3,923 Short-term investments 116,871 — 116,871 Trade accounts receivable, net 5,402 — 5,402 Inventories 20,501 — 20,501 Prepaid expenses and other current assets 3,775 — 3,775 Total current assets 150,472 — 150,472 Restricted cash 9,017 — 9,017 Property and equipment, net 40,165 275 (B) 40,440 Operating lease right-of-use assets 21,493 — 21,493 Intangible assets, net 625 — 625 Deferred income taxes 237 — 237 Other non-current assets 4,454 — 4,454 Total assets $ 226,463 $ 275 $ 226,738 LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIT) Current liabilities: Accounts payable $ 4,826 $ — $ 4,826 Accrued compensation and benefits 7,210 — 7,210 Accrued expenses and other current liabilities 15,490 — 15,490 Current portion of long-term debt — — — Current portion of operating lease liability 3,033 — 3,033 Current portion of finance lease obligation 598 — 598 Total current liabilities 31,157 — 31,157 Long-term debt, less current portion 153,024 3,237 (A) 156,261 Operating lease liability, less current portion 19,914 — 19,914 Finance lease obligation, less current portion 1,117 — 1,117 Deferred income taxes — — — Defined benefit pension plan obligation 6,353 — 6,353 7% Cumulative redeemable preference shares 20,425 — 20,425 Total liabilities 231,990 3,237 235,227 Commitments and contingencies — — — Shareholders' equity (deficit): Ordinary shares ( nil 459,931 — 459,931 Additional paid in capital 33,132 — 33,132 Accumulated other comprehensive loss (15,155 ) 2,483 (D) (12,672 ) Accumulated deficit (483,435 ) (5,445 ) (A)(B)(D) (488,880 ) Total shareholders' equity (deficit) (5,527 ) (2,962 ) (8,489 ) Total liabilities and shareholders' equity (deficit) $ 226,463 $ 275 $ 226,738 Year ended March 31, 2021 As previously Reported Restatement Impacts Restatement Reference As Restated Revenue: Product sales $ 35,787 $ — $ 35,787 Other revenues 7,592 — 7,592 Total revenue 43,379 — 43,379 Cost of revenue (20,074 ) — (20,074 ) Gross profit 23,305 — 23,305 Operating expenses: Sales and marketing (9,849 ) — (9,849 ) Research and development, net of government grants (54,168 ) 441 (B)(F) (53,727 ) General and administrative expense: Compensation expense in respect of share options and management equity incentives (4,984 ) — (4,984 ) Other general and administrative expenses (36,812 ) (630 ) (C)(F) (37,442 ) Total general and administrative expense (41,796 ) (630 ) (42,426 ) Total operating expense (105,813 ) (189 ) (106,002 ) Operating loss (82,508 ) (189 ) (82,697 ) Other income (expense): Interest expense, net (25,918 ) (3,886 ) (A) (29,804 ) Other, net 1,882 841 (D) 2,723 Other income (expense), net (24,036 ) (3,045 ) (27,081 ) Loss before income taxes (106,544 ) (3,234 ) (109,778 ) Provision for income taxes (1,926 ) 672 (E) (1,254 ) Net loss $ (108,470 ) $ (2,562 ) $ (111,032 ) Other comprehensive income (loss): Change in fair value of effective portion of foreign currency cash flow hedges $ 582 $ — $ 582 Unrealized gain (loss) on short-term investments (898 ) — (898 ) Foreign currency gain (loss) (1,216 ) (841 ) (D) (2,057 ) Provision for pension benefit obligation 622 (175 ) (F) 447 Other comprehensive loss, net (910 ) (1,016 ) (1,926 ) Comprehensive loss $ (109,380 ) $ (3,578 ) $ (112,958 ) Net loss available to ordinary shareholders - basic and diluted $ (108,470 ) $ (2,562 ) $ (111,032 ) Loss per share - basic and diluted $ (1.18 ) $ (0.03 ) $ (1.21 ) Weighted-average shares outstanding - basic and diluted 91,637,966 — 91,637,966 Year ended March 31, 2020 As previously Reported Restatement Impacts Restatement Reference As Restated Revenue: Product sales $ 31,601 $ — $ 31,601 Other revenues 1,055 — 1,055 Total revenue 32,656 — 32,656 Cost of revenue (17,800 ) — (17,800 ) Gross profit 14,856 — 14,856 Operating expenses: Sales and marketing (9,853 ) — (9,853 ) Research and development, net of government grants (53,744 ) 306 (B)(F) (53,438 ) General and administrative expense: Compensation expense in respect of share options and management equity incentives (4,467 ) — (4,467 ) Other general and administrative expenses (27,483 ) — (27,483 ) Total general and administrative expense (31,950 ) — (31,950 ) Total operating expense (95,547 ) 306 (95,241 ) Operating loss (80,691 ) 306 (80,385 ) Other income (expense): Interest expense, net (23,859 ) (3,041 ) (A) (26,900 ) Other, net 2,438 (233 ) (D) 2,205 Other income (expense), net (21,421 ) (3,274 ) (24,695 ) Loss before income taxes (102,112 ) (2,968 ) (105,080 ) Provision for income taxes (661 ) 603 (E) (58 ) Net loss $ (102,773 ) $ (2,365 ) $ (105,138 ) Other comprehensive income (loss): Change in fair value of effective portion of foreign currency cash flow hedges $ (157 ) $ — $ (157 ) Unrealized gain (loss) on short-term investments 554 — 554 Foreign currency gain (loss) (2,702 ) 233 (D) (2,469 ) Provision for pension benefit obligation 2,034 175 (F) 2,209 Other comprehensive loss, net (271 ) 408 137 Comprehensive loss $ (103,044 ) $ (1,957 ) $ (105,001 ) Net loss available to ordinary shareholders - basic and diluted $ (102,773 ) $ (2,365 ) $ (105,138 ) Loss per share - basic and diluted $ (1.44 ) $ (0.03 ) $ (1.47 ) Weighted-average shares outstanding - basic and diluted 71,610,035 — 71,610,035 Year ended March 31, 2019 As previously Reported Restatement Impacts Restatement Reference As Restated Revenue: Product sales $ 28,665 $ — $ 28,665 Other revenues 469 — 469 Total revenue 29,134 — 29,134 Cost of revenue (17,230 ) — (17,230 ) Gross profit 11,904 — 11,904 Operating expenses: Sales and marketing (8,637 ) — (8,637 ) Research and development, net of government grants (50,677 ) (206 ) (B) (50,883 ) General and administrative expense: Compensation expense in respect of share options and management equity incentives (4,957 ) — (4,957 ) Other general and administrative expenses (26,588 ) — (26,588 ) Total general and administrative expense (31,545 ) — (31,545 ) Total operating expense (90,859 ) (206 ) (91,065 ) Operating loss (78,955 ) (206 ) (79,161 ) Other income (expense): Interest expense, net (20,018 ) (259 ) (A) (20,277 ) Other, net (6,369 ) (574 ) (D) (6,943 ) Other income (expense), net (26,387 ) (833 ) (27,220 ) Loss before income taxes (105,342 ) (1,039 ) (106,381 ) Provision for income taxes (44 ) 14 (E) (30 ) Net loss $ (105,386 ) $ (1,025 ) $ (106,411 ) Other comprehensive income (loss): Change in fair value of effective portion of foreign currency cash flow hedges $ (123 ) $ — $ (123 ) Unrealized gain (loss) on short-term investments 796 — 796 Foreign currency gain (loss) 1,964 574 (D) 2,538 Provision for pension benefit obligation (887 ) — (887 ) Other comprehensive loss, net 1,750 574 2,324 Comprehensive loss $ (103,636 ) $ (451 ) $ (104,087 ) Net loss available to ordinary shareholders - basic and diluted $ (105,386 ) $ (1,025 ) $ (106,411 ) Loss per share - basic and diluted $ (1.92 ) $ (0.02 ) $ (1.94 ) Weighted-average shares outstanding - basic and diluted 54,874,391 — 54,874,391 Ordinary shares Shares Amount Additional paid in Capital Accumulated Other Comprehensive Loss Accumulated Deficit Total Shareholders' Equity (Deficit) As Previously Reported March 31, 2018 45,646,424 253,934 23,708 (16,634 ) (275,639 ) (14,631 ) Issue of shares, net of issue costs of $4,052 19,635,068 113,724 — — — 113,724 Issue of shares upon exercise of incentive share options and vesting of RSUS 618,955 1,300 — — — 1,300 Net loss — — — — (105,386 ) (105,386 ) Change in fair value of the effective portion of foreign currency cash flow hedges — — — (123 ) — (123 ) Change in unrealized gain in short-term investments — — — 796 — 796 Foreign currency gain (loss) on: Long-term investment nature intra-entity balances — — — 5,074 — 5,074 Retranslation of foreign entities — — — (3,110 ) — (3,110 ) Provision for pension benefit obligation — — — (887 ) — (887 ) Other comprehensive loss 1,750 1,750 Stock-based compensation — — 4,957 — — 4,957 March 31, 2019 65,900,447 368,958 28,665 (14,884 ) (381,025 ) 1,714 Restatement Impacts March 31, 2018 — — — 1,501 (2,055 ) (554 ) Issue of shares, net of issue costs of $4,052 — — — — — — Issue of shares upon exercise of incentive share options and vesting of RSUS — — — — — — Net loss — — — — (1,025 ) (1,025 ) Change in fair value of the effective portion of foreign currency cash flow hedges — — — — — — Change in unrealized gain in short-term investments — — — — — — Foreign currency gain (loss) on: Long-term investment nature intra-entity balances — — — — — — Retranslation of foreign entities — — — 574 — 574 Provision for pension benefit obligation — — — — — — Other comprehensive loss 574 574 Stock-based compensation — — — — — — March 31, 2019 — — — 2,075 (3,080 ) (1,005 ) As Restated March 31, 2018 45,646,424 253,934 23,708 (15,133 ) (277,694 ) (15,185 ) Issue of shares, net of issue costs of $4,052 19,635,068 113,724 — — — 113,724 Issue of shares upon exercise of incentive share options and vesting of RSUS 618,955 1,300 — — — 1,300 Net loss — — — — (106,411 ) (106,411 ) Change in fair value of the effective portion of foreign currency cash flow hedges — — — (123 ) — (123 ) Change in unrealized gain in short-term investments — — — 796 — 796 Foreign currency gain (loss) on: — Long-term investment nature intra-entity balances — — — 5,074 — 5,074 Retranslation of foreign entities — — — (2,536 ) — (2,536 ) Provision for pension benefit obligation — — — (887 ) — (887 ) Other comprehensive loss 2,324 2,324 Stock-based compensation — — 4,957 — — 4,957 March 31, 2019 65,900,447 368,958 28,665 (12,809 ) (384,105 ) 709 Ordinary shares Shares Amount Additional paid in Capital Accumulated Other Comprehensive Loss Accumulated Deficit Total Shareholders' Equity (Deficit) As Previously Reported March 31, 2019 65,900,447 $ 368,958 $ 28,665 $ (14,884 ) $ (381,025 ) $ 1,714 Issue of shares, net of issue costs of $6,072 13,800,000 90,528 — — — 90,528 Issue of shares upon exercise of incentive share options and vesting of RSUS 697,879 445 — — — 445 Net loss — — — — (102,773 ) (102,773 ) Change in fair value of the effective portion of foreign currency cash flow hedges — — — (157 ) — (157 ) Change in unrealized gain in short-term investments — — — 554 — 554 Foreign currency gain (loss) on: Long-term investment nature intra-entity balances — — — 18,394 — 18,394 Retranslation of foreign entities — — — (21,096 ) — (21,096 ) Provision for pension benefit obligation — — — 2,034 — 2,034 Other comprehensive loss (271 ) (271 ) Stock-based compensation — — 4,467 — — 4,467 Cumulative effect of accounting changes — — — 363 363 March 31, 2020 80,398,326 459,931 33,132 (15,155 ) (483,435 ) (5,527 ) Restatement Impacts March 31, 2019 — $ — $ — $ 2,075 $ (3,080 ) $ (1,005 ) Issue of shares, net of issue costs of $6,072 — — — — — — Issue of shares upon exercise of incentive share options and vesting of RSUS — — — — — — Net loss — — — — (2,365 ) (2,365 ) Change in fair value of the effective portion of foreign currency cash flow hedges — — — — — — Change in unrealized gain in short-term investments — — — — — — Foreign currency gain (loss) on: Long-term investment nature intra-entity balances — — — — — — Retranslation of foreign entities — — — 233 — 233 Provision for pension benefit obligation — — — 175 — 175 Other comprehensive loss 408 408 Stock-based compensation — — — — — — Cumulative effect of accounting changes — — — — — — March 31, 2020 — — — 2,483 (5,445 ) (2,962 ) As Restated March 31, 2019 65,900,447 $ 368,958 $ 28,665 $ (12,809 ) $ (384,105 ) $ 709 Issue of shares, net of issue costs of $6,072 13,800,000 90,528 — — — 90,528 Issue of shares upon exercise of incentive share options and vesting of RSUS 697,879 445 — — — 445 Net loss — — — — (105,138 ) (105,138 ) Change in fair value of the effective portion of foreign currency cash flow hedges — — — (157 ) — (157 ) Change in unrealized gain in short-term investments — — — 554 — 554 Foreign currency gain (loss) on: Long-term investment nature intra-entity balances — — — 18,394 — 18,394 Retranslation of foreign entities — — — (20,863 ) — (20,863 ) Provision for pension benefit obligation — — — 2,209 — 2,209 Other comprehensive loss 137 137 Stock-based compensation — — 4,467 — — 4,467 Cumulative effect of accounting changes — — — — 363 363 March 31, 2020 80,398,326 459,931 33,132 (12,672 ) (488,880 ) (8,489 ) Ordinary shares Shares Amount Additional paid in Capital Accumulated Other Comprehensive Loss Accumulated Deficit Total Shareholders' Equity (Deficit) As Previously Reported March 31, 2020 80,398,326 459,931 33,132 (15,155 ) (483,435 ) (5,527 ) Issue of shares, net of issue costs of $5,565 20,294,117 80,685 — — — 80,685 Issue of shares upon exercise of incentive share options and vesting of RSUS 571,969 197 — — — 197 Net loss — — — — (108,470 ) (108,470 ) Change in fair value of the effective portion of foreign currency cash flow hedges — — — 582 — 582 Change in unrealized gain in short-term investments — — — (898 ) — (898 ) Foreign currency gain (loss) on: Long-term investment nature intra-entity balances — — — (27,251 ) — (27,251 ) Retranslation of foreign entities — — — 26,035 — 26,035 Provision for pension benefit obligation — — — 622 — 622 Other comprehensive loss (910 ) (910 ) Stock-based compensation — — 4,984 — — 4,984 March 31, 2021 101,264,412 540,813 38,116 (16,065 ) (591,905 ) (29,041 ) Restatement Impacts March 31, 2020 — — — 2,483 (5,445 ) (2,962 ) Issue of shares, net of issue costs of $5,565 — — — — — — Issue of shares upon exercise of incentive share options and vesting of RSUS — — — — — — Net loss — — — — (2,562 ) (2,562 ) Change in fair value of the effective portion of foreign currency cash flow hedges — — — — — — Change in unrealized gain in short-term investments — — — — — — Foreign currency gain (loss) on: Long-term investment nature intra-entity balances — — — — — — Retranslation of foreign entities — — — (841 ) — (841 ) Provision for pension benefit obligation — — — (175 ) — (175 ) Other comprehensive loss (1,016 ) (1,016 ) Stock-based compensation — — — — — — March 31, 2021 — — — (1,016 ) (8,007 ) (6,540 ) As Restated March 31, 2020 80,398,326 459,931 33,132 (12,672 ) (488,880 ) (8,489 ) Issue of shares, net of issue costs of $5,565 20,294,117 80,685 — — — 80,685 Issue of shares upon exercise of incentive share options and vesting of RSUS 571,969 197 — — — 197 Net loss — — — — (111,032 ) (111,032 ) Change in fair value of the effective portion of foreign currency cash flow hedges — — — 582 — 582 Change in unrealized gain in short-term investments — — — (898 ) — (898 ) Foreign currency gain (loss) on: Long-term investment nature intra-entity balances — — — (27,251 ) — (27,251 ) Retranslation of foreign entities — — — 25,194 — 25,194 Provision for pension benefit obligation — — — 447 — 447 Other comprehensive loss (1,926 ) (1,926 ) Stock-based compensation — — 4,984 — — 4,984 March 31, 2021 101,264,412 540,813 38,116 (14,598 ) (599,912 ) (35,581 ) Year ended March 31, 2021 As previously Reported Restatement Impacts As Restated OPERATING ACTIVITIES: Net loss $ (108,470 ) $ (2,562 ) $ (111,032 ) Adjustments to reconcile net loss to net cash provided by operating activities: Depreciation, amortization and loss on disposal of fixed assets 8,620 (266 ) 8,354 Share-based compensation 4,984 — 4,984 Increase in deferred lease rentals 726 — 726 Swiss pension obligation 1,054 — 1,054 Amortization of deferred debt issue costs 9,079 3,886 12,965 Impairment of short term investments 2,285 — 2,285 Accrued preference share dividends 1,050 — 1,050 Income taxes 1,926 (672 ) 1,254 Net change in assets and liabilities: Trade accounts receivable, net 568 — 568 Inventories (475 ) — (475 ) Accounts payable and accrued liabilities (2,514 ) (896 ) (3,410 ) Accrued compensation and benefits 4,039 510 4,549 Other assets (454 ) — (454 ) Net cash used in operating activities (77,582 ) — (77,582 ) INVESTING ACTIVITIES: Increase in short-term investments (87,247 ) — (87,247 ) Realization of short-term investments 134,936 — 134,936 Purchase of property and equipment (4,240 ) — (4,240 ) Purchase of intangible assets — — — Net cash from (used in) investing activities 43,449 — 43,449 FINANCING ACTIVITIES: Repayment of finance leases (633 ) — (633 ) Proceeds from drawdown of new debt — — — Debt issue costs — — — Fee paid to noteholders — — — Proceeds from issuance of ordinary shares and warrants 80,881 — 80,881 Net cash generated from financing activities 80,248 — 80,248 Effect of exchange rate fluctuations on cash and cash equivalents (4,358 ) — (4,358 ) Change in cash and cash equivalents 41,757 — 41,757 Beginning cash and cash equivalents 12,940 — 12,940 Ending cash and cash equivalents $ 54,697 $ — $ 54,697 Supplemental cash flow disclosures: Income taxes paid $ — $ — $ — Interest paid $ 17,529 $ — $ 17,529 Reconciliation of cash, cash equivalents and restricted cash: Cash and cash equivalents $ 45,673 $ — $ 45,673 Restricted cash $ 9,024 $ — $ 9,024 Total cash, cash equivalents and restricted cash $ 54,697 $ — $ 54,697 Year ended March 31, 2020 As previously Reported Restatement Impacts As Restated OPERATING ACTIVITIES: Net loss $ (102,773 ) $ (2,365 ) $ (105,138 ) Adjustments to reconcile net loss to net cash provided by operating activities: Depreciation, amortization and loss on disposal of fixed assets 12,276 (275 ) 12,001 Share-based compensation 4,467 — 4,467 Increase in deferred lease rentals 293 — 293 Swiss pension obligation 756 — 756 Amortization of deferred debt issue costs 7,043 3,041 10,084 Impairment of short term investments — — — Accrued preference share dividends 1,050 — 1,050 Income taxes 368 (537 ) (169 ) Net change in assets and liabilities: Trade accounts receivable, net (2,177 ) — (2,177 ) Inventories (4,967 ) (206 ) (5,173 ) Accounts payable and accrued liabilities 2,456 342 2,798 Accrued compensation and benefits 1,218 — 1,218 Other assets (656 ) — (656 ) Net cash used in operating activities (80,646 ) — (80,646 ) INVESTING ACTIVITIES: Increase in short-term investments (95,000 ) — (95,000 ) Realization of short-term investments 69,412 — 69,412 Purchase of property and equipment (4,598 ) — (4,598 ) Purchase of intangible assets (2 ) — (2 ) Net cash from (used in) investing activities (30,188 ) — (30,188 ) FINANCING ACTIVITIES: Repayment of finance leases (524 ) — (524 ) Proceeds from drawdown of new debt 25,000 — 25,000 Debt issue costs (874 ) — (874 ) Fee paid to noteholders — — — Proceeds from issuance of ordinary shares and warrants 90,973 — 90,973 Net cash generated from financing activities 114,575 — 114,575 Effect of exchange rate fluctuations on cash and cash equivalents (2,404 ) — (2,404 ) Change in cash and cash equivalents 1,337 — 1,337 Beginning cash and cash equivalents 11,603 — 11,603 Ending cash and cash equivalents $ 12,940 $ — $ 12,940 Supplemental cash flow disclosures: Income taxes paid $ — $ — $ — Interest paid $ 15,776 $ — $ 15,776 Reconciliation of cash, cash equivalents and restricted cash: Cash and cash equivalents $ 3,923 $ — $ 3,923 Restricted cash $ 9,017 $ — $ 9,017 Total cash, cash equivalents and restricted cash $ 12,940 $ — $ 12,940 Year ended March 31, 2019 As previously Reported Restatement Impacts As Restated OPERATING ACTIVITIES: Net loss $ (105,386 ) $ (1,025 ) $ (106,411 ) Adjustments to reconcile net loss to net cash provided by operating activities: Depreciation, amortization and loss on disposal of fixed assets 12,767 — 12,767 Share-based compensation 4,957 — 4,957 Increase in deferred lease rentals 372 — 372 Swiss pension obligation 575 — 575 Amortization of deferred debt issue costs 5,908 259 6,167 Impairment of short term investments — — — Accrued preference share dividends 1,050 — 1,050 Income taxes 44 (105 ) (61 ) Net change in assets and liabilities: Trade accounts receivable, net (637 ) — (637 ) Inventories (93 ) 206 113 Accounts payable and accrued liabilities 370 665 1,035 Accrued compensation and benefits 1,121 — 1,121 Other assets 3,297 — 3,297 Net cash used in operating activities (75,655 ) — (75,655 ) INVESTING ACTIVITIES: Increase in short-term investments (119,000 ) — (119,000 ) Realization of short-term investments 34,735 — 34,735 Purchase of property and equipment (4,791 ) — (4,791 ) Purchase of intangible assets (3 ) — (3 ) Net cash from (used in) investing activities (89,059 ) — (89,059 ) FINANCING ACTIVITIES: Repayment of finance leases (486 ) — (486 ) Proceeds from drawdown of new debt 36,000 — 36,000 Debt issue costs (1,216 ) — (1,216 ) Fee paid to noteholders (3,900 ) — (3,900 ) Proceeds from issuance of ordinary shares and warrants 115,024 — 115,024 Net cash generated from financing activities 145,422 — 145,422 Effect of exchange rate fluctuations on cash and cash equivalents 5,690 — 5,690 Change in cash and cash equivalents (13,602 ) — (13,602 ) Beginning cash and cash equivalents 25,205 — 25,205 Ending cash and cash equivalents $ 11,603 $ — $ 11,603 Supplemental cash flow disclosures: Income taxes paid $ — $ — $ — Interest paid $ 11,838 $ — $ 11,838 Reconciliation of cash, cash equivalents and restricted cash: Cash and cash equivalents $ 4,096 $ — $ 4,096 Restricted cash $ 7,507 $ — $ 7,507 Total cash, cash equivalents and restricted cash $ 11,603 $ — $ 11,603 16. Restatement of Previously Issued Unaudited Condensed Consolidated Financial Statements In lieu of filing amended quarterly reports on Form 10-Q, the following tables represent our restated unaudited condensed consolidated financial statements for the quarters ended December 31, 2020, September 30, 2020, and June 30, 2020 during the annual year ended March 31, 2021. See Note 2, Restatement of Previously Issued Consolidated Financial Statements, for additional information. Following the restated consolidated financial statement tables, we have presented a reconciliation from our prior periods, as previously reported, to the restated values. The values as previously reported were derived from our Quarterly Reports on Form 10-Q for the interim periods ended December 31, 2020, September 30, 2020 and June 30, 2020. Description of Misstatements (A) The Company historically accounted for its term debt and royalty rights agreements on a combined basis instead of separately recognizing them as standalone financial instruments. Over time, the subsequent accounting on a standalone basis differed from the combined accounting treatment and resulted in an increase to Interest expense, increase to long-term debt, and increase or decrease to foreign exchange gains/(losses) over the impacted periods. (B) Over recognition of depreciation expense related to specific property and equipment. The Company has recorded adjustments to recognize these amounts in the appropriate period(s). (C) Under-accrual for fringe benefits and taxes associated with employee compensation arrangements. The Company has recorded adjustments to recognize these amounts in the appropriate period(s). (D) Adjustment to recognize the foreign currency impact of certain immaterial monetary items within Other, net previously recognized in Foreign currency gain (loss) within other comprehensive income (loss). (E) The Company recognized an out of period adjustment for deferred tax assets related to certain research and development initiatives. (F) Correction of other immaterial errors. (G) As previously disclosed, the Company's condensed consolidated balance sheet as of June 30, 2020 incorrectly classified $12.1 million of indebtedness as non-current liabilities instead of as current liabilities. (unaudited) December 31, 2020 September 30, 2020 June 30, 2020 ASSETS As Restated As Restated As Restated Current assets: Cash and cash equivalents $ 3,401 $ 18,125 $ 7,325 Short-term investments 131,062 144,618 87,152 Trade accounts receivable, net 4,539 4,518 5,972 Inventories 23,709 22,798 21,291 Prepaid expenses and other current assets 4,928 5,851 4,091 Total current assets 167,639 195,910 125,831 Restricted cash 9,046 9,031 9,021 Property and equipment, net 41,299 40,182 39,563 Operating lease right-of-use assets 22,364 21,557 21,124 Intangible assets, net 632 614 606 Deferred income taxes 741 573 405 Other non-current assets 4,914 4,634 4,438 Total assets $ 246,635 $ 272,501 $ 200,988 LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIT) Current liabilities: Accounts payable $ 5,860 $ 5,138 $ 5,621 Accrued compensation and benefits 4,844 5,191 5,190 Accrued expenses and other current liabilities 11,351 17,410 13,317 Current portion of long-term debt 24,167 12,083 12,083 Current portion of operating lease liability 3,309 3,138 3,045 Current portion of finance lease obligation 878 577 573 Total current liabilities 50,409 43,537 39,829 Long-term debt, less current portion 141,822 149,007 147,260 Operating lease liability, less current portion 21,203 20,282 19,695 Finance lease obligation, less current portion 582 921 1,017 Deferred income taxes 1,455 — — Defined benefit pension plan obligation 7,707 7,169 6,623 7% Cumulative redeemable preference shares 21,213 20,950 20,688 Total liabilities 244,391 241,866 235,112 Commitments and contingencies — — — Shareholders' equity (deficit): Ordinary shares ( nil 540,819 540,769 459,990 Additional paid in capital 36,630 35,416 34,092 Accumulated other comprehensive loss (14,634 ) (16,659 ) (13,070 ) Accumulated deficit (560,571 ) (528,891 ) (515,136 ) Total shareholders' equity (deficit) 2,244 30,635 (34,124 ) Total liabilities and shareholders' equity (deficit) $ 246,635 $ 272,501 $ 200,988 (unaudited) December 31, 2020 September 30, 2020 June 30, 2020 December 31 2020 September 30, 2020 Quarter ended Quarter ended Quarter ended Nine months ended Six months ended As Restated As Restated As Restated As Restated As Restated Revenue: Product sales $ 8,740 $ 8,543 $ 8,924 $ 26,207 $ 17,467 Other revenues 11 7,523 — 7,534 7,523 Total revenue 8,751 16,066 8,924 33,741 24,990 Cost of revenue (4,970 ) (4,499 ) (5,414 ) (14,883 ) (9,913 ) Gross profit 3,781 11,567 3,510 18,858 15,077 Operating expenses: Sales and marketing (2,283 ) (2,231 ) (2,243 ) (6,757 ) (4,474 ) Research and development, net of government grants (14,350 ) (12,743 ) (11,415 ) (38,508 ) (24,158 ) General and administrative expense: Compensation expense in respect of share options and management equity incentives (1,214 ) (1,324 ) (960 ) (3,498 ) (2,284 ) Other general and administrative expenses (7,524 ) (8,232 ) (8,578 ) (24,334 ) (16,810 ) Total general and administrative expense (8,738 ) (9,556 ) (9,538 ) (27,832 ) (19,094 ) Total operating expense (25,371 ) (24,530 ) (23,196 ) (73,097 ) (47,726 ) Operating loss (21,590 ) (12,963 ) (19,686 ) (54,239 ) (32,649 ) Other income (expense): Interest expense, net (9,404 ) (6,297 ) (6,931 ) (22,632 ) (13,228 ) Other, net 617 5,354 208 6,179 5,562 Other income (expense), net (8,787 ) (943 ) (6,723 ) (16,453 ) (7,666 ) Loss before income taxes (30,377 ) (13,906 ) (26,409 ) (70,692 ) (40,315 ) Provision for income taxes (1,303 ) 151 153 (999 ) 304 Net loss $ (31,680 ) $ (13,755 ) $ (26,256 ) $ (71,691 ) $ (40,011 ) Other comprehensive income (loss): Change in fair value of effective portion of foreign currency cash flow hedges $ 295 $ 279 $ (3 ) $ 571 $ 276 Unrealized gain (loss) on short-term investments 111 (79 ) (404 ) (372 ) (483 ) Foreign currency gain (loss) 1,606 (3,803 ) 171 (2,026 ) (3,632 ) Provision for pension benefit obligation 13 14 (162 ) (135 ) (148 ) Other comprehensive loss, net 2,025 (3,589 ) (398 ) (1,962 ) (3,987 ) Comprehensive loss $ (29,655 ) $ (17,344 ) $ (26,654 ) $ (73,652 ) $ (43,998 ) Net loss available to ordinary shareholders - basic and diluted $ (31,680 ) $ (13,755 ) $ (26,256 ) $ (71,691 ) $ (40,011 ) Loss per share - basic and diluted $ (0.31 ) $ (0.16 ) $ (0.33 ) $ (0.81 ) $ (0.49 ) Weighted-average shares outstanding - basic and diluted 101,016,040 83,949,195 80,485,985 88,512,823 82,227,052 (unaudited) Ordinary shares Shares Amount Additional paid in Capital Accumulated Other Comprehensive Loss Accumulated Deficit Total Shareholders' Equity (Deficit) March 31, 2020 As Restated 80,398,326 $ 459,931 $ 33,132 $ (12,672 ) $ (488,880 ) $ (8,489 ) Issue of shares upon exercise of incentive share options and vesting of RSUS 195,114 59 — — — 59 Net loss — — — — (26,256 ) (26,256 ) Change in fair value of the effective portion of foreign currency cash flow hedges — — — (3 ) — (3 ) Change in unrealized gain in short-term investments — — — (404 ) — (404 ) Foreign currency gain (loss) on: — — Long-term investment nature intra-entity balances — — — 4,685 — 4,685 Retranslation of foreign entities — — — (4,514 ) — (4,514 ) Provision for pension benefit obligation — — — (162 ) — (162 ) Other comprehensive loss (398 ) (398 ) Stock-based compensation — — 960 — — 960 June 30, 2020 As Restated 80,593,440 459,990 34,092 (13,070

Intangible Assets

Intangible Assets	12 Months Ended
	Mar. 31, 2021
Goodwill And Intangible Assets Disclosure [Abstract]
Intangible Assets	Note 3. Intangible Assets March 31, 2021 Gross Carrying Amount Accumulated Amortization Net Amount Weighted Average Remaining Useful Customer relationships $ 2,711 $ (2,711 ) $ — — Brands associated with acquired cell lines 559 (190 ) 369 26.4 years Product licenses 944 (694 ) 250 2.6 years Other intangibles 176 (176 ) — — Total $ 4,390 $ (3,771 ) $ 619 16.8 years March 31, 2020 Gross Carrying Amount Accumulated Amortization Net Amount Weighted Average Remaining Useful Customer relationships $ 2,436 $ (2,436 ) $ — — Brands associated with acquired cell lines 502 (158 ) 344 27.4 years Product licenses 849 (568 ) 281 3.5 years Other intangibles 158 (158 ) — — Total $ 3,945 $ (3,320 ) $ 625 16.3 years Amortization expense was $73, $94, and $104 in financial years 2021, 2020, and 2019, respectively. Total future amortization expense for intangible assets that have definite lives, based upon the Company’s existing intangible assets and their current estimated useful lives as of March 31, 2021, is estimated as follows: 2022 $ 76 2023 76 2024 76 2025 77 2026 14 Thereafter 300 Total $ 619

Debt

Debt	12 Months Ended
	Mar. 31, 2021
Debt Disclosure [Abstract]
Debt	Note 4. Debt Total debt comprises: March 31, 2021 March 31, 2020 As Restated As Restated Secured Notes $ 145,000 $ 145,000 Debt discount, net of amortization (11,127 ) (16,261 ) Deferred debt costs, net of amortization (4,261 ) (6,375 ) Carrying value Secured Notes 129,612 122,364 Royalty liability 39,614 33,897 Total Debt $ 169,226 $ 156,261 The Company’s debt at March 31, 2021 and at March 31, 2020 comprises the Secured Notes, and the royalty liability. As of March 31, 2021, the Company’s long term debt, included $24,167 of principal payments due within 1 year which is classified as current within the balance sheet. Secured Notes On October 14, 2016, the Company completed the private placement of up to $120 million aggregate principal amount of the Secured Notes and entered into an indenture governing the Secured Notes with the guarantors party thereto and U.S. Bank National Association, a national banking association, as trustee and collateral agent. The Company issued $84 million aggregate principal amount of the Secured Notes on October 14, 2016 and an additional $36 million aggregate principal amount of the Secured Notes on June 29, 2018. On December 18, 2018, the Company also completed certain amendments to the indenture governing the Secured Notes. The amendments included an increase to the aggregate principal amount of Secured Notes that can be issued under the indenture from $120 million to up to $145 million following the European CE Marking of the Company’s initial MosaiQ IH Microarray. On April 30, 2019, the Company was notified that it had received the European CE Marking of the initial MosaiQ IH Microarray and, on May 15, 2019, the Company issued the additional $25 million of Secured Notes. The obligations of the Company under the indenture and the Secured Notes are unconditionally guaranteed on a secured basis by the guarantors, which include all the Company’s subsidiaries, and the indenture governing the Secured Notes contains customary events of default. The Company and its subsidiaries must also comply with certain customary affirmative and negative covenants, including a requirement to maintain six-months of interest in a cash reserve account maintained with the collateral agent. Upon the occurrence of a Change of Control, subject to certain conditions, or certain Asset Sales (each, as defined in the indenture), holders of the Secured Notes may require the Company to repurchase for cash all or part of their Secured Notes at a repurchase price equal to 101% or 100%, respectively, of the principal amount of the Secured Notes to be repurchased, plus accrued and unpaid interest to the date of repurchase. The Company paid $8.7 million of the total proceeds of the three issuances into the cash reserve account maintained with the collateral agent under the terms of the indenture, $1.5 million of which related to the third issuance on May 15, 2019. Following the April 15, 2021 repayment of the Secured Notes the balance held in the cash reserve account was reduced to $8.0 million. Interest on the Secured Notes accrues at a rate of 12% per annum and is payable semi-annually on April 15 and October 15 of each year commencing on April 15, 2017. On April 15, 2021, the Company made a $12.1 million principal payment on the Secured Notes. Additionally, principal payments are due on each April 15 and October 15 until April 15, 2024 pursuant to a fixed amortization schedule. The outstanding debt at March 31, 2021 falls due for repayment as follows: Within 1 year $ 24,167 Between 1 and 2 years 42,291 Between 2 and 3 years 48,334 Between 3 and 4 years 30,208 Between 4 and 5 years — Total debt $ 145,000 Royalty liability In connection with the three issuances of the Secured Notes as well as the December 2018 amendment of the related indenture, the Company has entered into royalty rights agreements, pursuant to which the Company has agreed to pay 3.4% of the aggregate net sales of MosaiQ instruments and consumables made in the donor testing market in the United States and the European Union. The royalties will be payable beginning on the date that the Company or its affiliates makes its first sale of MosaiQ consumables in the donor testing market in the European Union or the United States and will end on the last day of the calendar quarter in which the eighth anniversary of the first sale date occurs. The royalty rights agreements are treated as sales of future revenues that meet the requirements of Accounting Standards Codification Topic 470 “Debt” to be treated as debt. The future cash outflows under the royalty rights agreements were estimated at $106.5 million at March 31, 2021 and $87.0 million at March 31, 2020. The royalty rights agreements are accounted for separately as freestanding financial instruments. Consideration received for the debt and royalty rights was allocated to each component on a relative fair value basis. The difference between the relative fair value of the royalty rights agreements and the principle on the Secured Notes is accounted for as debt discount and amortized through non-cash interest expense over the life of the Secured Notes. Estimating the future cash outflows under the royalty rights agreements requires the Company to make certain estimates and assumptions about future sales of MosaiQ products. These estimates of the magnitude and timing of MosaiQ sales are subject to significant variability due to the current status of development of MosaiQ products, and thus are subject to significant uncertainty. Therefore, the estimates are likely to change as the Company gains experience of marketing MosaiQ, which may result in future adjustments to the accretion of the interest expense and amortized cost based carrying value of the royalty liability.

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Mar. 31, 2021
Fair Value Disclosures [Abstract]
Fair Value Measurements	Note 5. Fair Value Measurements Assets and liabilities measured and recorded at fair value on a recurring basis The following table summarizes the Company’s assets and liabilities that are measured at fair value on a recurring basis, by level, within the fair value hierarchy: March 31, 2021 Level 1 Level 2 Level 3 Total Assets: Pension plan assets ( 1) $ — $ 15,751 $ — $ 15,751 Short-term investments ( 2) — 15,000 — 15,000 Foreign currency forward contracts ( 3) $ — $ 355 $ — $ 355 Total assets measured at fair value $ — $ 31,106 $ — $ 31,106 March 31, 2020 Level 1 Level 2 Level 3 Total Assets: Pension plan assets ( 1) $ — $ 12,436 $ — $ 12,436 Short-term investments ( 2) 116,871 — — 116,871 Total assets measured at fair value $ 116,871 $ 12,436 $ — $ 129,307 March 31, 2020 Level 1 Level 2 Level 3 Total Liabilities: Foreign currency forward contracts ( 3) $ — $ 227 $ — $ 227 Total liabilities measured at fair value $ — $ 227 $ — $ 227 (1) The fair value of pension plan assets has been determined as the surrender value of the portfolio of active insured employees held within the AXA LLP Foundation Suisse Romande collective investment fund. (2) The fair value of short-term investments has been determined based on the quoted value of the units held in the money market fund at the balance sheet date. The short-term investments as of March 31, 2021, relate to new investments made in a Treasury Money Market Fund. See Note 1, “Summary of Significant Accounting Policies – Short-term Investments”. (3) The fair value of foreign currency forward contracts has been determined by calculating the present value of future cash flows, estimated using market-based observable inputs including forward and spot exchange rates and interest rate curves obtained from third party market price quotations. On March 12, 2021, the Company announced that two funds managed by CSAM in which the Company had invested an aggregate of approximately $110.35 million had suspended redemptions. The investments into these funds were made in accordance with the Company’s investment policy of making individual investments with a minimum of an A rating from a leading credit-rating agency. Each fund holds short-term credit obligations of various obligors. According to a press release issued by CSAM, redemptions in the funds were suspended because “certain part of the Subfunds’ assets is currently subject to considerable uncertainties with respect to their accurate valuation.” CSAM subsequently began a liquidation of the funds. Pursuant to the liquidation, the Company has already received cash distributions of approximately $75.6 million. Based on information provided by Credit Suisse, the Company expects to receive further cash distributions from the funds in the next several months; however, there can be no assurance as to the timing or amount of any such distributions. Credit Suisse has advised that the credit assets held by the funds are covered by insurance that potentially will be available to cover losses the funds would incur if any of the obligors on the funds’ credit assets were to default. On April 22, 2021, Credit Suisse published its FY 2021 Q1 press release with commentary related to the supply chain financing funds. Notably, Credit Suisse indicated that the investors in the funds should assume losses will be incurred. For the year ended March 31, 2021, Credit Suisse’s decision to liquidate funds in which the Company held short-term investments served as a trigger to evaluate the investments for impairment. Accordingly, we performed a qualitative assessment for impairment. As a result of this assessment, Quotient determined that an impairment was required. The Credit Suisse linked short-term investment asset with a carrying value of $110.3 million was written down to its estimated fair value of $108.0 million, resulting in an impairment of $2.3 million. This impairment was included in Other, net within our consolidated statements of comprehensive loss for the year ended March 31, 2021. The carrying value of the investments at March 31, 2021 was $51.0 million. The Company views the liquidation of the supply chain finance funds as a fluid situation with a significant amount of valuation uncertainty. The Company will closely monitor the situation and in the event that new information is released that provides valuation clarity, it will evaluate the accounting implications accordingly. The Company believes, and has advised Credit Suisse, that any losses on the supply chain funds should be borne by Credit Suisse. The Company will pursue all available options to recoup the full amount of its investment in the supply chain funds prior to liquidation. The total unrealized gains on the short-term investments were $734, $1,881 and $1,127 in financial years 2021, 2020 and 2019, respectively. The amount of these unrealized gains reclassified to earnings were $1,632, $1,327 and $331 in the financial years 2021, 2020 and 2019, respectively.

Consolidated Balance Sheet Deta

Consolidated Balance Sheet Detail	12 Months Ended
	Mar. 31, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Consolidated Balance Sheet Detail	Note 6. Inventory The following table summarizes inventory by category for the periods presented: March 31, 2021 March 31, 2020 Raw materials $ 9,189 $ 9,737 Work in progress 9,105 8,522 Finished goods 3,717 2,242 Total inventories $ 22,011 $ 20,501 Inventory at March 31, 2021 included $6,829 of raw materials, $4,321 of work in progress and $1,465 of finished goods related to the MosaiQ project. Inventory at March 31, 2020 included $8,093 of raw materials, $4,395 of work in progress, and $368 of finished goods related to the MosaiQ project. During the year ended March 31, 2021 the Company recorded inventory provisions of $2,015 in respect of certain raw materials and work-in-progress items related to the MosaiQ project following evaluation of further development data and corresponding changes in manufacturing processes. Property and equipment The following table summarizes property and equipment by categories for the periods presented: March 31, 2021 March 31, 2020 As Restated As Restated Plant and equipment $ 62,940 $ 57,726 Leasehold improvements $ 33,369 31,395 Total property and equipment 96,309 89,121 Less: accumulated depreciation (57,238 ) (48,681 ) Total property and equipment, net $ 39,071 $ 40,440 Depreciation expenses were $8,813, $12,457,and $12,663 in financial years 2021, 2020 and 2019, respectively. At the beginning of the year ended March 31, 2021, the Company reassessed the useful economic lives of equipment used in the production line at its facility in Eysins, Switzerland. Based on lower utilization rates than initially estimated, the remaining useful lives of the equipment was increased from 4 years to 6 years. The impact of these changes in remaining useful lives was to reduce the depreciation expenses for the year ended March 31, 2021 by $1,164. Accrued compensation and benefits Accrued compensation and benefits consist of the following: March 31, 2021 March 31, 2020 As Restated Salary and related benefits $ 666 $ 635 Accrued vacation 931 521 Accrued payroll taxes 1,765 1,200 Accrued incentive payments 5,392 3,700 Accrued termination and transition payments 3,589 1,154 Total accrued compensation and benefits $ 12,343 $ 7,210 In the year ended March 31, 2021 the Company incurred $3,825 in respect of transition arrangements with its new chief executive officer. Payments of $1,800 were made prior to March 31, 2021 and the remaining $2,025 is expected to be paid during the first quarter of the next financial year. The company also incurred $1,193 and $371 in respect of transition arrangements with its former chief executive officer and former chief operating officer, respectively, which are expected to be paid during the next financial year. In the year ended March 31, 2020, the Company incurred termination benefit costs of $1,323 in respect of a restructuring of its operations. The restructuring was completed during the year ended March 31, 2020. In the year ended March 31, 2020 the Company also incurred transition benefit costs of $807 in respect of the transitional arrangements with its former chief financial officer and its former group financial controller. Accrued expenses and other current liabilities Accrued expenses and other current liabilities consist of the following: March 31, 2021 March 31, 2020 As Restated Accrued legal and professional fees $ 1,005 $ 829 Accrued interest 8,009 8,056 Goods received not invoiced 1,722 1,724 Accrued capital expenditure 1,201 1,287 Other accrued expenses 2,072 3,594 Total accrued expenses and other current liabilities $ 14,009 $ 15,490

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Mar. 31, 2021
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 7. Hedging arrangements The Company’s subsidiary in the United Kingdom (“UK”) has entered into three foreign currency forward contracts to sell $500 and purchase pounds sterling at a rate of £1:$1.2630 in each calendar month from April 2021 through June 2021, three contracts to sell $500 in each calendar month from July 2021 through September 2021 at £1:$1.26, three contracts to sell $500 in each calendar month from October 2021 through December 2021 at £1:$1.3090, and three contracts to sell $500 in each calendar month from January 2022 through March 2022 at £1:$1.3735, as hedges of its U.S. dollar denominated revenues. The fair values of these contracts in place at March 31, 2021, and similar contracts in place at March 31, 2020, amounted to assets of $355 and liabilities of $227 respectively. The foreign currency forward contracts were entered into to mitigate the foreign exchange risk arising from the fluctuations in the value of U.S. dollar denominated transactions entered into by our UK subsidiary. These foreign currency forward contracts are designated as cash flow hedges and are carried on the Company’s balance sheet at fair value with the effective portion of the contracts’ gains or losses included in accumulated other comprehensive loss and subsequently recognized in revenue/expense in the same period the hedged items are recognized . Ortho Arbitration and Settlement The Company’s subsidiaries, Quotient Suisse and QBD (QS-IP) Limited were party to the Prior Ortho Agreement with Ortho related to the commercialization and distribution of certain MosaiQ products. See Note 1, “Summary of Significant Accounting Policies—Revenue Recognition,” for information regarding the Prior Ortho Agreement. The Company and an affiliate of Ortho also entered into a subscription agreement pursuant to which the affiliate subscribed for newly issued ordinary shares of the Company and newly issued 7% cumulative redeemable preference shares, of no On November 27, 2019, the Company delivered a notice to Ortho that it had terminated the Prior Ortho Agreement, effective as of December 27, 2019. The Company did not realize any revenue under the Prior Ortho Agreement prior to its termination. On or about November 17, 2019, Ortho initiated an arbitration proceeding in which it sought a declaration that the Company did not have the right to terminate the Prior Ortho Agreement, specific performance of certain provisions of the Prior Ortho Agreement, and damages including in respect of the difference in amounts Ortho invested in the Company’s shares and their market value. The Company pursued counterclaims against Ortho, including that it had the right to terminate the Prior Ortho Agreement and damages that included the milestone payments due under the Prior Ortho Agreement (see Note 1, "Summary of Significant Accounting Policies—Revenue Recognition," for details). In addition, on December 20, 2019, the Company entered into an agreement with Ortho pursuant to which it agreed, while the arbitration was pending, not to grant commercialization rights in respect of products that overlapped with Ortho’s rights under the Prior Ortho Agreement without prior written notice to Ortho. On September 4, 2020, the Company and Ortho entered into the Letter Agreement, pursuant to which the Company and Ortho agreed to confirm the termination of the Prior Ortho Agreement and various related contracts and to end the parties’ disputes regarding the Prior Ortho Agreement by executing mutual releases and terminating their pending arbitration proceeding related to the Prior Ortho Agreement. The Company and Ortho also agreed to negotiate in good faith, and use their respective reasonable best efforts to execute, the New Distribution Agreement based on the terms set forth in the Letter Agreement, but if for any reason no such definitive agreement is reached, the Letter Agreement will govern the parties’ respective rights and obligations as a binding contract. See Note 1, "Summary of Significant Accounting Policies—Revenue Recognition," for further details regarding the commercial terms included in the Letter Agreement. Purchase obligations The Company has purchase obligations that are associated with agreements for purchases of goods or services. Management believes that cancellation of these contracts is unlikely and thus the Company expects to make future cash payments according to the contract terms. The following is a schedule by years of purchase obligations as of March 31, 2021: 2022 $ 19,142 2023 13,480 2024 15,878 2025 17,301 2026 23,642 Thereafter — Total minimum future purchase obligations $ 89,443 The Company is also party to certain royalty arrangements related to net sales of MosaiQ products. These include a low single digit royalty to TTP plc based on our net sales of certain MosaiQ products for 20 years from first commercialization, or for so long as the licensed intellectual property is protected by patent in the country of sale, and a low single digit royalty to Catalloid Products, Inc. on net sales of MosaiQ Microarrays that would be covered by that royalty agreement, for a period of 10 years post launch of that Microarray.

Geographic Information

Geographic Information	12 Months Ended
	Mar. 31, 2021
Geographic Areas Revenues And Long Lived Assets [Abstract]
Geographic Information	Note 8. Geographic Information The Company operates in one business segment. Revenues are attributed to countries based on the location of the Company’s channel partners as well as direct customers. The following table represents revenue attributed to countries based on the location of the customer: Year ended March 31, 2021 2020 2019 Revenue: United States $ 28,135 $ 17,831 $ 14,754 France 7,406 7,105 6,501 Japan 4,506 4,333 3,846 Other foreign countries (1) 3,332 3,387 4,033 $ 43,379 $ 32,656 $ 29,134 (1) No individual country represented more than 10% of the respective totals. The table below lists the Company’s property and equipment, net of accumulated depreciation, by country. With the exception of property and equipment, the Company does not identify or allocate its assets by geographic area: March 31, 2021 March 31, 2020 As Restated As Restated Long-lived assets: United Kingdom $ 16,890 $ 17,388 Switzerland 22,181 23,052 $ 39,071 $ 40,440 Other income (expense), net includes foreign exchange gains and losses arising on the settlement of transactions in currencies other than the functional currencies of the entity concerned and from retranslation of assets and liabilities denominated in foreign currencies at period end rates. In the year ended March 31, 2021, there was a gain of $4,998. In the year ended March 31, 2020 there was a gain of $2,205 and in the year ended March 31, 2019 a loss of $5,984.

Ordinary and Preference Shares

Ordinary and Preference Shares	12 Months Ended
	Mar. 31, 2021
Equity [Abstract]
Ordinary and Preference Shares	Note 9. Ordinary shares The Company’s issued and outstanding ordinary shares consist of the following: Shares Issued and Outstanding March 31, 2021 March 31, 2020 Par value Ordinary shares 101,264,412 80,398,326 $ — Total 101,264,412 80,398,326 $ — On September 15, 2020, the Company completed a public offering of 20,294,117 newly issued ordinary shares at $4.25 per share which raised $86.3 million of gross proceeds before underwriting discounts and other offering expenses of $5.6 million. Preference shares The Company’s issued and outstanding preference shares consist of the following: Shares Issued and Outstanding Liquidation amount per share March 31, 2021 March 31, 2020 March 31, 2021 March 31, 2020 7% Cumulative Redeemable Preference shares 666,665 666,665 $ 32.21 $ 30.64 Total 666,665 666,665 The 7% Cumulative Redeemable Preference shares were issued to Ortho-Clinical Diagnostics Finco S.Á.R.L., an affiliate of Ortho on January 29, 2015 at a subscription price of $22.50 per share. These preference shares are redeemable at the request of the shareholder on the “Redemption Trigger Date” which is currently the date of the eighth anniversary of the date of issue of the preference shares, but the Company may further extend the redemption date in one year increments up to the tenth anniversary of the date of issue. Because the 7% Cumulative Redeemable Preference shares are redeemable at the option of the shareholders, they are shown as a liability in the Consolidated Balance Sheet.

Share-Based Compensation

Share-Based Compensation	12 Months Ended
	Mar. 31, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Share-Based Compensation	Note 10. Share-Based Compensation The Company records share-based compensation expense in respect of options and restricted share units (“RSUs”), issued under its share incentive plans and in respect of deferred shares issued to employees. Share-based compensation expense amounted to $4,984 in the year ended March 31, 2021, $4,467 in the year ended March 31, 2020 and $4,957 in the year ended March 31, 2019. Option Plans The 2012 Option Plan (the “Option Plan”) was designed in order to grant options on ordinary shares in the capital of the Company to certain of its directors and employees. The purpose of the Option Plan is to provide employees with an opportunity to participate directly in the growth of the value of the Company by receiving options for shares. Each option may be exercised for one ordinary share of the Company. The 2012 Option Plan was approved by the shareholders on February 16, 2012. The total number of shares in respect of which options may be granted under the 2012 Option Plan is limited at 839,509. Options that lapse or are forfeited are available to be granted again. Options generally vest over a period of three years but certain employees have shorter vesting periods. The contractual life of all options is 10 years. Options were not exercisable before the Company became a public company and all outstanding options become exercisable in the event of an acquisition of 75% or more of the share capital of the Company by a third party. No further awards will be granted under the 2012 Option Plan. The 2014 Stock Incentive Plan was approved by the directors and shareholders immediately prior to the Company’s initial public offering in April 2014. The 2014 Plan was designed to provide flexibility to attract and retain the services of qualified employees, officers, directors, consultants and other service providers upon whose judgment, initiative and efforts the successful conduct and development of the business depends, and to provide additional incentives to such persons to devote their effort and skill to the advancement and betterment of the Company, by providing them an opportunity to participate in the ownership of the Company and thereby have an interest in its success and increased value. Under the 2014 Plan, 1,500,000 ordinary shares were initially reserved for issuance. This number is subject to adjustment in the event of a recapitalization, share split, share consolidation, reclassification, share dividend or other change in the Company’s capital structure and automatically increases annually on April 1 of each year. A resolution passed at the Annual Shareholder meeting held on October 29, 2020 amended this annual automatic increase to 0.75 % of the number of ordinary shares issued and outstanding on the immediately preceding March 31, or such lesser number of shares as determined by the Board or the remuneration committee. The number of shares reserved for issuance under the plan was also increased by 750,000 as a result of a resolution passed at the Annual Shareholder meeting held on October 28, 2016 , by 550,000 as a result of a resolution passed at the Annual Shareholder meeting held on October 31, 2018 and by a further 750,000 as a result of a resolution passed at the Annual Shareholder meeting held on October 29, 2020 . The plan provides for the issuance of share options, restricted shares, RSUs (including multi-year performance based restricted share units or “ MRSUs ” ) or share appreciation rights (“SARs”). The Company has only issued options, RSUs and MRSUs under the plan prior to March 31, 20 2 1 . To the extent that an award terminates, or expires for any reason, then any shares subject to the award may be used again for new grants. However, shares which are ( i ) not issued or delivered as a result of the net settlement of outstanding SARs or options; (ii) used to pay the exercise price related to outstanding options; (iii) used to pay withholding taxes related to outstanding options or SARs; or (iv) repurchased on the open market with the proceeds from an option exercise, will not be available for grant under the 2014 Plan. Share option activity The following table summarizes share option activity: Number of Share Options Outstanding Weighted Average Exercise Price Weighted Average Remaining Contractual (Months) Outstanding — March 31, 2018 2,096,283 $ 7.79 84 Granted 189,552 6.59 120 Exercised (253,066 ) 5.14 — Forfeited (96,372 ) 12.69 — Outstanding — March 31, 2019 1,936,397 $ 7.77 78 Granted 110,623 8.44 120 Exercised (103,264 ) 4.77 — Forfeited (95,704 ) 12.53 — Outstanding — March 31, 2020 1,848,052 $ 7.73 70 Granted 258,026 5.38 120 Exercised (147,264 ) 1.18 — Forfeited (148,029 ) 10.76 — Outstanding — March 31, 2021 1,810,785 $ 7.69 68 Exercisable —March 31, 2021 1,497,464 $ 8.11 59 The following table summarizes the options granted in the year ended March 31, 2021 with their exercise prices, the fair value of ordinary shares as of the applicable grant date, and the intrinsic value, if any: Grant Date Number of Options Granted Exercise Price Ordinary Shares Fair Value Per Share at Grant Date Per Share Intrinsic Value of Options May 24, 2020 60,438 $ 7.69 $ 7.69 $ 4.96 September 1, 2020 (1) 45,922 4.81 4.81 3.07 October 29, 2020 81,666 4.55 4.55 2.93 October 31, 2020 70,000 4.72 4.72 3.05 (1) On September 1, 2020, in connection with the appointment of Dr Catherine Larue and Dr Isabelle Buckle to the Board of Directors, we granted each of Dr Larue and Dr Buckle 20,790 options to purchase ordinary shares at an exercise price of $4.81 per share. These grants, which were issued outside of our 2014 Stock Incentive Plan, were approved by our Board of Directors and the Remuneration Committee of our Board pursuant to the inducement grant exception under Nasdaq Rule 5635(c)(4), as an inducement that is material to Dr Larue and Dr Buckle joining our Board. The options vest in three equal installments on each first, second and third anniversary of the grant date. The options have a term of ten years and will be forfeited if not exercised before the expiration of their term. In addition, in the event Dr Larue’s or Dr Buckle’s Board service is terminated, any options not vested shall be forfeited upon termination . Determining the fair value of share options The fair value of each grant of share options was determined by the Company using the Black-Scholes options pricing model. The total fair value of option awards in the years ended March 31, 2021, March 31, 2020 and March 31, 2019 amounted to $889, $588 and $676, respectively. Assumptions used in the option pricing models are discussed below. Each of these inputs is subjective and generally requires significant judgment to determine. Expected volatility . The expected volatility was based on the historical share volatility of the Company’s ordinary shares over a period equal to the expected terms of the options. Fair value of ordinary shares. Since the Company’s initial public offering in April 2014, the fair value of ordinary shares has been based on the share price of the Company’s shares on the Nasdaq Global Market immediately prior to the grant of the options concerned. Risk-Free Interest Rate. The risk-free interest rate is based on the UK Government 10 year bond yield curve in effect at the time of grant prior to the initial public offering and 10 year U.S. Treasury Stock for awards from April 2014 onwards. Expected term. The expected term is determined after giving consideration to the contractual terms of the share-based awards, graded vesting schedules ranging from one to three years and expectations of future employee behavior as influenced by changes to the terms of its share-based awards. Expected dividend. According to the terms of the awards, the exercise price of the options is adjusted to take into account any dividends paid. As a result, dividends are not required as an input to the model, as these reductions in the share price are offset by a corresponding reduction in exercise price. A summary of the weighted-average assumptions applicable to the share options is as follows: Year ended March 31, 2021 2020 2019 Risk-free interest rate 0.77 % 1.84 % 3.08 % Expected lives (years) 6 6 6 Volatility 73.70 % 69.43 % 67.19 % Dividend yield — — — Grant date fair value (per share) $ 5.38 $ 8.44 $ 6.14 Number granted 258,026 110,623 189,552 RSU Activity A summary of the RSUs in issue at March 31, 2021 is as follows: Number of RSUs Outstanding Weighted Average Remaining Vesting Period (Months) Period in which the target must be achieved RSUs subject to time based vesting 783,759 10 N/A RSUs subject to milestone based vesting 118,650 N/A N/A At March 31, 2021, 783,759 RSUs were subject to time based vesting and the weighted average remaining vesting period was 10 months. In addition, 118,650 RSUs were subject to vesting based on the achievement of various milestones relating to the development, approval and marketing of MosaiQ. The fair value of the Company’s ordinary shares was $3.68 per share on March 31, 2021. As of March 31, 2021, total compensation cost related to share options and RSUs granted but not yet recognized was $4,608 net of estimated forfeitures. This cost will be amortized to expense over a weighted average remaining period of 18 months and will be adjusted for subsequent changes in estimated forfeitures.

Income Taxes

Income Taxes	12 Months Ended
	Mar. 31, 2021
Income Tax Disclosure [Abstract]
Income Taxes	Note 11. Income Taxes The components of the provision for income taxes are as follows: Year ended March 31, 2021 2020 2019 Income tax (provision) benefit: As Restated As Restated As Restated Current - Federal $ (126 ) $ — $ — Deferred - Federal (1,128 ) (58 ) (30 ) $ (1,254 ) $ (58 ) $ (30 ) The statutory standard corporate income tax rate of the Company in Jersey is 0%. Utilization of the net operating losses carried forward against the profits of the subsidiary in the year ended March 31, 2019 resulted in a reduction in the deferred tax asset of $30, with a corresponding provision for income taxes of the same amount. In connection with the sale and leaseback transaction of the Company’s conventional reagents manufacturing facility, near Edinburgh, Scotland (the “Alan Robb Campus (“ARC”) facility”) that was completed in March 2018, the Company has agreed to transfer tax allowances related to certain other property, plant and equipment to the purchaser of the facility. An election to effect the transfer of these allowances to the purchaser has been made, but due to uncertainty regarding whether the election will be effective, the tax effect of the transfer of the allowances had not previously been recorded in the financial statements. The Company has determined that during the year ended March 31, 2021 it is now more likely than not that this election will be effective and accordingly a net deferred tax expense of $1,200 and an equivalent deferred tax liability have been recorded, including associated adjustments to valuation allowances. A reconciliation of the income tax expense at the statutory rate to the provision for income taxes is as follows: Year ended March 31, 2021 2020 2019 As Restated As Restated As Restated Income tax expense at statutory rate $ — $ — $ — Impact of tax uncertainties (1,200 ) — 14 Foreign tax rate differential 2,362 2,255 5,287 (Increase) decrease in valuation allowance against deferred tax assets (2,416 ) (2,313 ) (5,331 ) Provision for income tax $ (1,254 ) $ (58 ) $ (30 ) Significant components of deferred tax assets are as follows: March 31, 2021 March 31, 2020 As Restated As Restated Provisions and reserves $ 1,022 $ 1,315 Operating lease liability 4,100 3,409 Fixed asset basis difference — — Research and development 672 — Net operating loss carry forwards 22,628 19,526 Gross deferred tax assets 28,422 24,250 Fixed asset basis difference (2,289 ) (90 ) Operating lease right-of-use assets (4,100 ) (3,409 ) Gross deferred tax liabilities (6,389 ) (3,499 ) Net deferred tax asset 22,033 20,751 Valuation allowance (22,930 ) (20,514 ) Net deferred taxes $ (897 ) $ 237 The balance sheet classification of net deferred tax assets is as follows: March 31, 2021 March 31, 2020 As Restated As Restated Net noncurrent deferred tax assets $ 255 $ 237 Net noncurrent deferred tax liabilities $ (1,152 ) $ — Total $ (897 ) $ 237 The Company maintains a valuation allowance on net operating losses and other deferred tax assets in jurisdictions for which it does not believe it is more-likely-than-not to realize those deferred tax assets based upon all available positive and negative evidence, including historical operating performance, carryback periods, reversal of taxable temporary differences, tax planning strategies, and earnings expectations. As of March 31, 2021, the Company has net operating loss carry forwards of approximately $286,595 which will be available to offset future taxable income. If not used, losses with a tax effect of approximately $22,354 will expire between 2022 and 2028. The remaining portion of the carry forward losses arose in jurisdictions where losses do not expire. During the fiscal year the United Kingdom government announced an increase to the rate of corporate income tax to 25%, effective from April 1, 2023. These changes were not substantively enacted at the balance sheet date and is therefore not reflected in the measurement of deferred tax for the year ended March 31, 2021. The Company has estimated that if the United Kingdom deferred tax balances at March 31, 2021 that are expected to unwind after April 1, 2023 were remeasured at 25%, this would result in an increase in the net deferred tax liability and an equivalent deferred tax expense of $576. The following table summarizes the activity related to the Company’s uncertain tax positions (excluding interest and penalties and related tax attributes): 2021 2020 2019 As Restated As Restated As Restated Balance at beginning of year $ 1,216 $ 603 $ 617 Increases related to current year tax positions — 613 (14 ) Increases related to prior years tax positions — — — Balance at end of year $ 1,216 $ 1,216 $ 603 As of March 31, 2021, 2020, and 2019 the Company has an unrecognized benefit of $1,216, $1,216, and $603 respectively, that if recognized would be recorded as a component of tax expense. The Company’s unrecognized tax benefits include exposures related to positions taken on all jurisdictions’ income tax returns. The Company has interest expense carryforward from March 31, 2017 that potentially would be disqualified as interest expense in the amount of $613. Additionally, the Company has reassessed its transfer pricing policies in certain jurisdictions from 2015 to 2017, the impact of which is $603. In the normal course of business, the Company’s tax returns are subject to examination by various taxing authorities. Such examinations may result in future tax and interest assessments by these taxing authorities and the Company has accrued a liability when it believes it is more likely than not that the tax position claimed on tax returns will not be sustained by the taxing authorities on the technical merits of the position. Changes in the recognition of the liability are reflected in the period in which the change in judgment occurs. The Company files separate company income tax returns in its domestic and foreign jurisdictions. All necessary income tax filings in all jurisdictions have been completed for all years up to and including March 31, 2020 and there are no ongoing tax examinations in any jurisdiction. The Company recognizes interest and penalties accrued related to unrecognized tax benefits in tax expense. During the fiscal years ended March 31, 2021, March 31, 2020 and March 31, 2019, the Company had no amounts accrued for interest and penalties. The Company does not currently anticipate that the total amount of unrecognized tax benefits will result in material changes to its financial position within the next 12 months. No tax charge arose on any element of other comprehensive loss.

Pension Plans

Pension Plans	12 Months Ended
	Mar. 31, 2021
Defined Benefit Plan Net Periodic Benefit Cost [Abstract]
Pension Plans	Note 12. The Company operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the Company in an independently administered fund. The pension cost charge represents the contribution payable by the Company to the fund during the year. Defined contribution pension costs during the years ended March 31, 2021, 2020 and 2019 amounted to $581, $963 and $750, respectively. In addition, These circumstances require that the Swiss employee pension arrangements be treated as a defined benefit plan under ASC 715 Compensation – Retirement Benefits The following provides a reconciliation of the benefit obligations, the plan assets and the funded status. Year ended March 31, 2021 March 31, 2020 As Restated As Restated Pension benefit obligation, beginning of year $ 18,789 $ 17,784 Service cost 2,272 2,003 Contributions paid by plan participants 2,704 2,180 Interest cost 126 131 Benefits paid (2,207 ) (2,841 ) Prior service cost — 836 Actuarial loss / (gain) 648 (1,915 ) Foreign currency translation 316 611 Pension benefit obligation, end of year $ 22,648 $ 18,789 The actuarial losses on the projected benefit obligation as at March 31, 2021 result in part from changes in the assumptions compared to those adopted at March 31, 2020. There was a loss due to decrease in the discount rate assumption, which was offset by a gain due to changing the base mortality tables from BVG2015 to BVG2020 tables. A further loss due to experience resulted in an overall net actuarial loss to March 31, 2021. The experience loss can be attributed to the membership movements during the financial year. Year ended March 31, 2021 March 31, 2020 Fair value of plan assets, beginning of year $ 12,436 $ 10,416 Actual return on plan assets 1,293 1,008 Contributions paid by employer 1,333 1,280 Contributions paid by plan participants 2,704 2,180 Benefits paid (2,207 ) (2,841 ) Foreign currency translation 192 393 Fair value of plan assets, end of year $ 15,751 $ 12,436 Contributions paid by plan participants include $1,768 and $1,375 of payments into the scheme on new employees joining in the years ended March 31, 2021 and March 31, 2020, respectively. Year ended March 31, 2021 March 31, 2020 Pension benefit obligation, end of year $ 22,648 $ 18,789 Fair value of plan assets, end of year 15,751 12,436 Net funding obligation, end of year $ 6,897 $ 6,353 The assumptions used to determine the pension benefit obligation at the end of each financial year are: Year ended March 31, 2021 March 31, 2020 March 31, 2019 Price inflation 1.00 % 1.00 % 1.00 % Discount rate 0.35 % 0.60 % 0.70 % Interest rate on retirement savings capital 0.60 % 0.60 % 1.20 % Expected return on plan assets 1.75 % 1.75 % 1.20 % Average rate of salary increase 1.00 % 1.00 % 1.00 % Each employee participating in the plan has an individual portfolio that is managed by AXA under a collective arrangement. Plan assets comprise the surrender value of the portfolio of active insured scheme participants. The expected return on plan assets was determined after consideration of current and historical levels of return and discussions with AXA. The discount rate is based on bond yields at March 31, 2021 and March 31, 2020 of high quality corporate bonds taking into account the duration of the liabilities. The net pension costs for the year are based on the assumptions adopted at the start of each financial year and comprise: Year ended March 31, 2021 March 31, 2020 March 31, 2019 As Restated As Restated Employer service cost $ 2,272 $ 2,003 $ 1,574 Interest cost 126 131 153 Expected return on plan assets (243 ) (130 ) (131 ) Amortization of prior service credit 58 (23 ) (14 ) Amortization of net loss — 216 154 Net pension cost $ 2,213 $ 2,197 $ 1,736 The provision for pension benefit obligation recognized in other comprehensive income comprises: Year ended As Restated As Restated March 31, 2021 March 31, 2020 March 31, 2019 Net actuarial (gain) / loss $ (389 ) $ (2,016 ) $ 1,027 Amortization of prior service credit (58 ) 23 14 Amortization of net loss — (216 ) (154 ) $ (447 ) $ (2,209 ) $ 887 The cumulative amounts recognized in other comprehensive income were $3,035 and $3,482 at March 31, 2021 and March 31, 2020 respectively. This represented a net loss of $2,431 and $2,819 at March 31, 2021 and March 31, 2020 respectively and a prior service cost of $605 at March 31, 2021 and $663 at March 31, 2020. The following benefit payments are expected to be paid in the following periods: 2022 $ 1,122 2023 $ 1,161 2024 $ 1,178 2025 $ 1,199 2026 $ 1,215 2027 to 2030 $ 6,397 Expected annual employer contributions to the plan in the year ending March 31, 2022 amount to $1,436.

Net Loss Per Share

Net Loss Per Share	12 Months Ended
	Mar. 31, 2021
Earnings Per Share [Abstract]
Net Loss Per Share	Note 13. In accordance with ASC 260 Earnings Per Share The following table sets forth the computation of basic loss per ordinary share. Diluted earnings per share figures are not applicable due to losses. Year ended March 31, 2021 2020 2019 As Restated As Restated As Restated Numerator: Net loss $ (111,032 ) $ (105,138 ) $ (106,411 ) Net loss available to ordinary shareholders - basic and diluted $ (111,032 ) $ (105,138 ) $ (106,411 ) Denominator: Weighted-average shares outstanding - basic and diluted 91,637,966 71,610,035 54,874,391 Loss per share - basic and diluted $ (1.21 ) $ (1.47 ) $ (1.94 ) The following sets out the numbers of the options, RSUs and warrants to purchase ordinary shares excluded from the above computation of earnings per share for the years ended March 31, 2021, March 31, 2020 and March 31, 2019, as their inclusion would have been anti-dilutive. March 31, 2021 March 31, 2020 March 31, 2019 Ordinary shares issuable on exercise of options to purchase ordinary shares 1,810,785 1,848,052 1,936,397 Restricted share units awarded 902,409 694,347 966,689 Ordinary shares issuable on exercise of warrants at $16.14 per share 111,525 111,525 111,525 Ordinary shares issuable on exercise of warrants at $9.375 per share 64,000 64,000 64,000 2,888,719 2,717,924 3,078,611

Lease Commitments

Lease Commitments	12 Months Ended
	Mar. 31, 2021
Leases [Abstract]
Lease Commitments	14. Lease Commitments The Company has operating lease commitments for real estate and certain equipment in the United States, the United Kingdom, the Republic of Ireland and Switzerland. There are no sublease agreements in place. The Company has finance lease commitments for equipment in the United Kingdom and Switzerland. The Company leases an 87,200 square foot conventional reagents manufacturing facility, the ARC facility, with integrated offices and laboratories, in Edinburgh, Scotland. This lease commenced in March 2018, following completion of a sale and leaseback transaction, and expires in September 2052. Rent is recognized in the consolidated statement of comprehensive loss on a straight-line basis over the lease term. Additionally, the lease required the Company to provide a rent deposit of £3.6 million, which amounted to $5.0 million at March 31, 2021 and $4.5 million at March 31, 2020, and is included within other non-current assets in the consolidated balance sheets. In March 2015, the Company signed a five-year five-year three-year The operating lease commitments relating to equipment are not material. The finance lease commitments relate to specialized equipment required for manufacturing operations in both Edinburgh, Scotland and Eysins, Switzerland. Many of the Company’s leases contain options to renew and extend lease terms and options to terminate leases early. Reflected in the right-of-use asset and lease liability on the Company’s balance sheet are the periods provided by renewal and extension options that the Company is reasonably certain to exercise, as well as the periods provided by termination options that the Company is reasonably certain not to exercise. The Company does not have any existing lease agreements with variable lease components. In calculating the present value of future lease payments, the Company has elected to utilize its incremental borrowing rate based on the remaining lease term at the date of adoption. Incremental borrowing rates are the rates incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. The Company has elected to account for each lease component and its associated non-lease component as a single lease component and has allocated all the contract consideration across the lease component only. There are no material non-lease components. As of March 31, 2021, an operating lease right-of-use asset of $22,011 and an operating lease liability of $24,354 (including a current portion of $3,446) were reflected on the consolidated balance sheet. As of March 31, 2020, an operating lease right-of-use asset of $21,493 and an operating lease liability of $22,947 (including a current portion of $3,033) were reflected on the consolidated balance sheet. As of March 31, 2021, the Company had entered into finance leases for the purchase of plant and equipment that had net book values of $1,384. An associated finance lease liability of $1,280 (including a current portion of $835) was reflected on the consolidated balance sheet. As of March 31, 2020, the Company had entered into finance leases for the purchase of plant and equipment that had net book values of $2,126. An associated finance lease liability of $1,715 (including a current portion of $598) was reflected on the consolidated balance sheet. The elements of lease expense were as follows: Year ended March 31, 2021 2020 Operating lease cost $ 4,414 $ 3,694 Finance lease cost Amortization of right-of-use asset 998 832 Interest on lease liabilities 129 119 Short-term lease cost 62 69 Total lease cost $ 5,603 $ 4,714 Other information related to leases was as follows: Year ended March 31, 2021 2020 Cash paid for amounts included in the measurement of lease liabilities Operating leases - operating cash flows $ 3,793 $ 3,043 Finance leases - financing cash flows $ 633 $ 524 Finance leases - operating cash flows $ 129 $ 119 Non-cash leases activity Right-of-use assets obtained in exchange for new operating lease liabilities $ 332 $ 5,160 Right-of-use assets obtained in exchange for new finance lease liabilities $ 130 $ 969 As of March 31, 2021 As of March 31, 2020 Weighted average remaining lease terms (in years) Operating leases 29.5 30 Finance leases 1.6 2.3 Weighted average discount rate Operating leases 10.9 % 10.8 % Finance leases 9.1 % 4.5 % Future lease payments required under non-cancellable operating leases in effect as of March 31, 2021 were as follows: March 31, 2021 March 31, 2020 2022 $ 3,819 $ 3,335 2023 3,295 3,319 2024 3,285 3,050 2025 3,334 3,055 2026 2,237 3,105 Thereafter 71,347 66,138 Total lease payments $ 87,317 $ 82,002 Less : imputed interest (62,963 ) (59,055 ) Total operating lease liabilities $ 24,354 $ 22,947 Future lease payments required under finance leases in effect as of March 31, 2021 were as follows: March 31, 2021 March 31, 2020 2022 $ 935 $ 720 2023 422 838 2024 42 349 2025 12 7 2026 — — Total lease payments 1,411 1,914 Less : imputed interest (131 ) (199 ) Total finance lease liabilities $ 1,280 $ 1,715

Subsequent Events

Subsequent Events	12 Months Ended
	Mar. 31, 2021
Subsequent Events [Abstract]
Subsequent Events	15. Subsequent Events

Restatement of Previously Issue

Restatement of Previously Issued Unaudited Condensed Consolidated Financial Statements	12 Months Ended
	Mar. 31, 2021
Accounting Changes And Error Corrections [Abstract]
Restatement of Previously Reported Consolidated Financial Statements	Note 2. Restatement of Previously Reported Consolidated Financial Statements Restatement In connection with the preparation of the Company’s unaudited consolidated financial statements for the fiscal quarter ended September 30, 2021 , management of the Company identified an error related to the accounting of the Senior Secured Notes and royalty rights agreements originating in October 2016, August 2018, and June 2019. Specifically, management of the Company determined that it did not identify the correct accounting treatment at the time of entering into these transactions, and accounted for these instruments on a combined basis instead of treating these as separate freestanding financial instruments. Description of Misstatements (A) The Company historically accounted for its term debt and royalty rights agreements on a combined basis instead of separately recognizing them as standalone financial instruments. Over time, the subsequent accounting on a standalone basis differed from the combined accounting treatment and resulted in an increase to Interest expense, increase to long-term debt, and increase or decrease to foreign exchange gains/(losses) over the impacted periods. (B) Over recognition of depreciation expense related to specific property and equipment. The Company has recorded adjustments to recognize these amounts in the appropriate period(s). (C) Under-accrual for fringe benefits and taxes associated with employee compensation arrangements. The Company has recorded adjustments to recognize these amounts in the appropriate period(s). (D) Adjustment to recognize the foreign currency impact of certain immaterial monetary items within Other, net previously recognized in Foreign currency gain (loss) (E) The Company recognized an out of period adjustment for deferred tax assets related to certain research and development initiatives. (F) Correction of other immaterial errors. March 31, 2021 As previously Reported Restatement Impacts Restatement Reference As Restated ASSETS Current assets: Cash and cash equivalents $ 45,673 $ — $ 45,673 Short-term investments 65,999 — 65,999 Trade accounts receivable, net 5,323 — 5,323 Inventories 22,011 — 22,011 Prepaid expenses and other current assets 4,870 — 4,870 Total current assets 143,876 — 143,876 Restricted cash 9,024 — 9,024 Property and equipment, net 38,530 541 (B) 39,071 Operating lease right-of-use assets 22,011 — 22,011 Intangible assets, net 619 — 619 Deferred income taxes 255 — 255 Other non-current assets 4,956 — 4,956 Total assets $ 219,271 $ 541 $ 219,812 LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIT) Current liabilities: Accounts payable $ 4,659 $ — $ 4,659 Accrued compensation and benefits 11,833 510 (C) 12,343 Accrued expenses and other current liabilities 13,889 120 (F) 14,009 Current portion of long-term debt 24,167 — 24,167 Current portion of operating lease liability 3,446 — 3,446 Current portion of finance lease obligation 835 — 835 Total current liabilities 58,829 630 59,459 Long-term debt, less current portion 137,936 7,123 (A) 145,059 Operating lease liability, less current portion 20,907 — 20,907 Finance lease obligation, less current portion 445 — 445 Deferred income taxes 1,824 (672 ) (E) 1,152 Defined benefit pension plan obligation 6,896 — 6,896 7% Cumulative redeemable preference shares 21,475 — 21,475 Total liabilities 248,312 7,081 255,393 Commitments and contingencies — — — Shareholders' equity (deficit): Ordinary shares ( nil 540,813 — 540,813 Additional paid in capital 38,116 — 38,116 Accumulated other comprehensive loss (16,065 ) 1,467 (D) (14,598 ) Accumulated deficit (591,905 ) (8,007 ) (A)(B)(C)(D)(E)(F) (599,912 ) Total shareholders' equity (deficit) (29,041 ) (6,540 ) (35,581 ) Total liabilities and shareholders' equity (deficit) $ 219,271 $ 541 $ 219,812 March 31, 2020 As previously Reported Restatement Impacts Restatement Reference As Restated ASSETS Current assets: Cash and cash equivalents $ 3,923 $ — $ 3,923 Short-term investments 116,871 — 116,871 Trade accounts receivable, net 5,402 — 5,402 Inventories 20,501 — 20,501 Prepaid expenses and other current assets 3,775 — 3,775 Total current assets 150,472 — 150,472 Restricted cash 9,017 — 9,017 Property and equipment, net 40,165 275 (B) 40,440 Operating lease right-of-use assets 21,493 — 21,493 Intangible assets, net 625 — 625 Deferred income taxes 237 — 237 Other non-current assets 4,454 — 4,454 Total assets $ 226,463 $ 275 $ 226,738 LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIT) Current liabilities: Accounts payable $ 4,826 $ — $ 4,826 Accrued compensation and benefits 7,210 — 7,210 Accrued expenses and other current liabilities 15,490 — 15,490 Current portion of long-term debt — — — Current portion of operating lease liability 3,033 — 3,033 Current portion of finance lease obligation 598 — 598 Total current liabilities 31,157 — 31,157 Long-term debt, less current portion 153,024 3,237 (A) 156,261 Operating lease liability, less current portion 19,914 — 19,914 Finance lease obligation, less current portion 1,117 — 1,117 Deferred income taxes — — — Defined benefit pension plan obligation 6,353 — 6,353 7% Cumulative redeemable preference shares 20,425 — 20,425 Total liabilities 231,990 3,237 235,227 Commitments and contingencies — — — Shareholders' equity (deficit): Ordinary shares ( nil 459,931 — 459,931 Additional paid in capital 33,132 — 33,132 Accumulated other comprehensive loss (15,155 ) 2,483 (D) (12,672 ) Accumulated deficit (483,435 ) (5,445 ) (A)(B)(D) (488,880 ) Total shareholders' equity (deficit) (5,527 ) (2,962 ) (8,489 ) Total liabilities and shareholders' equity (deficit) $ 226,463 $ 275 $ 226,738 Year ended March 31, 2021 As previously Reported Restatement Impacts Restatement Reference As Restated Revenue: Product sales $ 35,787 $ — $ 35,787 Other revenues 7,592 — 7,592 Total revenue 43,379 — 43,379 Cost of revenue (20,074 ) — (20,074 ) Gross profit 23,305 — 23,305 Operating expenses: Sales and marketing (9,849 ) — (9,849 ) Research and development, net of government grants (54,168 ) 441 (B)(F) (53,727 ) General and administrative expense: Compensation expense in respect of share options and management equity incentives (4,984 ) — (4,984 ) Other general and administrative expenses (36,812 ) (630 ) (C)(F) (37,442 ) Total general and administrative expense (41,796 ) (630 ) (42,426 ) Total operating expense (105,813 ) (189 ) (106,002 ) Operating loss (82,508 ) (189 ) (82,697 ) Other income (expense): Interest expense, net (25,918 ) (3,886 ) (A) (29,804 ) Other, net 1,882 841 (D) 2,723 Other income (expense), net (24,036 ) (3,045 ) (27,081 ) Loss before income taxes (106,544 ) (3,234 ) (109,778 ) Provision for income taxes (1,926 ) 672 (E) (1,254 ) Net loss $ (108,470 ) $ (2,562 ) $ (111,032 ) Other comprehensive income (loss): Change in fair value of effective portion of foreign currency cash flow hedges $ 582 $ — $ 582 Unrealized gain (loss) on short-term investments (898 ) — (898 ) Foreign currency gain (loss) (1,216 ) (841 ) (D) (2,057 ) Provision for pension benefit obligation 622 (175 ) (F) 447 Other comprehensive loss, net (910 ) (1,016 ) (1,926 ) Comprehensive loss $ (109,380 ) $ (3,578 ) $ (112,958 ) Net loss available to ordinary shareholders - basic and diluted $ (108,470 ) $ (2,562 ) $ (111,032 ) Loss per share - basic and diluted $ (1.18 ) $ (0.03 ) $ (1.21 ) Weighted-average shares outstanding - basic and diluted 91,637,966 — 91,637,966 Year ended March 31, 2020 As previously Reported Restatement Impacts Restatement Reference As Restated Revenue: Product sales $ 31,601 $ — $ 31,601 Other revenues 1,055 — 1,055 Total revenue 32,656 — 32,656 Cost of revenue (17,800 ) — (17,800 ) Gross profit 14,856 — 14,856 Operating expenses: Sales and marketing (9,853 ) — (9,853 ) Research and development, net of government grants (53,744 ) 306 (B)(F) (53,438 ) General and administrative expense: Compensation expense in respect of share options and management equity incentives (4,467 ) — (4,467 ) Other general and administrative expenses (27,483 ) — (27,483 ) Total general and administrative expense (31,950 ) — (31,950 ) Total operating expense (95,547 ) 306 (95,241 ) Operating loss (80,691 ) 306 (80,385 ) Other income (expense): Interest expense, net (23,859 ) (3,041 ) (A) (26,900 ) Other, net 2,438 (233 ) (D) 2,205 Other income (expense), net (21,421 ) (3,274 ) (24,695 ) Loss before income taxes (102,112 ) (2,968 ) (105,080 ) Provision for income taxes (661 ) 603 (E) (58 ) Net loss $ (102,773 ) $ (2,365 ) $ (105,138 ) Other comprehensive income (loss): Change in fair value of effective portion of foreign currency cash flow hedges $ (157 ) $ — $ (157 ) Unrealized gain (loss) on short-term investments 554 — 554 Foreign currency gain (loss) (2,702 ) 233 (D) (2,469 ) Provision for pension benefit obligation 2,034 175 (F) 2,209 Other comprehensive loss, net (271 ) 408 137 Comprehensive loss $ (103,044 ) $ (1,957 ) $ (105,001 ) Net loss available to ordinary shareholders - basic and diluted $ (102,773 ) $ (2,365 ) $ (105,138 ) Loss per share - basic and diluted $ (1.44 ) $ (0.03 ) $ (1.47 ) Weighted-average shares outstanding - basic and diluted 71,610,035 — 71,610,035 Year ended March 31, 2019 As previously Reported Restatement Impacts Restatement Reference As Restated Revenue: Product sales $ 28,665 $ — $ 28,665 Other revenues 469 — 469 Total revenue 29,134 — 29,134 Cost of revenue (17,230 ) — (17,230 ) Gross profit 11,904 — 11,904 Operating expenses: Sales and marketing (8,637 ) — (8,637 ) Research and development, net of government grants (50,677 ) (206 ) (B) (50,883 ) General and administrative expense: Compensation expense in respect of share options and management equity incentives (4,957 ) — (4,957 ) Other general and administrative expenses (26,588 ) — (26,588 ) Total general and administrative expense (31,545 ) — (31,545 ) Total operating expense (90,859 ) (206 ) (91,065 ) Operating loss (78,955 ) (206 ) (79,161 ) Other income (expense): Interest expense, net (20,018 ) (259 ) (A) (20,277 ) Other, net (6,369 ) (574 ) (D) (6,943 ) Other income (expense), net (26,387 ) (833 ) (27,220 ) Loss before income taxes (105,342 ) (1,039 ) (106,381 ) Provision for income taxes (44 ) 14 (E) (30 ) Net loss $ (105,386 ) $ (1,025 ) $ (106,411 ) Other comprehensive income (loss): Change in fair value of effective portion of foreign currency cash flow hedges $ (123 ) $ — $ (123 ) Unrealized gain (loss) on short-term investments 796 — 796 Foreign currency gain (loss) 1,964 574 (D) 2,538 Provision for pension benefit obligation (887 ) — (887 ) Other comprehensive loss, net 1,750 574 2,324 Comprehensive loss $ (103,636 ) $ (451 ) $ (104,087 ) Net loss available to ordinary shareholders - basic and diluted $ (105,386 ) $ (1,025 ) $ (106,411 ) Loss per share - basic and diluted $ (1.92 ) $ (0.02 ) $ (1.94 ) Weighted-average shares outstanding - basic and diluted 54,874,391 — 54,874,391 Ordinary shares Shares Amount Additional paid in Capital Accumulated Other Comprehensive Loss Accumulated Deficit Total Shareholders' Equity (Deficit) As Previously Reported March 31, 2018 45,646,424 253,934 23,708 (16,634 ) (275,639 ) (14,631 ) Issue of shares, net of issue costs of $4,052 19,635,068 113,724 — — — 113,724 Issue of shares upon exercise of incentive share options and vesting of RSUS 618,955 1,300 — — — 1,300 Net loss — — — — (105,386 ) (105,386 ) Change in fair value of the effective portion of foreign currency cash flow hedges — — — (123 ) — (123 ) Change in unrealized gain in short-term investments — — — 796 — 796 Foreign currency gain (loss) on: Long-term investment nature intra-entity balances — — — 5,074 — 5,074 Retranslation of foreign entities — — — (3,110 ) — (3,110 ) Provision for pension benefit obligation — — — (887 ) — (887 ) Other comprehensive loss 1,750 1,750 Stock-based compensation — — 4,957 — — 4,957 March 31, 2019 65,900,447 368,958 28,665 (14,884 ) (381,025 ) 1,714 Restatement Impacts March 31, 2018 — — — 1,501 (2,055 ) (554 ) Issue of shares, net of issue costs of $4,052 — — — — — — Issue of shares upon exercise of incentive share options and vesting of RSUS — — — — — — Net loss — — — — (1,025 ) (1,025 ) Change in fair value of the effective portion of foreign currency cash flow hedges — — — — — — Change in unrealized gain in short-term investments — — — — — — Foreign currency gain (loss) on: Long-term investment nature intra-entity balances — — — — — — Retranslation of foreign entities — — — 574 — 574 Provision for pension benefit obligation — — — — — — Other comprehensive loss 574 574 Stock-based compensation — — — — — — March 31, 2019 — — — 2,075 (3,080 ) (1,005 ) As Restated March 31, 2018 45,646,424 253,934 23,708 (15,133 ) (277,694 ) (15,185 ) Issue of shares, net of issue costs of $4,052 19,635,068 113,724 — — — 113,724 Issue of shares upon exercise of incentive share options and vesting of RSUS 618,955 1,300 — — — 1,300 Net loss — — — — (106,411 ) (106,411 ) Change in fair value of the effective portion of foreign currency cash flow hedges — — — (123 ) — (123 ) Change in unrealized gain in short-term investments — — — 796 — 796 Foreign currency gain (loss) on: — Long-term investment nature intra-entity balances — — — 5,074 — 5,074 Retranslation of foreign entities — — — (2,536 ) — (2,536 ) Provision for pension benefit obligation — — — (887 ) — (887 ) Other comprehensive loss 2,324 2,324 Stock-based compensation — — 4,957 — — 4,957 March 31, 2019 65,900,447 368,958 28,665 (12,809 ) (384,105 ) 709 Ordinary shares Shares Amount Additional paid in Capital Accumulated Other Comprehensive Loss Accumulated Deficit Total Shareholders' Equity (Deficit) As Previously Reported March 31, 2019 65,900,447 $ 368,958 $ 28,665 $ (14,884 ) $ (381,025 ) $ 1,714 Issue of shares, net of issue costs of $6,072 13,800,000 90,528 — — — 90,528 Issue of shares upon exercise of incentive share options and vesting of RSUS 697,879 445 — — — 445 Net loss — — — — (102,773 ) (102,773 ) Change in fair value of the effective portion of foreign currency cash flow hedges — — — (157 ) — (157 ) Change in unrealized gain in short-term investments — — — 554 — 554 Foreign currency gain (loss) on: Long-term investment nature intra-entity balances — — — 18,394 — 18,394 Retranslation of foreign entities — — — (21,096 ) — (21,096 ) Provision for pension benefit obligation — — — 2,034 — 2,034 Other comprehensive loss (271 ) (271 ) Stock-based compensation — — 4,467 — — 4,467 Cumulative effect of accounting changes — — — 363 363 March 31, 2020 80,398,326 459,931 33,132 (15,155 ) (483,435 ) (5,527 ) Restatement Impacts March 31, 2019 — $ — $ — $ 2,075 $ (3,080 ) $ (1,005 ) Issue of shares, net of issue costs of $6,072 — — — — — — Issue of shares upon exercise of incentive share options and vesting of RSUS — — — — — — Net loss — — — — (2,365 ) (2,365 ) Change in fair value of the effective portion of foreign currency cash flow hedges — — — — — — Change in unrealized gain in short-term investments — — — — — — Foreign currency gain (loss) on: Long-term investment nature intra-entity balances — — — — — — Retranslation of foreign entities — — — 233 — 233 Provision for pension benefit obligation — — — 175 — 175 Other comprehensive loss 408 408 Stock-based compensation — — — — — — Cumulative effect of accounting changes — — — — — — March 31, 2020 — — — 2,483 (5,445 ) (2,962 ) As Restated March 31, 2019 65,900,447 $ 368,958 $ 28,665 $ (12,809 ) $ (384,105 ) $ 709 Issue of shares, net of issue costs of $6,072 13,800,000 90,528 — — — 90,528 Issue of shares upon exercise of incentive share options and vesting of RSUS 697,879 445 — — — 445 Net loss — — — — (105,138 ) (105,138 ) Change in fair value of the effective portion of foreign currency cash flow hedges — — — (157 ) — (157 ) Change in unrealized gain in short-term investments — — — 554 — 554 Foreign currency gain (loss) on: Long-term investment nature intra-entity balances — — — 18,394 — 18,394 Retranslation of foreign entities — — — (20,863 ) — (20,863 ) Provision for pension benefit obligation — — — 2,209 — 2,209 Other comprehensive loss 137 137 Stock-based compensation — — 4,467 — — 4,467 Cumulative effect of accounting changes — — — — 363 363 March 31, 2020 80,398,326 459,931 33,132 (12,672 ) (488,880 ) (8,489 ) Ordinary shares Shares Amount Additional paid in Capital Accumulated Other Comprehensive Loss Accumulated Deficit Total Shareholders' Equity (Deficit) As Previously Reported March 31, 2020 80,398,326 459,931 33,132 (15,155 ) (483,435 ) (5,527 ) Issue of shares, net of issue costs of $5,565 20,294,117 80,685 — — — 80,685 Issue of shares upon exercise of incentive share options and vesting of RSUS 571,969 197 — — — 197 Net loss — — — — (108,470 ) (108,470 ) Change in fair value of the effective portion of foreign currency cash flow hedges — — — 582 — 582 Change in unrealized gain in short-term investments — — — (898 ) — (898 ) Foreign currency gain (loss) on: Long-term investment nature intra-entity balances — — — (27,251 ) — (27,251 ) Retranslation of foreign entities — — — 26,035 — 26,035 Provision for pension benefit obligation — — — 622 — 622 Other comprehensive loss (910 ) (910 ) Stock-based compensation — — 4,984 — — 4,984 March 31, 2021 101,264,412 540,813 38,116 (16,065 ) (591,905 ) (29,041 ) Restatement Impacts March 31, 2020 — — — 2,483 (5,445 ) (2,962 ) Issue of shares, net of issue costs of $5,565 — — — — — — Issue of shares upon exercise of incentive share options and vesting of RSUS — — — — — — Net loss — — — — (2,562 ) (2,562 ) Change in fair value of the effective portion of foreign currency cash flow hedges — — — — — — Change in unrealized gain in short-term investments — — — — — — Foreign currency gain (loss) on: Long-term investment nature intra-entity balances — — — — — — Retranslation of foreign entities — — — (841 ) — (841 ) Provision for pension benefit obligation — — — (175 ) — (175 ) Other comprehensive loss (1,016 ) (1,016 ) Stock-based compensation — — — — — — March 31, 2021 — — — (1,016 ) (8,007 ) (6,540 ) As Restated March 31, 2020 80,398,326 459,931 33,132 (12,672 ) (488,880 ) (8,489 ) Issue of shares, net of issue costs of $5,565 20,294,117 80,685 — — — 80,685 Issue of shares upon exercise of incentive share options and vesting of RSUS 571,969 197 — — — 197 Net loss — — — — (111,032 ) (111,032 ) Change in fair value of the effective portion of foreign currency cash flow hedges — — — 582 — 582 Change in unrealized gain in short-term investments — — — (898 ) — (898 ) Foreign currency gain (loss) on: Long-term investment nature intra-entity balances — — — (27,251 ) — (27,251 ) Retranslation of foreign entities — — — 25,194 — 25,194 Provision for pension benefit obligation — — — 447 — 447 Other comprehensive loss (1,926 ) (1,926 ) Stock-based compensation — — 4,984 — — 4,984 March 31, 2021 101,264,412 540,813 38,116 (14,598 ) (599,912 ) (35,581 ) Year ended March 31, 2021 As previously Reported Restatement Impacts As Restated OPERATING ACTIVITIES: Net loss $ (108,470 ) $ (2,562 ) $ (111,032 ) Adjustments to reconcile net loss to net cash provided by operating activities: Depreciation, amortization and loss on disposal of fixed assets 8,620 (266 ) 8,354 Share-based compensation 4,984 — 4,984 Increase in deferred lease rentals 726 — 726 Swiss pension obligation 1,054 — 1,054 Amortization of deferred debt issue costs 9,079 3,886 12,965 Impairment of short term investments 2,285 — 2,285 Accrued preference share dividends 1,050 — 1,050 Income taxes 1,926 (672 ) 1,254 Net change in assets and liabilities: Trade accounts receivable, net 568 — 568 Inventories (475 ) — (475 ) Accounts payable and accrued liabilities (2,514 ) (896 ) (3,410 ) Accrued compensation and benefits 4,039 510 4,549 Other assets (454 ) — (454 ) Net cash used in operating activities (77,582 ) — (77,582 ) INVESTING ACTIVITIES: Increase in short-term investments (87,247 ) — (87,247 ) Realization of short-term investments 134,936 — 134,936 Purchase of property and equipment (4,240 ) — (4,240 ) Purchase of intangible assets — — — Net cash from (used in) investing activities 43,449 — 43,449 FINANCING ACTIVITIES: Repayment of finance leases (633 ) — (633 ) Proceeds from drawdown of new debt — — — Debt issue costs — — — Fee paid to noteholders — — — Proceeds from issuance of ordinary shares and warrants 80,881 — 80,881 Net cash generated from financing activities 80,248 — 80,248 Effect of exchange rate fluctuations on cash and cash equivalents (4,358 ) — (4,358 ) Change in cash and cash equivalents 41,757 — 41,757 Beginning cash and cash equivalents 12,940 — 12,940 Ending cash and cash equivalents $ 54,697 $ — $ 54,697 Supplemental cash flow disclosures: Income taxes paid $ — $ — $ — Interest paid $ 17,529 $ — $ 17,529 Reconciliation of cash, cash equivalents and restricted cash: Cash and cash equivalents $ 45,673 $ — $ 45,673 Restricted cash $ 9,024 $ — $ 9,024 Total cash, cash equivalents and restricted cash $ 54,697 $ — $ 54,697 Year ended March 31, 2020 As previously Reported Restatement Impacts As Restated OPERATING ACTIVITIES: Net loss $ (102,773 ) $ (2,365 ) $ (105,138 ) Adjustments to reconcile net loss to net cash provided by operating activities: Depreciation, amortization and loss on disposal of fixed assets 12,276 (275 ) 12,001 Share-based compensation 4,467 — 4,467 Increase in deferred lease rentals 293 — 293 Swiss pension obligation 756 — 756 Amortization of deferred debt issue costs 7,043 3,041 10,084 Impairment of short term investments — — — Accrued preference share dividends 1,050 — 1,050 Income taxes 368 (537 ) (169 ) Net change in assets and liabilities: Trade accounts receivable, net (2,177 ) — (2,177 ) Inventories (4,967 ) (206 ) (5,173 ) Accounts payable and accrued liabilities 2,456 342 2,798 Accrued compensation and benefits 1,218 — 1,218 Other assets (656 ) — (656 ) Net cash used in operating activities (80,646 ) — (80,646 ) INVESTING ACTIVITIES: Increase in short-term investments (95,000 ) — (95,000 ) Realization of short-term investments 69,412 — 69,412 Purchase of property and equipment (4,598 ) — (4,598 ) Purchase of intangible assets (2 ) — (2 ) Net cash from (used in) investing activities (30,188 ) — (30,188 ) FINANCING ACTIVITIES: Repayment of finance leases (524 ) — (524 ) Proceeds from drawdown of new debt 25,000 — 25,000 Debt issue costs (874 ) — (874 ) Fee paid to noteholders — — — Proceeds from issuance of ordinary shares and warrants 90,973 — 90,973 Net cash generated from financing activities 114,575 — 114,575 Effect of exchange rate fluctuations on cash and cash equivalents (2,404 ) — (2,404 ) Change in cash and cash equivalents 1,337 — 1,337 Beginning cash and cash equivalents 11,603 — 11,603 Ending cash and cash equivalents $ 12,940 $ — $ 12,940 Supplemental cash flow disclosures: Income taxes paid $ — $ — $ — Interest paid $ 15,776 $ — $ 15,776 Reconciliation of cash, cash equivalents and restricted cash: Cash and cash equivalents $ 3,923 $ — $ 3,923 Restricted cash $ 9,017 $ — $ 9,017 Total cash, cash equivalents and restricted cash $ 12,940 $ — $ 12,940 Year ended March 31, 2019 As previously Reported Restatement Impacts As Restated OPERATING ACTIVITIES: Net loss $ (105,386 ) $ (1,025 ) $ (106,411 ) Adjustments to reconcile net loss to net cash provided by operating activities: Depreciation, amortization and loss on disposal of fixed assets 12,767 — 12,767 Share-based compensation 4,957 — 4,957 Increase in deferred lease rentals 372 — 372 Swiss pension obligation 575 — 575 Amortization of deferred debt issue costs 5,908 259 6,167 Impairment of short term investments — — — Accrued preference share dividends 1,050 — 1,050 Income taxes 44 (105 ) (61 ) Net change in assets and liabilities: Trade accounts receivable, net (637 ) — (637 ) Inventories (93 ) 206 113 Accounts payable and accrued liabilities 370 665 1,035 Accrued compensation and benefits 1,121 — 1,121 Other assets 3,297 — 3,297 Net cash used in operating activities (75,655 ) — (75,655 ) INVESTING ACTIVITIES: Increase in short-term investments (119,000 ) — (119,000 ) Realization of short-term investments 34,735 — 34,735 Purchase of property and equipment (4,791 ) — (4,791 ) Purchase of intangible assets (3 ) — (3 ) Net cash from (used in) investing activities (89,059 ) — (89,059 ) FINANCING ACTIVITIES: Repayment of finance leases (486 ) — (486 ) Proceeds from drawdown of new debt 36,000 — 36,000 Debt issue costs (1,216 ) — (1,216 ) Fee paid to noteholders (3,900 ) — (3,900 ) Proceeds from issuance of ordinary shares and warrants 115,024 — 115,024 Net cash generated from financing activities 145,422 — 145,422 Effect of exchange rate fluctuations on cash and cash equivalents 5,690 — 5,690 Change in cash and cash equivalents (13,602 ) — (13,602 ) Beginning cash and cash equivalents 25,205 — 25,205 Ending cash and cash equivalents $ 11,603 $ — $ 11,603 Supplemental cash flow disclosures: Income taxes paid $ — $ — $ — Interest paid $ 11,838 $ — $ 11,838 Reconciliation of cash, cash equivalents and restricted cash: Cash and cash equivalents $ 4,096 $ — $ 4,096 Restricted cash $ 7,507 $ — $ 7,507 Total cash, cash equivalents and restricted cash $ 11,603 $ — $ 11,603 16. Restatement of Previously Issued Unaudited Condensed Consolidated Financial Statements In lieu of filing amended quarterly reports on Form 10-Q, the following tables represent our restated unaudited condensed consolidated financial statements for the quarters ended December 31, 2020, September 30, 2020, and June 30, 2020 during the annual year ended March 31, 2021. See Note 2, Restatement of Previously Issued Consolidated Financial Statements, for additional information. Following the restated consolidated financial statement tables, we have presented a reconciliation from our prior periods, as previously reported, to the restated values. The values as previously reported were derived from our Quarterly Reports on Form 10-Q for the interim periods ended December 31, 2020, September 30, 2020 and June 30, 2020. Description of Misstatements (A) The Company historically accounted for its term debt and royalty rights agreements on a combined basis instead of separately recognizing them as standalone financial instruments. Over time, the subsequent accounting on a standalone basis differed from the combined accounting treatment and resulted in an increase to Interest expense, increase to long-term debt, and increase or decrease to foreign exchange gains/(losses) over the impacted periods. (B) Over recognition of depreciation expense related to specific property and equipment. The Company has recorded adjustments to recognize these amounts in the appropriate period(s). (C) Under-accrual for fringe benefits and taxes associated with employee compensation arrangements. The Company has recorded adjustments to recognize these amounts in the appropriate period(s). (D) Adjustment to recognize the foreign currency impact of certain immaterial monetary items within Other, net previously recognized in Foreign currency gain (loss) within other comprehensive income (loss). (E) The Company recognized an out of period adjustment for deferred tax assets related to certain research and development initiatives. (F) Correction of other immaterial errors. (G) As previously disclosed, the Company's condensed consolidated balance sheet as of June 30, 2020 incorrectly classified $12.1 million of indebtedness as non-current liabilities instead of as current liabilities. (unaudited) December 31, 2020 September 30, 2020 June 30, 2020 ASSETS As Restated As Restated As Restated Current assets: Cash and cash equivalents $ 3,401 $ 18,125 $ 7,325 Short-term investments 131,062 144,618 87,152 Trade accounts receivable, net 4,539 4,518 5,972 Inventories 23,709 22,798 21,291 Prepaid expenses and other current assets 4,928 5,851 4,091 Total current assets 167,639 195,910 125,831 Restricted cash 9,046 9,031 9,021 Property and equipment, net 41,299 40,182 39,563 Operating lease right-of-use assets 22,364 21,557 21,124 Intangible assets, net 632 614 606 Deferred income taxes 741 573 405 Other non-current assets 4,914 4,634 4,438 Total assets $ 246,635 $ 272,501 $ 200,988 LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIT) Current liabilities: Accounts payable $ 5,860 $ 5,138 $ 5,621 Accrued compensation and benefits 4,844 5,191 5,190 Accrued expenses and other current liabilities 11,351 17,410 13,317 Current portion of long-term debt 24,167 12,083 12,083 Current portion of operating lease liability 3,309 3,138 3,045 Current portion of finance lease obligation 878 577 573 Total current liabilities 50,409 43,537 39,829 Long-term debt, less current portion 141,822 149,007 147,260 Operating lease liability, less current portion 21,203 20,282 19,695 Finance lease obligation, less current portion 582 921 1,017 Deferred income taxes 1,455 — — Defined benefit pension plan obligation 7,707 7,169 6,623 7% Cumulative redeemable preference shares 21,213 20,950 20,688 Total liabilities 244,391 241,866 235,112 Commitments and contingencies — — — Shareholders' equity (deficit): Ordinary shares ( nil 540,819 540,769 459,990 Additional paid in capital 36,630 35,416 34,092 Accumulated other comprehensive loss (14,634 ) (16,659 ) (13,070 ) Accumulated deficit (560,571 ) (528,891 ) (515,136 ) Total shareholders' equity (deficit) 2,244 30,635 (34,124 ) Total liabilities and shareholders' equity (deficit) $ 246,635 $ 272,501 $ 200,988 (unaudited) December 31, 2020 September 30, 2020 June 30, 2020 December 31 2020 September 30, 2020 Quarter ended Quarter ended Quarter ended Nine months ended Six months ended As Restated As Restated As Restated As Restated As Restated Revenue: Product sales $ 8,740 $ 8,543 $ 8,924 $ 26,207 $ 17,467 Other revenues 11 7,523 — 7,534 7,523 Total revenue 8,751 16,066 8,924 33,741 24,990 Cost of revenue (4,970 ) (4,499 ) (5,414 ) (14,883 ) (9,913 ) Gross profit 3,781 11,567 3,510 18,858 15,077 Operating expenses: Sales and marketing (2,283 ) (2,231 ) (2,243 ) (6,757 ) (4,474 ) Research and development, net of government grants (14,350 ) (12,743 ) (11,415 ) (38,508 ) (24,158 ) General and administrative expense: Compensation expense in respect of share options and management equity incentives (1,214 ) (1,324 ) (960 ) (3,498 ) (2,284 ) Other general and administrative expenses (7,524 ) (8,232 ) (8,578 ) (24,334 ) (16,810 ) Total general and administrative expense (8,738 ) (9,556 ) (9,538 ) (27,832 ) (19,094 ) Total operating expense (25,371 ) (24,530 ) (23,196 ) (73,097 ) (47,726 ) Operating loss (21,590 ) (12,963 ) (19,686 ) (54,239 ) (32,649 ) Other income (expense): Interest expense, net (9,404 ) (6,297 ) (6,931 ) (22,632 ) (13,228 ) Other, net 617 5,354 208 6,179 5,562 Other income (expense), net (8,787 ) (943 ) (6,723 ) (16,453 ) (7,666 ) Loss before income taxes (30,377 ) (13,906 ) (26,409 ) (70,692 ) (40,315 ) Provision for income taxes (1,303 ) 151 153 (999 ) 304 Net loss $ (31,680 ) $ (13,755 ) $ (26,256 ) $ (71,691 ) $ (40,011 ) Other comprehensive income (loss): Change in fair value of effective portion of foreign currency cash flow hedges $ 295 $ 279 $ (3 ) $ 571 $ 276 Unrealized gain (loss) on short-term investments 111 (79 ) (404 ) (372 ) (483 ) Foreign currency gain (loss) 1,606 (3,803 ) 171 (2,026 ) (3,632 ) Provision for pension benefit obligation 13 14 (162 ) (135 ) (148 ) Other comprehensive loss, net 2,025 (3,589 ) (398 ) (1,962 ) (3,987 ) Comprehensive loss $ (29,655 ) $ (17,344 ) $ (26,654 ) $ (73,652 ) $ (43,998 ) Net loss available to ordinary shareholders - basic and diluted $ (31,680 ) $ (13,755 ) $ (26,256 ) $ (71,691 ) $ (40,011 ) Loss per share - basic and diluted $ (0.31 ) $ (0.16 ) $ (0.33 ) $ (0.81 ) $ (0.49 ) Weighted-average shares outstanding - basic and diluted 101,016,040 83,949,195 80,485,985 88,512,823 82,227,052 (unaudited) Ordinary shares Shares Amount Additional paid in Capital Accumulated Other Comprehensive Loss Accumulated Deficit Total Shareholders' Equity (Deficit) March 31, 2020 As Restated 80,398,326 $ 459,931 $ 33,132 $ (12,672 ) $ (488,880 ) $ (8,489 ) Issue of shares upon exercise of incentive share options and vesting of RSUS 195,114 59 — — — 59 Net loss — — — — (26,256 ) (26,256 ) Change in fair value of the effective portion of foreign currency cash flow hedges — — — (3 ) — (3 ) Change in unrealized gain in short-term investments — — — (404 ) — (404 ) Foreign currency gain (loss) on: — — Long-term investment nature intra-entity balances — — — 4,685 — 4,685 Retranslation of foreign entities — — — (4,514 ) — (4,514 ) Provision for pension benefit obligation — — — (162 ) — (162 ) Other comprehensive loss (398 ) (398 ) Stock-based compensation — — 960 — — 960 June 30, 2020 As Restated 80,593,440 459,990 34,092 (13,070

Organization and Summary of S_2

Organization and Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries after elimination of intercompany transactions and balances. All gains and losses realized from foreign currency transactions denominated in currencies other than the foreign subsidiary’s functional currency are included in foreign currency exchange gain (loss) as part of other income or expenses in the Consolidated Statements of Comprehensive Loss. Adjustments resulting from translating the financial statements of all foreign subsidiaries into U.S. dollars are reported as a separate component of accumulated other comprehensive loss and changes in shareholders’ equity (deficit). The assets and liabilities of the Company’s foreign subsidiaries are translated from their respective functional currencies into U.S. dollars at the rates in effect at the balance sheet date, and revenue and expense amounts are translated at rates approximating the weighted average rates during the period. The translation effects of inter-company loans designated as long term net investments in subsidiaries are included in accumulated other comprehensive loss.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from these estimates. On March 11, 2020, the World Health Organization declared the outbreak of a strain of novel coronavirus disease, COVID-19, a global pandemic. The extent to which the COVID-19 pandemic will impact the Company’s business, operations and financial results will depend on future developments and numerous evolving factors, which are highly uncertain and difficult to predict.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company’s valuation techniques used to measure fair value maximized the use of observable inputs and minimized the use of unobservable inputs. The fair value hierarchy is based on the following three levels of inputs: Level 1—Quoted prices in active markets for identical assets or liabilities. Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. See Note 5, “Fair Value Measurements,” for information and related disclosures regarding our fair value measurements.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. As of March 31, 2021 and 2020, all cash and cash equivalents comprised cash balances and highly liquid investments having an original maturity of three months or less held with the banks used by the Company and its subsidiaries. Restricted cash comprised $8.7 million at both March 31, 2021 and March 31, 2020 , held in a cash reserve account pursuant to the indenture governing the Company’s 12% Senior Secured Notes (the “Secured Notes”) and $324 and $317, respectively, held in a restricted account as security for the property rental obligations of the Company’s Swiss subsidiary.
Short-term Investments	Short-term Investments Short-term investments comprise investments in money-market funds which are valued daily and have minimal notice periods for withdrawals. The money market funds are invested in a portfolio of holdings and the creditworthiness requirement for individual investment holdings is a minimum of an A rating from a leading credit-rating agency. The Company records the value of its investments in the funds based on the quoted value of the funds at the balance sheet date (Note 5) . Unrealized gains or losses are recorded in accumulated other comprehensive loss and are transferred to the statement of comprehensive loss when they are realized.
Trade Accounts Receivable	Trade Accounts Receivable Trade accounts receivable are recorded at the invoiced amount and are not interest bearing. The Company maintains an allowance for doubtful accounts to reserve for potentially uncollectible trade receivables. Movements in the allowance for doubtful accounts are recorded as general and administrative expenses. The Company reviews its trade receivables to identify specific customers with known disputes or collectability issues. In addition, the Company maintains an allowance for all other receivables not included in the specific reserve by applying specific rates of projected uncollectible receivables to the various aging categories. In determining these percentages, the Company analyzes its historical collection experience, customer credit-worthiness, current economic trends and changes in customer payment terms. The allowance for doubtful accounts at March 31, 2021 and 2020 was $48 and $111, respectively.
Concentration of Credit Risks and Other Uncertainties	Concentration of Credit Risks and Other Uncertainties The carrying amounts for financial instruments consisting of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate fair value due to their short maturities. Derivative instruments, consisting of foreign exchange contracts and short-term investments are stated at their estimated fair values, based on quoted market prices for the same or similar instruments. The counterparties to the foreign exchange contracts consist of large financial institutions of high credit standing. The short-term investments are invested in funds which is invested in a portfolio of holdings and the creditworthiness requirement for individual investment holdings is a minimum of an A rating from a leading credit-rating agency. On March 12, 2021, the Company announced that two funds managed by CSAM in which the Company had invested an aggregate of approximately $110.35 million had suspended redemptions. The investments into these funds were made in accordance with the Company’s investment policy of making individual investments with a minimum of an A rating from a leading credit-rating agency. Each fund holds short-term credit obligations of various obligors. According to a press release issued by CSAM, redemptions in the funds were suspended because “certain part of the Subfunds’ assets is currently subject to considerable uncertainties with respect to their accurate valuation.” CSAM subsequently began a liquidation of the funds. Pursuant to the liquidation, the Company has already received cash distributions of approximately $75.6 million. Based on information provided by Credit Suisse, the Company expects to receive further cash distributions from the funds in the next several months; however, there can be no assurance as to the timing or amount of any such distributions. While Credit Suisse has advised that the credit assets held by the funds are covered by insurance that potentially will be available to cover losses the funds would incur if any of the obligors on the funds’ credit assets were to default, the Company does not know if the funds will incur losses (net of insurance) on the credit assets held by the funds. Additionally, on April 22, 2021, Credit Suisse published its FY 2021 Q1 press release with commentary related to the supply chain financing funds. Notably, Credit Suisse indicated that the investors in the funds should assume losses will be incurred. The Company evaluated the investments in the CSAM managed funds for impairment, in accordance with ASC 321-10-35, Investments – Equity Securities The Company views the liquidation of the supply chain finance funds as a fluid situation with a significant amount of valuation uncertainty. The Company will closely monitor the situation and in the event that new information is released that provides valuation clarity, it will evaluate the accounting implications accordingly. The Company believes, and has advised Credit Suisse, that any losses on the supply chain funds should be borne by Credit Suisse. The Company will pursue all available options to recoup the full amount of its investment in the supply chain funds prior to liquidation. The Company’s main financial institutions for banking operation held all of the Company’s cash and cash equivalents as of March 31, 2021 and March 31, 2020. The Company’s accounts receivable are derived from net revenue to customers and distributors located in the United States and other countries. The Company performs credit evaluations of its customers’ financial condition. The Company provides reserves for potential credit losses but has not experienced significant losses to date. There was one customer whose accounts receivable balance represented 10% or more of total accounts receivable, net, as of March 31, 2021 and March 31, 2020. This customer represented 74% and 70% of the accounts receivable balances, as of March 31, 2021 and March 31, 2020, respectively. The Company currently sells products through its direct sales force and through third-party distributors. There was one direct customer that accounted for 10% or more of total product sales for the fiscal years ended March 31, 2021, 2020 and 2019. This customer represented 60%, 61% and 60% of total product sales for the fiscal years March 31, 2021, 2020 and 2019, respectively.
Inventory	Inventory Inventory is stated at the lower of standard cost or market, net of reserves. Cost is determined at standard cost, approximating average cost. Allocation of fixed production overheads to conversion costs is based on normal capacity of production. Abnormal amounts of idle facility expense, freight, handling costs and spoilage are expensed as incurred and not included in overhead. Variances between standard cost and actual cost, arising in the production process, are analyzed to determine whether they reflect part of the normal cost of production, and should therefore be reflected as inventory value, or whether they are a period cost and should thus not be included in inventory. Inventory reserves are recorded based upon historic usage, expected future demand and shelf life of the products held in inventory. No stock-based compensation cost was included in inventory as of March 31, 2021 and 2020.
Property and Equipment	Property and Equipment Property, equipment and leasehold improvements are stated at cost, net of accumulated depreciation and amortization. Depreciation and amortization are computed on a straight-line basis over the estimated useful lives of the related assets as follows: Land—not depreciated. Plant, machinery and equipment—4 to 25 years. Leasehold improvements—the shorter of the lease term or the estimated useful life of the asset. Repairs and maintenance expenditures, which are not considered improvements and do not extend the useful life of property and equipment, are expensed as incurred. Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by comparing the carrying amount of the assets to the future undiscounted cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. During the fiscal years ended March 31, 2021, 2020 and 2019, no impairment losses have been recorded.
Intangible Assets	Intangible Assets Intangible assets related to product licenses are recorded at cost, less accumulated amortization. Intangible assets related to technology and other intangible assets acquired in acquisitions are recorded at fair value at the date of acquisition, less accumulated amortization. Intangible assets are amortized over their estimated useful lives, on a straight-line basis as follows: Customer relationships—5 years Brands associated with acquired cell lines—40 years Product licenses—10 years Other intangibles—7 years The Company reviews its intangible assets for impairment and conducts the impairment review when events or circumstances indicate the carrying value of a long-lived asset may be impaired by estimating the future undiscounted cash flows to be derived from an asset to assess whether or not a potential impairment exists. If the carrying value exceeds the Company’s estimate of future undiscounted cash flows, an impairment value is calculated as the excess of the carrying value of the asset over the Company’s estimate of its fair market value. Events or circumstances which could trigger an impairment review include a significant adverse change in the business climate, an adverse action or assessment by a regulator, unanticipated competition, significant changes in the Company’s use of acquired assets, the Company’s overall business strategy, or significant negative industry or economic trends. No impairment losses have been recorded in any of the years ended March 31, 2021, 2020 or 2019.
Revenue Recognition	Revenue Recognition Revenue is recognized in accordance with ASU 2014-09, Revenue from Contracts with Customers. Product revenue is recognized at a point in time upon transfer of control of a product to a customer, which is generally at the time of delivery at an amount based on the transaction price. Customers have no right of return except in the case of damaged or ineffective goods and the Company has not experienced any significant returns of its products. Shipping and handling costs are expensed as incurred and included in cost of product sales. Revenue is also earned from the provision of development services to a small number of original equipment manufacturer (“OEM”) customers. These development service contracts are reviewed individually to determine the nature of the performance obligations and the associated transaction prices. In recent years, product development revenues have been commensurate with achieving milestones specified in the respective development agreements relating to those products. These milestones may include the approval of new products by the European or U.S. regulatory authorities, which are not within the Company’s control. While there can be no assurance that this will continue to be the case, the milestones have been such that they effectively represent completion of the Company’s performance obligations under a particular part of a development program. Should the Company fail to achieve these milestones the Company would not be entitled under the terms of the development agreements to any compensation for the work undertaken to date. As a result, the milestone-related revenues have been recognized as the contractual milestones are achieved. Pursuant to an Umbrella Supply Agreement with Ortho-Clinical Diagnostics, Inc. (“Ortho”), the Company executed a product attachment relating to the development of a range of rare antisera products. During the year ended March 31, 2020, the Company recognized milestones totaling $1,050 related to the approval by the FDA of an application submitted during the year ended March 31, 2019, and a further FDA submission and approval related to the use of the products on another of Ortho’s automation platforms. There are no further milestone revenues due under this agreement. In January 2015, t he Company’s subsidiaries, Quotient Suisse and QBD (QS-IP) Limited, Ortho initiated an arbitration proceeding as result of the Company's termination of the Prior Ortho Agreement. See Note 7, "Commitments and Contingencies—Ortho Arbitration and Settlement," for details. On September 4, 2020, the Company and Ortho entered into a binding letter agreement (the “Letter Agreement”) pursuant to which the Company and Ortho agreed: • to confirm the termination of the Prior Ortho Agreement and various related contracts; • to end the parties’ disputes regarding the Prior Ortho Agreement by executing mutual releases and terminating their pending arbitration proceeding related to the Prior Ortho Agreement (see Note 7); and • to negotiate in good faith, and use their respective reasonable best efforts to execute, a new distribution agreement (the “New Distribution Agreement”) based on the terms set forth in the Letter Agreement, but if for any reason no such definitive agreement is reached, the Letter Agreement will govern the parties’ respective rights and obligations as a binding contract. Pursuant to the Letter Agreement, Ortho made an initial, non-refundable milestone payment of $7.5 million to the Company on the date of the Letter Agreement. In the Letter Agreement, the Company and Ortho have agreed that Ortho has the right to distribute, market and sell a dedicated MosaiQ microarray optimized for the patient transfusion diagnostics market (the “MosaiQ IH3 Microarray”) in the European Territory (defined as the European Economic Area plus the United Kingdom and Switzerland) and in the United States, solely for use in testing the immuno-hematological profile of the blood of medical patients in the course of their care or treatment. Ortho’s rights in the two territories each are for one ten-year In addition to the initial $7.5 million milestone payment, Ortho is required to make up to another $60 million of additional milestone payments upon achievement of certain regulatory milestones and commercial sales benchmarks, including up to $25 million upon the achievement by Ortho of certain cumulative gross revenue hurdles. The Company has concluded that the initial $7.5 million milestone represents a payment in respect of development work undertaken to date in respect of the MosaiQ IH3 Microarray and accordingly has recognized the revenue in the year ended March 31, 2021. The Company has also concluded that each of the remaining milestones under the Letter Agreement require significant levels of development work to be undertaken and there is no certainty at the start of the projects that the development work will be successful, these milestones are substantive and, accordingly, the revenue will be recognized when the milestones are achieved. In the year ended March 31, 2021, revenue recognized from performance obligations related to prior periods was not material. At March 31, 2021 revenues expected to be recognized in future periods related to remaining performance obligations under the Ortho Letter Agreement were as described above. There were no other material revenues to be recognized in future periods related to remaining performance obligations at March 31, 2021.
Research and Development	Research and Development Research and development expenses consist of costs incurred for company-sponsored and collaborative research and development activities. These costs include direct and research-related overhead expenses. Other than materials assessed as having alternative future uses and which are recognized as prepaid expenses, the Company expenses research and development costs, including products manufactured for research and development purposes and the expenses for research under collaborative agreements, as such costs are incurred. Where government grants are available for the sponsorship of such research, the grant receipt is included as a credit against the related expense.
Stock-Based Compensation	Stock-Based Compensation Stock-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as an expense on a straight-line basis over the requisite service period, which is generally the vesting period. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in the Company’s Consolidated Statements of Comprehensive Loss. In determining fair value of the stock-based compensation payments, the Company uses the Black–Scholes model and a single option award approach for share options , which require s the input of subjective assumptions. These assumptions include: the fair value of the underlying share, estimating the length of time employees will retain their awards before exercising them (expected term), the estimated volatility of the Company’s ordinary share price over the expected term (expected volatility), risk-free interest rate (interest rate), expected dividends and the number of shares subject to awards that will ultimately not complete their vesting requirements (forfeitures). Where modifications are made to vesting conditions, the Company considers the nature of the change and accounts for the change in accordance with ASC 718 Compensation – Stock Compensation
Share Warrants	Share Warrants As of March 31, 2021, the Company had one class of warrants to purchase ordinary shares outstanding which comprised warrants that were issued in December 2013 and August 2015 in connection with the establishment and subsequent increase of the Company’s then existing secured term loan facility. None of these warrants contain any obligation to transfer value and, as such, the issuance of these warrants has been recorded in additional paid in capital as part of shareholders’ (deficit) equity.
Leases	Leases At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. A lease is a contract, or part of a contract, that conveys the right to control the use of identified property, plant or equipment (an identified asset) for a period of time, in exchange for consideration. The Company determines if the contract conveys the right to control the use of an identified asset for a period of time. The Company assesses throughout the period of use whether the Company has both of the following: (1) the right to obtain substantially all of the economic benefits for use of the identified asset, and (2) the right to direct the use of the identified asset. This determination is reassessed if the terms of the contract are changed. The Company also reviews the terms of the lease in accordance with Accounting Standard Update, or ASU, 2016-02 in order to determine whether the lease concerned is a finance or an operating lease. Most leases with a term greater than one year are recognized on the balance sheet as right-of-use assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize on the balance sheet leases with terms of one year or less. For finance leases, an asset is included within property and equipment and a lease liability equal to the present value of the minimum lease payments is included in current or long-term liabilities. Interest expense is recorded over the life of the lease at a constant rate. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected remaining lease term. The operating lease right-of-use assets also include any lease payments made prior to the commencement date and any initial direct costs incurred, less any lease incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rates, which are the rates incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. The incremental borrowing rate is determined at lease commencement, or as of April 1, 2019 for operating leases existing upon adoption of ASU 2016-02. The incremental borrowing rate is subsequently reassessed upon modification to the lease arrangement. Operating lease expense is recognized on a straight-line basis over the lease term. In accordance with the guidance in ASU 2016-02, components of a lease should be split into three categories: lease components (e.g., land, building, etc.), non-lease components (e.g., common area maintenance, maintenance, consumables, etc.), and non-components (e.g., property taxes, insurance, etc.). Although separation of lease and non-lease components is required, certain practical expedients are available. In particular, entities may elect a practical expedient to not separate lease and non-lease components and instead account for each lease component and the related non-lease component together as a single component. The Company has elected to account for the lease and non-lease components of each of its operating leases as a single lease component and allocate all of the contract consideration to the lease component only. The lease component results in an operating lease right-of-use asset being recorded on the balance sheet and amortized on a straight-line basis as lease expense. The finance lease assets and operating lease right-of-use assets are assessed for impairment in accordance with the Company’s accounting policy for long-lived assets.
Derivative Financial Instruments	Derivative Financial Instruments In the normal course of business, the Company’s financial position is routinely subjected to market risk associated with foreign currency exchange rate fluctuations. The Company’s policy is to mitigate the effect of these exchange rate fluctuations on certain foreign currency denominated business exposures. The Company has a policy that allows the use of derivative financial instruments to hedge foreign currency exchange rate fluctuations on forecasted revenue denominated in foreign currencies. The Company carries derivative financial instruments (derivatives) on the balance sheet at their fair values. The Company does not use derivatives for trading or speculative purposes. The Company does not believe that it is exposed to more than a nominal amount of credit risk in its foreign currency hedges, as counterparties are large, global and well-capitalized financial institutions. To hedge foreign currency risks, the Company uses foreign currency exchange forward contracts, where possible and prudent. These forward contracts are valued using standard valuation formulas with assumptions about future foreign currency exchange rates derived from existing exchange rates, interest rates, and other market factors. The Company considers its most current forecast in determining the level of foreign currency denominated revenue to hedge as cash flow hedges. The Company combines these forecasts with historical trends to establish the portion of its expected volume to be hedged. The revenue and expenses are hedged and designated as cash flow hedges to protect the Company from exposures to fluctuations in foreign currency exchange rates. If the underlying forecasted transaction does not occur, or it becomes probable that it will not occur, the related hedge gains and losses on the cash flow hedge are reclassified from accumulated other comprehensive loss to the consolidated statement of comprehensive loss at that time.
Income Taxes	Income Taxes The Company accounts for income taxes using an asset and liability approach, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements, but have not been reflected in taxable income. A valuation allowance is established to reduce deferred tax assets to their estimated realizable value. Therefore, the Company provides a valuation allowance to the extent that is more likely than not that it will generate sufficient taxable income in future periods to realize the benefit of its deferred tax assets. Deferred tax assets and liabilities are classified as noncurrent on the balance sheet. The Company accounts for uncertain tax positions using a “more-likely-than-not” threshold for recognizing and resolving uncertain tax positions. The Company evaluates uncertain tax positions on a quarterly basis and considers various factors, including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit and changes in facts or circumstances related to the tax position.
Pension Obligation	Pension Obligation The Company maintains a pension plan covering employees in Switzerland pursuant to the requirements of Swiss pension law. Certain aspects of the plan require that it be accounted for as a defined benefit plan pursuant to ASC 715 Compensation – Retirement Benefits The Company uses an actuarial valuation to determine its pension benefit costs and credits. The amounts calculated depend on a variety of key assumptions, including discount rates and expected return on plan assets. Details of the assumptions used to determine the net funded status are set out in Note 12. The Company’s pension plan assets are assigned to their respective levels in the fair value hierarchy in accordance with the valuation principles described in the ‘‘Fair Value of Financial Instruments’’ section above.
Termination and Transition Charges	Termination and Transition Charges Termination charges are recognized as a result of actions to restructure operations. Transition charges are recognized as a result of the retirement of senior employees. Such charges are recognized upon meeting certain criteria, including the finalization of committed plans or agreements and discussions with the impacted employees.
Loss Contingencies	Loss Contingencies Loss contingencies from legal proceedings and claims may occur from contractual and other related matters. Accruals are recognized when it is probable that a liability will be incurred and the amount of the loss can be reasonably estimated. Gain contingencies are not recognized until realized. Legal fees are expensed as incurred.
Debt Issuance Costs and Royalty Rights	Debt Issuance Costs and Royalty Rights The Company follows the requirements of Accounting Standards Update 2015-03, Interest — Imputation of Interest (Subtopic 835-30) — Simplifying the Presentation of Debt Issuance Costs, which requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the debt liability rather than as an asset. On October 14, 2016, June 29, 2018 and May 15, 2019, the Company issued Secured Notes, and, on December 4, 2018, the Company amended the indenture governing the Secured Notes, which amendments became effective on December 18, 2018. In connection with these issuances and this amendment, the Company entered into royalty rights agreements with the subscribers and the consenting note holders, as applicable, which, as of March 31, 2021, provided for an aggregate amount of royalties payable thereunder of 3.4% of net sales of MosaiQ instruments and consumables made in the donor testing market in the United States and the European Union. All of these royalty rights agreements are treated as sales of future revenues that meet the requirements of Accounting Standards Codification Topic 470 “Debt” (“ASC 470”) to be treated as debt. These royalty rights agreements are accounted for separately as freestanding financial instruments. Consideration received for the Secured Notes and royalty rights agreements was allocated to each component on a relative fair value basis. The difference between the relative fair value of the royalty rights agreements at issuance and the principle on the Secured Notes is accounted for as a debt discount and amortized through interest expense over the life of the Secured Notes. The royalty rights agreements are individually amortized under the effective interest rate method. The Company recognizes interest expense over the estimated term of the royalty rights agreements.
Adoption of New Accounting Standards	Adoption of New Accounting Standards In June 2016, the FASB issued ASU 2016-13, “Financial Instruments – Credit Losses”. The standard, including subsequently issued amendments, requires a financial asset measured on an amortized cost basis, such as accounts receivable, to be presented at the net amount expected to be collected based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. The Company adopted ASU 2016-13 on April 1, 2020. The adoption of this standard did not have a material impact on the consolidated financial statements and related disclosures. In August 2018, the FASB issued ASU 2018-14, “Compensation Retirement Benefits - Defined Benefit Plans -General (Subtopic 715-20)” or ASU 2018-14. ASU 2018-14 removes the requirements to disclose the amounts in accumulated other comprehensive income (loss) expected to be recognized as components of net periodic benefit cost over the next fiscal year and other disclosure requirements. In addition, the ASU adds the requirement to disclose an explanation for any significant gains and losses related to changes in the benefit obligation for the period. The ASU is effective for fiscal years ending after December 15, 2020 and will be applied on a retrospective basis to all periods presented. Early adoption is permitted. The Company adopted ASU 2018-14 on April 1, 2020. The adoption of this standard did not have a material impact on the consolidated financial statements and related disclosures.

Restatement of Previously Rep_2

Restatement of Previously Reported Consolidated Financial Statements (Tables)	12 Months Ended
	Mar. 31, 2021
Prior Period Adjustment [Abstract]
Schedule of Restatement of Previously Reported Consolidated Financial Statements	March 31, 2021 As previously Reported Restatement Impacts Restatement Reference As Restated ASSETS Current assets: Cash and cash equivalents $ 45,673 $ — $ 45,673 Short-term investments 65,999 — 65,999 Trade accounts receivable, net 5,323 — 5,323 Inventories 22,011 — 22,011 Prepaid expenses and other current assets 4,870 — 4,870 Total current assets 143,876 — 143,876 Restricted cash 9,024 — 9,024 Property and equipment, net 38,530 541 (B) 39,071 Operating lease right-of-use assets 22,011 — 22,011 Intangible assets, net 619 — 619 Deferred income taxes 255 — 255 Other non-current assets 4,956 — 4,956 Total assets $ 219,271 $ 541 $ 219,812 LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIT) Current liabilities: Accounts payable $ 4,659 $ — $ 4,659 Accrued compensation and benefits 11,833 510 (C) 12,343 Accrued expenses and other current liabilities 13,889 120 (F) 14,009 Current portion of long-term debt 24,167 — 24,167 Current portion of operating lease liability 3,446 — 3,446 Current portion of finance lease obligation 835 — 835 Total current liabilities 58,829 630 59,459 Long-term debt, less current portion 137,936 7,123 (A) 145,059 Operating lease liability, less current portion 20,907 — 20,907 Finance lease obligation, less current portion 445 — 445 Deferred income taxes 1,824 (672 ) (E) 1,152 Defined benefit pension plan obligation 6,896 — 6,896 7% Cumulative redeemable preference shares 21,475 — 21,475 Total liabilities 248,312 7,081 255,393 Commitments and contingencies — — — Shareholders' equity (deficit): Ordinary shares ( nil 540,813 — 540,813 Additional paid in capital 38,116 — 38,116 Accumulated other comprehensive loss (16,065 ) 1,467 (D) (14,598 ) Accumulated deficit (591,905 ) (8,007 ) (A)(B)(C)(D)(E)(F) (599,912 ) Total shareholders' equity (deficit) (29,041 ) (6,540 ) (35,581 ) Total liabilities and shareholders' equity (deficit) $ 219,271 $ 541 $ 219,812 March 31, 2020 As previously Reported Restatement Impacts Restatement Reference As Restated ASSETS Current assets: Cash and cash equivalents $ 3,923 $ — $ 3,923 Short-term investments 116,871 — 116,871 Trade accounts receivable, net 5,402 — 5,402 Inventories 20,501 — 20,501 Prepaid expenses and other current assets 3,775 — 3,775 Total current assets 150,472 — 150,472 Restricted cash 9,017 — 9,017 Property and equipment, net 40,165 275 (B) 40,440 Operating lease right-of-use assets 21,493 — 21,493 Intangible assets, net 625 — 625 Deferred income taxes 237 — 237 Other non-current assets 4,454 — 4,454 Total assets $ 226,463 $ 275 $ 226,738 LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIT) Current liabilities: Accounts payable $ 4,826 $ — $ 4,826 Accrued compensation and benefits 7,210 — 7,210 Accrued expenses and other current liabilities 15,490 — 15,490 Current portion of long-term debt — — — Current portion of operating lease liability 3,033 — 3,033 Current portion of finance lease obligation 598 — 598 Total current liabilities 31,157 — 31,157 Long-term debt, less current portion 153,024 3,237 (A) 156,261 Operating lease liability, less current portion 19,914 — 19,914 Finance lease obligation, less current portion 1,117 — 1,117 Deferred income taxes — — — Defined benefit pension plan obligation 6,353 — 6,353 7% Cumulative redeemable preference shares 20,425 — 20,425 Total liabilities 231,990 3,237 235,227 Commitments and contingencies — — — Shareholders' equity (deficit): Ordinary shares ( nil 459,931 — 459,931 Additional paid in capital 33,132 — 33,132 Accumulated other comprehensive loss (15,155 ) 2,483 (D) (12,672 ) Accumulated deficit (483,435 ) (5,445 ) (A)(B)(D) (488,880 ) Total shareholders' equity (deficit) (5,527 ) (2,962 ) (8,489 ) Total liabilities and shareholders' equity (deficit) $ 226,463 $ 275 $ 226,738 Year ended March 31, 2021 As previously Reported Restatement Impacts Restatement Reference As Restated Revenue: Product sales $ 35,787 $ — $ 35,787 Other revenues 7,592 — 7,592 Total revenue 43,379 — 43,379 Cost of revenue (20,074 ) — (20,074 ) Gross profit 23,305 — 23,305 Operating expenses: Sales and marketing (9,849 ) — (9,849 ) Research and development, net of government grants (54,168 ) 441 (B)(F) (53,727 ) General and administrative expense: Compensation expense in respect of share options and management equity incentives (4,984 ) — (4,984 ) Other general and administrative expenses (36,812 ) (630 ) (C)(F) (37,442 ) Total general and administrative expense (41,796 ) (630 ) (42,426 ) Total operating expense (105,813 ) (189 ) (106,002 ) Operating loss (82,508 ) (189 ) (82,697 ) Other income (expense): Interest expense, net (25,918 ) (3,886 ) (A) (29,804 ) Other, net 1,882 841 (D) 2,723 Other income (expense), net (24,036 ) (3,045 ) (27,081 ) Loss before income taxes (106,544 ) (3,234 ) (109,778 ) Provision for income taxes (1,926 ) 672 (E) (1,254 ) Net loss $ (108,470 ) $ (2,562 ) $ (111,032 ) Other comprehensive income (loss): Change in fair value of effective portion of foreign currency cash flow hedges $ 582 $ — $ 582 Unrealized gain (loss) on short-term investments (898 ) — (898 ) Foreign currency gain (loss) (1,216 ) (841 ) (D) (2,057 ) Provision for pension benefit obligation 622 (175 ) (F) 447 Other comprehensive loss, net (910 ) (1,016 ) (1,926 ) Comprehensive loss $ (109,380 ) $ (3,578 ) $ (112,958 ) Net loss available to ordinary shareholders - basic and diluted $ (108,470 ) $ (2,562 ) $ (111,032 ) Loss per share - basic and diluted $ (1.18 ) $ (0.03 ) $ (1.21 ) Weighted-average shares outstanding - basic and diluted 91,637,966 — 91,637,966 Year ended March 31, 2020 As previously Reported Restatement Impacts Restatement Reference As Restated Revenue: Product sales $ 31,601 $ — $ 31,601 Other revenues 1,055 — 1,055 Total revenue 32,656 — 32,656 Cost of revenue (17,800 ) — (17,800 ) Gross profit 14,856 — 14,856 Operating expenses: Sales and marketing (9,853 ) — (9,853 ) Research and development, net of government grants (53,744 ) 306 (B)(F) (53,438 ) General and administrative expense: Compensation expense in respect of share options and management equity incentives (4,467 ) — (4,467 ) Other general and administrative expenses (27,483 ) — (27,483 ) Total general and administrative expense (31,950 ) — (31,950 ) Total operating expense (95,547 ) 306 (95,241 ) Operating loss (80,691 ) 306 (80,385 ) Other income (expense): Interest expense, net (23,859 ) (3,041 ) (A) (26,900 ) Other, net 2,438 (233 ) (D) 2,205 Other income (expense), net (21,421 ) (3,274 ) (24,695 ) Loss before income taxes (102,112 ) (2,968 ) (105,080 ) Provision for income taxes (661 ) 603 (E) (58 ) Net loss $ (102,773 ) $ (2,365 ) $ (105,138 ) Other comprehensive income (loss): Change in fair value of effective portion of foreign currency cash flow hedges $ (157 ) $ — $ (157 ) Unrealized gain (loss) on short-term investments 554 — 554 Foreign currency gain (loss) (2,702 ) 233 (D) (2,469 ) Provision for pension benefit obligation 2,034 175 (F) 2,209 Other comprehensive loss, net (271 ) 408 137 Comprehensive loss $ (103,044 ) $ (1,957 ) $ (105,001 ) Net loss available to ordinary shareholders - basic and diluted $ (102,773 ) $ (2,365 ) $ (105,138 ) Loss per share - basic and diluted $ (1.44 ) $ (0.03 ) $ (1.47 ) Weighted-average shares outstanding - basic and diluted 71,610,035 — 71,610,035 Year ended March 31, 2019 As previously Reported Restatement Impacts Restatement Reference As Restated Revenue: Product sales $ 28,665 $ — $ 28,665 Other revenues 469 — 469 Total revenue 29,134 — 29,134 Cost of revenue (17,230 ) — (17,230 ) Gross profit 11,904 — 11,904 Operating expenses: Sales and marketing (8,637 ) — (8,637 ) Research and development, net of government grants (50,677 ) (206 ) (B) (50,883 ) General and administrative expense: Compensation expense in respect of share options and management equity incentives (4,957 ) — (4,957 ) Other general and administrative expenses (26,588 ) — (26,588 ) Total general and administrative expense (31,545 ) — (31,545 ) Total operating expense (90,859 ) (206 ) (91,065 ) Operating loss (78,955 ) (206 ) (79,161 ) Other income (expense): Interest expense, net (20,018 ) (259 ) (A) (20,277 ) Other, net (6,369 ) (574 ) (D) (6,943 ) Other income (expense), net (26,387 ) (833 ) (27,220 ) Loss before income taxes (105,342 ) (1,039 ) (106,381 ) Provision for income taxes (44 ) 14 (E) (30 ) Net loss $ (105,386 ) $ (1,025 ) $ (106,411 ) Other comprehensive income (loss): Change in fair value of effective portion of foreign currency cash flow hedges $ (123 ) $ — $ (123 ) Unrealized gain (loss) on short-term investments 796 — 796 Foreign currency gain (loss) 1,964 574 (D) 2,538 Provision for pension benefit obligation (887 ) — (887 ) Other comprehensive loss, net 1,750 574 2,324 Comprehensive loss $ (103,636 ) $ (451 ) $ (104,087 ) Net loss available to ordinary shareholders - basic and diluted $ (105,386 ) $ (1,025 ) $ (106,411 ) Loss per share - basic and diluted $ (1.92 ) $ (0.02 ) $ (1.94 ) Weighted-average shares outstanding - basic and diluted 54,874,391 — 54,874,391 Ordinary shares Shares Amount Additional paid in Capital Accumulated Other Comprehensive Loss Accumulated Deficit Total Shareholders' Equity (Deficit) As Previously Reported March 31, 2018 45,646,424 253,934 23,708 (16,634 ) (275,639 ) (14,631 ) Issue of shares, net of issue costs of $4,052 19,635,068 113,724 — — — 113,724 Issue of shares upon exercise of incentive share options and vesting of RSUS 618,955 1,300 — — — 1,300 Net loss — — — — (105,386 ) (105,386 ) Change in fair value of the effective portion of foreign currency cash flow hedges — — — (123 ) — (123 ) Change in unrealized gain in short-term investments — — — 796 — 796 Foreign currency gain (loss) on: Long-term investment nature intra-entity balances — — — 5,074 — 5,074 Retranslation of foreign entities — — — (3,110 ) — (3,110 ) Provision for pension benefit obligation — — — (887 ) — (887 ) Other comprehensive loss 1,750 1,750 Stock-based compensation — — 4,957 — — 4,957 March 31, 2019 65,900,447 368,958 28,665 (14,884 ) (381,025 ) 1,714 Restatement Impacts March 31, 2018 — — — 1,501 (2,055 ) (554 ) Issue of shares, net of issue costs of $4,052 — — — — — — Issue of shares upon exercise of incentive share options and vesting of RSUS — — — — — — Net loss — — — — (1,025 ) (1,025 ) Change in fair value of the effective portion of foreign currency cash flow hedges — — — — — — Change in unrealized gain in short-term investments — — — — — — Foreign currency gain (loss) on: Long-term investment nature intra-entity balances — — — — — — Retranslation of foreign entities — — — 574 — 574 Provision for pension benefit obligation — — — — — — Other comprehensive loss 574 574 Stock-based compensation — — — — — — March 31, 2019 — — — 2,075 (3,080 ) (1,005 ) As Restated March 31, 2018 45,646,424 253,934 23,708 (15,133 ) (277,694 ) (15,185 ) Issue of shares, net of issue costs of $4,052 19,635,068 113,724 — — — 113,724 Issue of shares upon exercise of incentive share options and vesting of RSUS 618,955 1,300 — — — 1,300 Net loss — — — — (106,411 ) (106,411 ) Change in fair value of the effective portion of foreign currency cash flow hedges — — — (123 ) — (123 ) Change in unrealized gain in short-term investments — — — 796 — 796 Foreign currency gain (loss) on: — Long-term investment nature intra-entity balances — — — 5,074 — 5,074 Retranslation of foreign entities — — — (2,536 ) — (2,536 ) Provision for pension benefit obligation — — — (887 ) — (887 ) Other comprehensive loss 2,324 2,324 Stock-based compensation — — 4,957 — — 4,957 March 31, 2019 65,900,447 368,958 28,665 (12,809 ) (384,105 ) 709 Ordinary shares Shares Amount Additional paid in Capital Accumulated Other Comprehensive Loss Accumulated Deficit Total Shareholders' Equity (Deficit) As Previously Reported March 31, 2019 65,900,447 $ 368,958 $ 28,665 $ (14,884 ) $ (381,025 ) $ 1,714 Issue of shares, net of issue costs of $6,072 13,800,000 90,528 — — — 90,528 Issue of shares upon exercise of incentive share options and vesting of RSUS 697,879 445 — — — 445 Net loss — — — — (102,773 ) (102,773 ) Change in fair value of the effective portion of foreign currency cash flow hedges — — — (157 ) — (157 ) Change in unrealized gain in short-term investments — — — 554 — 554 Foreign currency gain (loss) on: Long-term investment nature intra-entity balances — — — 18,394 — 18,394 Retranslation of foreign entities — — — (21,096 ) — (21,096 ) Provision for pension benefit obligation — — — 2,034 — 2,034 Other comprehensive loss (271 ) (271 ) Stock-based compensation — — 4,467 — — 4,467 Cumulative effect of accounting changes — — — 363 363 March 31, 2020 80,398,326 459,931 33,132 (15,155 ) (483,435 ) (5,527 ) Restatement Impacts March 31, 2019 — $ — $ — $ 2,075 $ (3,080 ) $ (1,005 ) Issue of shares, net of issue costs of $6,072 — — — — — — Issue of shares upon exercise of incentive share options and vesting of RSUS — — — — — — Net loss — — — — (2,365 ) (2,365 ) Change in fair value of the effective portion of foreign currency cash flow hedges — — — — — — Change in unrealized gain in short-term investments — — — — — — Foreign currency gain (loss) on: Long-term investment nature intra-entity balances — — — — — — Retranslation of foreign entities — — — 233 — 233 Provision for pension benefit obligation — — — 175 — 175 Other comprehensive loss 408 408 Stock-based compensation — — — — — — Cumulative effect of accounting changes — — — — — — March 31, 2020 — — — 2,483 (5,445 ) (2,962 ) As Restated March 31, 2019 65,900,447 $ 368,958 $ 28,665 $ (12,809 ) $ (384,105 ) $ 709 Issue of shares, net of issue costs of $6,072 13,800,000 90,528 — — — 90,528 Issue of shares upon exercise of incentive share options and vesting of RSUS 697,879 445 — — — 445 Net loss — — — — (105,138 ) (105,138 ) Change in fair value of the effective portion of foreign currency cash flow hedges — — — (157 ) — (157 ) Change in unrealized gain in short-term investments — — — 554 — 554 Foreign currency gain (loss) on: Long-term investment nature intra-entity balances — — — 18,394 — 18,394 Retranslation of foreign entities — — — (20,863 ) — (20,863 ) Provision for pension benefit obligation — — — 2,209 — 2,209 Other comprehensive loss 137 137 Stock-based compensation — — 4,467 — — 4,467 Cumulative effect of accounting changes — — — — 363 363 March 31, 2020 80,398,326 459,931 33,132 (12,672 ) (488,880 ) (8,489 ) Ordinary shares Shares Amount Additional paid in Capital Accumulated Other Comprehensive Loss Accumulated Deficit Total Shareholders' Equity (Deficit) As Previously Reported March 31, 2020 80,398,326 459,931 33,132 (15,155 ) (483,435 ) (5,527 ) Issue of shares, net of issue costs of $5,565 20,294,117 80,685 — — — 80,685 Issue of shares upon exercise of incentive share options and vesting of RSUS 571,969 197 — — — 197 Net loss — — — — (108,470 ) (108,470 ) Change in fair value of the effective portion of foreign currency cash flow hedges — — — 582 — 582 Change in unrealized gain in short-term investments — — — (898 ) — (898 ) Foreign currency gain (loss) on: Long-term investment nature intra-entity balances — — — (27,251 ) — (27,251 ) Retranslation of foreign entities — — — 26,035 — 26,035 Provision for pension benefit obligation — — — 622 — 622 Other comprehensive loss (910 ) (910 ) Stock-based compensation — — 4,984 — — 4,984 March 31, 2021 101,264,412 540,813 38,116 (16,065 ) (591,905 ) (29,041 ) Restatement Impacts March 31, 2020 — — — 2,483 (5,445 ) (2,962 ) Issue of shares, net of issue costs of $5,565 — — — — — — Issue of shares upon exercise of incentive share options and vesting of RSUS — — — — — — Net loss — — — — (2,562 ) (2,562 ) Change in fair value of the effective portion of foreign currency cash flow hedges — — — — — — Change in unrealized gain in short-term investments — — — — — — Foreign currency gain (loss) on: Long-term investment nature intra-entity balances — — — — — — Retranslation of foreign entities — — — (841 ) — (841 ) Provision for pension benefit obligation — — — (175 ) — (175 ) Other comprehensive loss (1,016 ) (1,016 ) Stock-based compensation — — — — — — March 31, 2021 — — — (1,016 ) (8,007 ) (6,540 ) As Restated March 31, 2020 80,398,326 459,931 33,132 (12,672 ) (488,880 ) (8,489 ) Issue of shares, net of issue costs of $5,565 20,294,117 80,685 — — — 80,685 Issue of shares upon exercise of incentive share options and vesting of RSUS 571,969 197 — — — 197 Net loss — — — — (111,032 ) (111,032 ) Change in fair value of the effective portion of foreign currency cash flow hedges — — — 582 — 582 Change in unrealized gain in short-term investments — — — (898 ) — (898 ) Foreign currency gain (loss) on: Long-term investment nature intra-entity balances — — — (27,251 ) — (27,251 ) Retranslation of foreign entities — — — 25,194 — 25,194 Provision for pension benefit obligation — — — 447 — 447 Other comprehensive loss (1,926 ) (1,926 ) Stock-based compensation — — 4,984 — — 4,984 March 31, 2021 101,264,412 540,813 38,116 (14,598 ) (599,912 ) (35,581 ) Year ended March 31, 2021 As previously Reported Restatement Impacts As Restated OPERATING ACTIVITIES: Net loss $ (108,470 ) $ (2,562 ) $ (111,032 ) Adjustments to reconcile net loss to net cash provided by operating activities: Depreciation, amortization and loss on disposal of fixed assets 8,620 (266 ) 8,354 Share-based compensation 4,984 — 4,984 Increase in deferred lease rentals 726 — 726 Swiss pension obligation 1,054 — 1,054 Amortization of deferred debt issue costs 9,079 3,886 12,965 Impairment of short term investments 2,285 — 2,285 Accrued preference share dividends 1,050 — 1,050 Income taxes 1,926 (672 ) 1,254 Net change in assets and liabilities: Trade accounts receivable, net 568 — 568 Inventories (475 ) — (475 ) Accounts payable and accrued liabilities (2,514 ) (896 ) (3,410 ) Accrued compensation and benefits 4,039 510 4,549 Other assets (454 ) — (454 ) Net cash used in operating activities (77,582 ) — (77,582 ) INVESTING ACTIVITIES: Increase in short-term investments (87,247 ) — (87,247 ) Realization of short-term investments 134,936 — 134,936 Purchase of property and equipment (4,240 ) — (4,240 ) Purchase of intangible assets — — — Net cash from (used in) investing activities 43,449 — 43,449 FINANCING ACTIVITIES: Repayment of finance leases (633 ) — (633 ) Proceeds from drawdown of new debt — — — Debt issue costs — — — Fee paid to noteholders — — — Proceeds from issuance of ordinary shares and warrants 80,881 — 80,881 Net cash generated from financing activities 80,248 — 80,248 Effect of exchange rate fluctuations on cash and cash equivalents (4,358 ) — (4,358 ) Change in cash and cash equivalents 41,757 — 41,757 Beginning cash and cash equivalents 12,940 — 12,940 Ending cash and cash equivalents $ 54,697 $ — $ 54,697 Supplemental cash flow disclosures: Income taxes paid $ — $ — $ — Interest paid $ 17,529 $ — $ 17,529 Reconciliation of cash, cash equivalents and restricted cash: Cash and cash equivalents $ 45,673 $ — $ 45,673 Restricted cash $ 9,024 $ — $ 9,024 Total cash, cash equivalents and restricted cash $ 54,697 $ — $ 54,697 Year ended March 31, 2020 As previously Reported Restatement Impacts As Restated OPERATING ACTIVITIES: Net loss $ (102,773 ) $ (2,365 ) $ (105,138 ) Adjustments to reconcile net loss to net cash provided by operating activities: Depreciation, amortization and loss on disposal of fixed assets 12,276 (275 ) 12,001 Share-based compensation 4,467 — 4,467 Increase in deferred lease rentals 293 — 293 Swiss pension obligation 756 — 756 Amortization of deferred debt issue costs 7,043 3,041 10,084 Impairment of short term investments — — — Accrued preference share dividends 1,050 — 1,050 Income taxes 368 (537 ) (169 ) Net change in assets and liabilities: Trade accounts receivable, net (2,177 ) — (2,177 ) Inventories (4,967 ) (206 ) (5,173 ) Accounts payable and accrued liabilities 2,456 342 2,798 Accrued compensation and benefits 1,218 — 1,218 Other assets (656 ) — (656 ) Net cash used in operating activities (80,646 ) — (80,646 ) INVESTING ACTIVITIES: Increase in short-term investments (95,000 ) — (95,000 ) Realization of short-term investments 69,412 — 69,412 Purchase of property and equipment (4,598 ) — (4,598 ) Purchase of intangible assets (2 ) — (2 ) Net cash from (used in) investing activities (30,188 ) — (30,188 ) FINANCING ACTIVITIES: Repayment of finance leases (524 ) — (524 ) Proceeds from drawdown of new debt 25,000 — 25,000 Debt issue costs (874 ) — (874 ) Fee paid to noteholders — — — Proceeds from issuance of ordinary shares and warrants 90,973 — 90,973 Net cash generated from financing activities 114,575 — 114,575 Effect of exchange rate fluctuations on cash and cash equivalents (2,404 ) — (2,404 ) Change in cash and cash equivalents 1,337 — 1,337 Beginning cash and cash equivalents 11,603 — 11,603 Ending cash and cash equivalents $ 12,940 $ — $ 12,940 Supplemental cash flow disclosures: Income taxes paid $ — $ — $ — Interest paid $ 15,776 $ — $ 15,776 Reconciliation of cash, cash equivalents and restricted cash: Cash and cash equivalents $ 3,923 $ — $ 3,923 Restricted cash $ 9,017 $ — $ 9,017 Total cash, cash equivalents and restricted cash $ 12,940 $ — $ 12,940 Year ended March 31, 2019 As previously Reported Restatement Impacts As Restated OPERATING ACTIVITIES: Net loss $ (105,386 ) $ (1,025 ) $ (106,411 ) Adjustments to reconcile net loss to net cash provided by operating activities: Depreciation, amortization and loss on disposal of fixed assets 12,767 — 12,767 Share-based compensation 4,957 — 4,957 Increase in deferred lease rentals 372 — 372 Swiss pension obligation 575 — 575 Amortization of deferred debt issue costs 5,908 259 6,167 Impairment of short term investments — — — Accrued preference share dividends 1,050 — 1,050 Income taxes 44 (105 ) (61 ) Net change in assets and liabilities: Trade accounts receivable, net (637 ) — (637 ) Inventories (93 ) 206 113 Accounts payable and accrued liabilities 370 665 1,035 Accrued compensation and benefits 1,121 — 1,121 Other assets 3,297 — 3,297 Net cash used in operating activities (75,655 ) — (75,655 ) INVESTING ACTIVITIES: Increase in short-term investments (119,000 ) — (119,000 ) Realization of short-term investments 34,735 — 34,735 Purchase of property and equipment (4,791 ) — (4,791 ) Purchase of intangible assets (3 ) — (3 ) Net cash from (used in) investing activities (89,059 ) — (89,059 ) FINANCING ACTIVITIES: Repayment of finance leases (486 ) — (486 ) Proceeds from drawdown of new debt 36,000 — 36,000 Debt issue costs (1,216 ) — (1,216 ) Fee paid to noteholders (3,900 ) — (3,900 ) Proceeds from issuance of ordinary shares and warrants 115,024 — 115,024 Net cash generated from financing activities 145,422 — 145,422 Effect of exchange rate fluctuations on cash and cash equivalents 5,690 — 5,690 Change in cash and cash equivalents (13,602 ) — (13,602 ) Beginning cash and cash equivalents 25,205 — 25,205 Ending cash and cash equivalents $ 11,603 $ — $ 11,603 Supplemental cash flow disclosures: Income taxes paid $ — $ — $ — Interest paid $ 11,838 $ — $ 11,838 Reconciliation of cash, cash equivalents and restricted cash: Cash and cash equivalents $ 4,096 $ — $ 4,096 Restricted cash $ 7,507 $ — $ 7,507 Total cash, cash equivalents and restricted cash $ 11,603 $ — $ 11,603 (unaudited) December 31, 2020 September 30, 2020 June 30, 2020 ASSETS As Restated As Restated As Restated Current assets: Cash and cash equivalents $ 3,401 $ 18,125 $ 7,325 Short-term investments 131,062 144,618 87,152 Trade accounts receivable, net 4,539 4,518 5,972 Inventories 23,709 22,798 21,291 Prepaid expenses and other current assets 4,928 5,851 4,091 Total current assets 167,639 195,910 125,831 Restricted cash 9,046 9,031 9,021 Property and equipment, net 41,299 40,182 39,563 Operating lease right-of-use assets 22,364 21,557 21,124 Intangible assets, net 632 614 606 Deferred income taxes 741 573 405 Other non-current assets 4,914 4,634 4,438 Total assets $ 246,635 $ 272,501 $ 200,988 LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIT) Current liabilities: Accounts payable $ 5,860 $ 5,138 $ 5,621 Accrued compensation and benefits 4,844 5,191 5,190 Accrued expenses and other current liabilities 11,351 17,410 13,317 Current portion of long-term debt 24,167 12,083 12,083 Current portion of operating lease liability 3,309 3,138 3,045 Current portion of finance lease obligation 878 577 573 Total current liabilities 50,409 43,537 39,829 Long-term debt, less current portion 141,822 149,007 147,260 Operating lease liability, less current portion 21,203 20,282 19,695 Finance lease obligation, less current portion 582 921 1,017 Deferred income taxes 1,455 — — Defined benefit pension plan obligation 7,707 7,169 6,623 7% Cumulative redeemable preference shares 21,213 20,950 20,688 Total liabilities 244,391 241,866 235,112 Commitments and contingencies — — — Shareholders' equity (deficit): Ordinary shares ( nil 540,819 540,769 459,990 Additional paid in capital 36,630 35,416 34,092 Accumulated other comprehensive loss (14,634 ) (16,659 ) (13,070 ) Accumulated deficit (560,571 ) (528,891 ) (515,136 ) Total shareholders' equity (deficit) 2,244 30,635 (34,124 ) Total liabilities and shareholders' equity (deficit) $ 246,635 $ 272,501 $ 200,988 (unaudited) December 31, 2020 September 30, 2020 June 30, 2020 December 31 2020 September 30, 2020 Quarter ended Quarter ended Quarter ended Nine months ended Six months ended As Restated As Restated As Restated As Restated As Restated Revenue: Product sales $ 8,740 $ 8,543 $ 8,924 $ 26,207 $ 17,467 Other revenues 11 7,523 — 7,534 7,523 Total revenue 8,751 16,066 8,924 33,741 24,990 Cost of revenue (4,970 ) (4,499 ) (5,414 ) (14,883 ) (9,913 ) Gross profit 3,781 11,567 3,510 18,858 15,077 Operating expenses: Sales and marketing (2,283 ) (2,231 ) (2,243 ) (6,757 ) (4,474 ) Research and development, net of government grants (14,350 ) (12,743 ) (11,415 ) (38,508 ) (24,158 ) General and administrative expense: Compensation expense in respect of share options and management equity incentives (1,214 ) (1,324 ) (960 ) (3,498 ) (2,284 ) Other general and administrative expenses (7,524 ) (8,232 ) (8,578 ) (24,334 ) (16,810 ) Total general and administrative expense (8,738 ) (9,556 ) (9,538 ) (27,832 ) (19,094 ) Total operating expense (25,371 ) (24,530 ) (23,196 ) (73,097 ) (47,726 ) Operating loss (21,590 ) (12,963 ) (19,686 ) (54,239 ) (32,649 ) Other income (expense): Interest expense, net (9,404 ) (6,297 ) (6,931 ) (22,632 ) (13,228 ) Other, net 617 5,354 208 6,179 5,562 Other income (expense), net (8,787 ) (943 ) (6,723 ) (16,453 ) (7,666 ) Loss before income taxes (30,377 ) (13,906 ) (26,409 ) (70,692 ) (40,315 ) Provision for income taxes (1,303 ) 151 153 (999 ) 304 Net loss $ (31,680 ) $ (13,755 ) $ (26,256 ) $ (71,691 ) $ (40,011 ) Other comprehensive income (loss): Change in fair value of effective portion of foreign currency cash flow hedges $ 295 $ 279 $ (3 ) $ 571 $ 276 Unrealized gain (loss) on short-term investments 111 (79 ) (404 ) (372 ) (483 ) Foreign currency gain (loss) 1,606 (3,803 ) 171 (2,026 ) (3,632 ) Provision for pension benefit obligation 13 14 (162 ) (135 ) (148 ) Other comprehensive loss, net 2,025 (3,589 ) (398 ) (1,962 ) (3,987 ) Comprehensive loss $ (29,655 ) $ (17,344 ) $ (26,654 ) $ (73,652 ) $ (43,998 ) Net loss available to ordinary shareholders - basic and diluted $ (31,680 ) $ (13,755 ) $ (26,256 ) $ (71,691 ) $ (40,011 ) Loss per share - basic and diluted $ (0.31 ) $ (0.16 ) $ (0.33 ) $ (0.81 ) $ (0.49 ) Weighted-average shares outstanding - basic and diluted 101,016,040 83,949,195 80,485,985 88,512,823 82,227,052 (unaudited) Ordinary shares Shares Amount Additional paid in Capital Accumulated Other Comprehensive Loss Accumulated Deficit Total Shareholders' Equity (Deficit) March 31, 2020 As Restated 80,398,326 $ 459,931 $ 33,132 $ (12,672 ) $ (488,880 ) $ (8,489 ) Issue of shares upon exercise of incentive share options and vesting of RSUS 195,114 59 — — — 59 Net loss — — — — (26,256 ) (26,256 ) Change in fair value of the effective portion of foreign currency cash flow hedges — — — (3 ) — (3 ) Change in unrealized gain in short-term investments — — — (404 ) — (404 ) Foreign currency gain (loss) on: — — Long-term investment nature intra-entity balances — — — 4,685 — 4,685 Retranslation of foreign entities — — — (4,514 ) — (4,514 ) Provision for pension benefit obligation — — — (162 ) — (162 ) Other comprehensive loss (398 ) (398 ) Stock-based compensation — — 960 — — 960 June 30, 2020 As Restated 80,593,440 459,990 34,092 (13,070 ) (515,136 ) (34,124 ) Issue of shares, net of issue costs of $5,565 20,294,117 80,685 — — — 80,685 Issue of shares upon exercise of incentive share options and vesting of RSUS 77,894 94 — — — 94 Net loss — — — — (13,755 ) (13,755 ) Change in fair value of the effective portion of foreign currency cash flow hedges — — — 279 — 279 Change in unrealized gain in short-term investments — — — (79 ) — (79 ) Foreign currency gain (loss) on: Long-term investment nature intra-entity balances — — — (3,841 ) — (3,841 ) Retranslation of foreign entities — — — 38 — 38 Provision for pension benefit obligation — — — 14 — 14 Other comprehensive loss (3,589 ) (3,589 ) Stock-based compensation — — 1,324 — — 1,324 September 30, 2020 As Restated 100,965,451 540,769 35,416 (16,659 ) (528,891 ) 30,635 Issue of shares — — — — — — Issue of shares upon exercise of incentive share options and vesting of RSUS 110,394 50 — — — 50 Net loss — — — — (31,680 ) (31,680 ) Change in fair value of the effective portion of foreign currency cash flow hedges — — — 295 — 295 Change in unrealized gain in short-term investments — — — 111 — 111 Foreign currency gain (loss) on: Long-term investment nature intra-entity balances — — — (4,692 ) — (4,692 ) Retranslation of foreign entities — — — 6,298 — 6,298 Provision for pension benefit obligation — — — 13 — 13 Other comprehensive loss 2,025 2,025 Stock-based compensation — — 1,214 — — 1,214 December 31, 2020 As Restated 101,075,845 540,819 36,630 (14,634 ) (560,571 ) 2,244 (unaudited) December 31 2020 September 30, 2020 June 30, 2020 OPERATING ACTIVITIES: Nine Months Ended Six Months Ended 3 Months Ended As Restated As Restated As Restated Net loss $ (71,691 ) $ (40,011 ) $ (26,256 ) Adjustments to reconcile net loss to net cash provided by operating activities: Depreciation, amortization and loss on disposal of fixed assets 6,354 4,131 2,093 Share-based compensation 3,498 2,284 960 Increase in deferred lease rentals 512 346 169 Swiss pension obligation 776 516 253 Amortization of deferred debt issue costs 9,728 4,830 3,083 Change in fair value of convertible loan derivatives — — — Impairment of short term investments — — — Accrued preference share dividends 788 525 263 Income taxes 999 (304 ) (153 ) Net change in assets and liabilities: — — — Trade accounts receivable, net 1,268 1,093 (587 ) Inventories (1,218 ) (1,411 ) (638 ) Accounts payable and accrued liabilities (4,601 ) 1,390 (1,664 ) Accrued compensation and benefits (2,825 ) (2,215 ) (2,025 ) Other assets (330 ) (1,807 ) (306 ) Net cash used in operating activities (56,742 ) (30,633 ) (24,808 ) INVESTING ACTIVITIES: Increase in short-term investments (72,247 ) (72,247 ) — Realization of short-term investments 57,683 44,016 29,314 Purchase of property and equipment (3,602 ) (2,069 ) (830 ) Purchase of intangible assets — — — Net cash from (used in) investing activities (18,166 ) (30,300 ) 28,484 FINANCING ACTIVITIES: Repayment of finance leases (491 ) (356 ) (171 ) Proceeds from drawdown of new debt — — — Debt issue costs — — — Fee paid to noteholders — — — Proceeds from issuance of ordinary shares and warrants 80,888 80,838 59 Net cash generated from financing activities 80,397 80,482 (112 ) Effect of exchange rate fluctuations on cash and cash equivalents (5,982 ) (5,333 ) (158 ) Change in cash and cash equivalents (493 ) 14,216 3,406 Beginning cash and cash equivalents 12,940 12,940 12,940 Ending cash and cash equivalents $ 12,447 $ 27,156 $ 16,346 Supplemental cash flow disclosures: Income taxes paid — $ — $ — Interest paid $ 17,499 $ 8,765 $ 8,731 Reconciliation of cash, cash equivalents and restricted cash: Cash and cash equivalents $ 3,401 $ 18,125 $ 7,325 Restricted cash $ 9,046 $ 9,031 $ 9,021 Total cash, cash equivalents and restricted cash $ 12,447 $ 27,156 $ 16,346 (unaudited) December 31, 2020 As previously Reported Restatement Impacts Restatement Reference As Restated ASSETS Current assets: Cash and cash equivalents $ 3,401 $ — $ 3,401 Short-term investments 131,062 — 131,062 Trade accounts receivable, net 4,539 — 4,539 Inventories 23,709 — 23,709 Prepaid expenses and other current assets 4,928 — 4,928 Total current assets 167,639 — 167,639 Rest

Intangible Assets (Tables)

Intangible Assets (Tables)	12 Months Ended
	Mar. 31, 2021
Goodwill And Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets	March 31, 2021 Gross Carrying Amount Accumulated Amortization Net Amount Weighted Average Remaining Useful Customer relationships $ 2,711 $ (2,711 ) $ — — Brands associated with acquired cell lines 559 (190 ) 369 26.4 years Product licenses 944 (694 ) 250 2.6 years Other intangibles 176 (176 ) — — Total $ 4,390 $ (3,771 ) $ 619 16.8 years March 31, 2020 Gross Carrying Amount Accumulated Amortization Net Amount Weighted Average Remaining Useful Customer relationships $ 2,436 $ (2,436 ) $ — — Brands associated with acquired cell lines 502 (158 ) 344 27.4 years Product licenses 849 (568 ) 281 3.5 years Other intangibles 158 (158 ) — — Total $ 3,945 $ (3,320 ) $ 625 16.3 years
Schedule of Future Amortization Expense	Total future amortization expense for intangible assets that have definite lives, based upon the Company’s existing intangible assets and their current estimated useful lives as of March 31, 2021, is estimated as follows: 2022 $ 76 2023 76 2024 76 2025 77 2026 14 Thereafter 300 Total $ 619

Debt (Tables)

Debt (Tables)	12 Months Ended
	Mar. 31, 2021
Debt Disclosure [Abstract]
Schedule of Long-Term Debt	Total debt comprises: March 31, 2021 March 31, 2020 As Restated As Restated Secured Notes $ 145,000 $ 145,000 Debt discount, net of amortization (11,127 ) (16,261 ) Deferred debt costs, net of amortization (4,261 ) (6,375 ) Carrying value Secured Notes 129,612 122,364 Royalty liability 39,614 33,897 Total Debt $ 169,226 $ 156,261
Schedule of Outstanding Debt	The outstanding debt at March 31, 2021 falls due for repayment as follows: Within 1 year $ 24,167 Between 1 and 2 years 42,291 Between 2 and 3 years 48,334 Between 3 and 4 years 30,208 Between 4 and 5 years — Total debt $ 145,000

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Mar. 31, 2021
Fair Value Disclosures [Abstract]
Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis	The following table summarizes the Company’s assets and liabilities that are measured at fair value on a recurring basis, by level, within the fair value hierarchy: March 31, 2021 Level 1 Level 2 Level 3 Total Assets: Pension plan assets ( 1) $ — $ 15,751 $ — $ 15,751 Short-term investments ( 2) — 15,000 — 15,000 Foreign currency forward contracts ( 3) $ — $ 355 $ — $ 355 Total assets measured at fair value $ — $ 31,106 $ — $ 31,106 March 31, 2020 Level 1 Level 2 Level 3 Total Assets: Pension plan assets ( 1) $ — $ 12,436 $ — $ 12,436 Short-term investments ( 2) 116,871 — — 116,871 Total assets measured at fair value $ 116,871 $ 12,436 $ — $ 129,307 March 31, 2020 Level 1 Level 2 Level 3 Total Liabilities: Foreign currency forward contracts ( 3) $ — $ 227 $ — $ 227 Total liabilities measured at fair value $ — $ 227 $ — $ 227 (1) The fair value of pension plan assets has been determined as the surrender value of the portfolio of active insured employees held within the AXA LLP Foundation Suisse Romande collective investment fund. (2) The fair value of short-term investments has been determined based on the quoted value of the units held in the money market fund at the balance sheet date. The short-term investments as of March 31, 2021, relate to new investments made in a Treasury Money Market Fund. See Note 1, “Summary of Significant Accounting Policies – Short-term Investments”. (3) The fair value of foreign currency forward contracts has been determined by calculating the present value of future cash flows, estimated using market-based observable inputs including forward and spot exchange rates and interest rate curves obtained from third party market price quotations.

Consolidated Balance Sheet De_2

Consolidated Balance Sheet Detail (Tables)	12 Months Ended
	Mar. 31, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Summary of Inventory	The following table summarizes inventory by category for the periods presented: March 31, 2021 March 31, 2020 Raw materials $ 9,189 $ 9,737 Work in progress 9,105 8,522 Finished goods 3,717 2,242 Total inventories $ 22,011 $ 20,501
Summary of Property and Equipment	The following table summarizes property and equipment by categories for the periods presented: March 31, 2021 March 31, 2020 As Restated As Restated Plant and equipment $ 62,940 $ 57,726 Leasehold improvements $ 33,369 31,395 Total property and equipment 96,309 89,121 Less: accumulated depreciation (57,238 ) (48,681 ) Total property and equipment, net $ 39,071 $ 40,440
Summary of Accrued Compensation and Benefits	Accrued compensation and benefits consist of the following: March 31, 2021 March 31, 2020 As Restated Salary and related benefits $ 666 $ 635 Accrued vacation 931 521 Accrued payroll taxes 1,765 1,200 Accrued incentive payments 5,392 3,700 Accrued termination and transition payments 3,589 1,154 Total accrued compensation and benefits $ 12,343 $ 7,210
Summary of Accrued Expenses and Other Current Liabilities	Accrued expenses and other current liabilities consist of the following: March 31, 2021 March 31, 2020 As Restated Accrued legal and professional fees $ 1,005 $ 829 Accrued interest 8,009 8,056 Goods received not invoiced 1,722 1,724 Accrued capital expenditure 1,201 1,287 Other accrued expenses 2,072 3,594 Total accrued expenses and other current liabilities $ 14,009 $ 15,490

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Mar. 31, 2021
Commitments And Contingencies Disclosure [Abstract]
Schedule of Purchase Obligations	The following is a schedule by years of purchase obligations as of March 31, 2021: 2022 $ 19,142 2023 13,480 2024 15,878 2025 17,301 2026 23,642 Thereafter — Total minimum future purchase obligations $ 89,443

Geographic Information (Tables)

Geographic Information (Tables)	12 Months Ended
	Mar. 31, 2021
Geographic Areas Revenues And Long Lived Assets [Abstract]
Schedule of Revenue From Customer By Geographic Area	The following table represents revenue attributed to countries based on the location of the customer: Year ended March 31, 2021 2020 2019 Revenue: United States $ 28,135 $ 17,831 $ 14,754 France 7,406 7,105 6,501 Japan 4,506 4,333 3,846 Other foreign countries (1) 3,332 3,387 4,033 $ 43,379 $ 32,656 $ 29,134 (1) No individual country represented more than 10% of the respective totals.
Consolidated Property and Equipment, Net by Country	The table below lists the Company’s property and equipment, net of accumulated depreciation, by country. With the exception of property and equipment, the Company does not identify or allocate its assets by geographic area: March 31, 2021 March 31, 2020 As Restated As Restated Long-lived assets: United Kingdom $ 16,890 $ 17,388 Switzerland 22,181 23,052 $ 39,071 $ 40,440

Ordinary and Preference Shares

Ordinary and Preference Shares (Tables)	12 Months Ended
	Mar. 31, 2021
7% Cumulative Redeemable Preference Shares [Member]
Class Of Stock [Line Items]
Summary of Shares Issued and Outstanding	The Company’s issued and outstanding preference shares consist of the following: Shares Issued and Outstanding Liquidation amount per share March 31, 2021 March 31, 2020 March 31, 2021 March 31, 2020 7% Cumulative Redeemable Preference shares 666,665 666,665 $ 32.21 $ 30.64 Total 666,665 666,665
Ordinary Shares [Member]
Class Of Stock [Line Items]
Summary of Shares Issued and Outstanding	The Company’s issued and outstanding ordinary shares consist of the following: Shares Issued and Outstanding March 31, 2021 March 31, 2020 Par value Ordinary shares 101,264,412 80,398,326 $ — Total 101,264,412 80,398,326 $ —

Share-Based Compensation (Table

Share-Based Compensation (Tables)	12 Months Ended
	Mar. 31, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Summary of Share Option Activity	The following table summarizes share option activity: Number of Share Options Outstanding Weighted Average Exercise Price Weighted Average Remaining Contractual (Months) Outstanding — March 31, 2018 2,096,283 $ 7.79 84 Granted 189,552 6.59 120 Exercised (253,066 ) 5.14 — Forfeited (96,372 ) 12.69 — Outstanding — March 31, 2019 1,936,397 $ 7.77 78 Granted 110,623 8.44 120 Exercised (103,264 ) 4.77 — Forfeited (95,704 ) 12.53 — Outstanding — March 31, 2020 1,848,052 $ 7.73 70 Granted 258,026 5.38 120 Exercised (147,264 ) 1.18 — Forfeited (148,029 ) 10.76 — Outstanding — March 31, 2021 1,810,785 $ 7.69 68 Exercisable —March 31, 2021 1,497,464 $ 8.11 59
Summary of Share Option Granted, Exercise Price, Fair Value, Intrinsic Value	The following table summarizes the options granted in the year ended March 31, 2021 with their exercise prices, the fair value of ordinary shares as of the applicable grant date, and the intrinsic value, if any: Grant Date Number of Options Granted Exercise Price Ordinary Shares Fair Value Per Share at Grant Date Per Share Intrinsic Value of Options May 24, 2020 60,438 $ 7.69 $ 7.69 $ 4.96 September 1, 2020 (1) 45,922 4.81 4.81 3.07 October 29, 2020 81,666 4.55 4.55 2.93 October 31, 2020 70,000 4.72 4.72 3.05 (1) On September 1, 2020, in connection with the appointment of Dr Catherine Larue and Dr Isabelle Buckle to the Board of Directors, we granted each of Dr Larue and Dr Buckle 20,790 options to purchase ordinary shares at an exercise price of $4.81 per share. These grants, which were issued outside of our 2014 Stock Incentive Plan, were approved by our Board of Directors and the Remuneration Committee of our Board pursuant to the inducement grant exception under Nasdaq Rule 5635(c)(4), as an inducement that is material to Dr Larue and Dr Buckle joining our Board. The options vest in three equal installments on each first, second and third anniversary of the grant date. The options have a term of ten years and will be forfeited if not exercised before the expiration of their term. In addition, in the event Dr Larue’s or Dr Buckle’s Board service is terminated, any options not vested shall be forfeited upon termination .
Summary of Weighted-Average Assumptions to Share Options Issued	A summary of the weighted-average assumptions applicable to the share options is as follows: Year ended March 31, 2021 2020 2019 Risk-free interest rate 0.77 % 1.84 % 3.08 % Expected lives (years) 6 6 6 Volatility 73.70 % 69.43 % 67.19 % Dividend yield — — — Grant date fair value (per share) $ 5.38 $ 8.44 $ 6.14 Number granted 258,026 110,623 189,552
Summary of RSUs	A summary of the RSUs in issue at March 31, 2021 is as follows: Number of RSUs Outstanding Weighted Average Remaining Vesting Period (Months) Period in which the target must be achieved RSUs subject to time based vesting 783,759 10 N/A RSUs subject to milestone based vesting 118,650 N/A N/A

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Mar. 31, 2021
Income Tax Disclosure [Abstract]
Schedule of Components of Provision for Income Taxes	The components of the provision for income taxes are as follows: Year ended March 31, 2021 2020 2019 Income tax (provision) benefit: As Restated As Restated As Restated Current - Federal $ (126 ) $ — $ — Deferred - Federal (1,128 ) (58 ) (30 ) $ (1,254 ) $ (58 ) $ (30 )
Reconciliation of the Income Tax Expenses at the Statutory Rate	A reconciliation of the income tax expense at the statutory rate to the provision for income taxes is as follows: Year ended March 31, 2021 2020 2019 As Restated As Restated As Restated Income tax expense at statutory rate $ — $ — $ — Impact of tax uncertainties (1,200 ) — 14 Foreign tax rate differential 2,362 2,255 5,287 (Increase) decrease in valuation allowance against deferred tax assets (2,416 ) (2,313 ) (5,331 ) Provision for income tax $ (1,254 ) $ (58 ) $ (30 )
Components of Deferred Tax Assets	Significant components of deferred tax assets are as follows: March 31, 2021 March 31, 2020 As Restated As Restated Provisions and reserves $ 1,022 $ 1,315 Operating lease liability 4,100 3,409 Fixed asset basis difference — — Research and development 672 — Net operating loss carry forwards 22,628 19,526 Gross deferred tax assets 28,422 24,250 Fixed asset basis difference (2,289 ) (90 ) Operating lease right-of-use assets (4,100 ) (3,409 ) Gross deferred tax liabilities (6,389 ) (3,499 ) Net deferred tax asset 22,033 20,751 Valuation allowance (22,930 ) (20,514 ) Net deferred taxes $ (897 ) $ 237
Classification of Net Deferred Tax Assets	The balance sheet classification of net deferred tax assets is as follows: March 31, 2021 March 31, 2020 As Restated As Restated Net noncurrent deferred tax assets $ 255 $ 237 Net noncurrent deferred tax liabilities $ (1,152 ) $ — Total $ (897 ) $ 237
Summary of Activity Related to Uncertain Tax Positions	The following table summarizes the activity related to the Company’s uncertain tax positions (excluding interest and penalties and related tax attributes): 2021 2020 2019 As Restated As Restated As Restated Balance at beginning of year $ 1,216 $ 603 $ 617 Increases related to current year tax positions — 613 (14 ) Increases related to prior years tax positions — — — Balance at end of year $ 1,216 $ 1,216 $ 603

Pension Plans (Tables)

Pension Plans (Tables)	12 Months Ended
	Mar. 31, 2021
Defined Benefit Plan Net Periodic Benefit Cost [Abstract]
Reconciliation of Benefit Obligations	The following provides a reconciliation of the benefit obligations, the plan assets and the funded status. Year ended March 31, 2021 March 31, 2020 As Restated As Restated Pension benefit obligation, beginning of year $ 18,789 $ 17,784 Service cost 2,272 2,003 Contributions paid by plan participants 2,704 2,180 Interest cost 126 131 Benefits paid (2,207 ) (2,841 ) Prior service cost — 836 Actuarial loss / (gain) 648 (1,915 ) Foreign currency translation 316 611 Pension benefit obligation, end of year $ 22,648 $ 18,789
Reconciliation of Plan Assets	Year ended March 31, 2021 March 31, 2020 Fair value of plan assets, beginning of year $ 12,436 $ 10,416 Actual return on plan assets 1,293 1,008 Contributions paid by employer 1,333 1,280 Contributions paid by plan participants 2,704 2,180 Benefits paid (2,207 ) (2,841 ) Foreign currency translation 192 393 Fair value of plan assets, end of year $ 15,751 $ 12,436
Reconciliation of Funded Status	Year ended March 31, 2021 March 31, 2020 Pension benefit obligation, end of year $ 22,648 $ 18,789 Fair value of plan assets, end of year 15,751 12,436 Net funding obligation, end of year $ 6,897 $ 6,353
Assumptions Used to Determine Pension Benefit Obligation	The assumptions used to determine the pension benefit obligation at the end of each financial year are: Year ended March 31, 2021 March 31, 2020 March 31, 2019 Price inflation 1.00 % 1.00 % 1.00 % Discount rate 0.35 % 0.60 % 0.70 % Interest rate on retirement savings capital 0.60 % 0.60 % 1.20 % Expected return on plan assets 1.75 % 1.75 % 1.20 % Average rate of salary increase 1.00 % 1.00 % 1.00 %
Schedule of Net Pension Costs	The net pension costs for the year are based on the assumptions adopted at the start of each financial year and comprise: Year ended March 31, 2021 March 31, 2020 March 31, 2019 As Restated As Restated Employer service cost $ 2,272 $ 2,003 $ 1,574 Interest cost 126 131 153 Expected return on plan assets (243 ) (130 ) (131 ) Amortization of prior service credit 58 (23 ) (14 ) Amortization of net loss — 216 154 Net pension cost $ 2,213 $ 2,197 $ 1,736
Schedule of Provision for Pension Benefit Obligation Recognized in Other Comprehensive Income	The provision for pension benefit obligation recognized in other comprehensive income comprises: Year ended As Restated As Restated March 31, 2021 March 31, 2020 March 31, 2019 Net actuarial (gain) / loss $ (389 ) $ (2,016 ) $ 1,027 Amortization of prior service credit (58 ) 23 14 Amortization of net loss — (216 ) (154 ) $ (447 ) $ (2,209 ) $ 887
Schedule of Benefit Payments Expected to be Paid	The following benefit payments are expected to be paid in the following periods: 2022 $ 1,122 2023 $ 1,161 2024 $ 1,178 2025 $ 1,199 2026 $ 1,215 2027 to 2030 $ 6,397

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	12 Months Ended
	Mar. 31, 2021
Earnings Per Share [Abstract]
Computation of Earnings Per Share Basic and Diluted	The following table sets forth the computation of basic loss per ordinary share. Diluted earnings per share figures are not applicable due to losses. Year ended March 31, 2021 2020 2019 As Restated As Restated As Restated Numerator: Net loss $ (111,032 ) $ (105,138 ) $ (106,411 ) Net loss available to ordinary shareholders - basic and diluted $ (111,032 ) $ (105,138 ) $ (106,411 ) Denominator: Weighted-average shares outstanding - basic and diluted 91,637,966 71,610,035 54,874,391 Loss per share - basic and diluted $ (1.21 ) $ (1.47 ) $ (1.94 )
Summary of Number of Ordinary Shares Excluded from Computation of Earnings Per Share	The following sets out the numbers of the options, RSUs and warrants to purchase ordinary shares excluded from the above computation of earnings per share for the years ended March 31, 2021, March 31, 2020 and March 31, 2019, as their inclusion would have been anti-dilutive. March 31, 2021 March 31, 2020 March 31, 2019 Ordinary shares issuable on exercise of options to purchase ordinary shares 1,810,785 1,848,052 1,936,397 Restricted share units awarded 902,409 694,347 966,689 Ordinary shares issuable on exercise of warrants at $16.14 per share 111,525 111,525 111,525 Ordinary shares issuable on exercise of warrants at $9.375 per share 64,000 64,000 64,000 2,888,719 2,717,924 3,078,611

Lease Commitments (Tables)

Lease Commitments (Tables)	12 Months Ended
	Mar. 31, 2021
Leases [Abstract]
Schedule of Elements of Lease Expense	The elements of lease expense were as follows: Year ended March 31, 2021 2020 Operating lease cost $ 4,414 $ 3,694 Finance lease cost Amortization of right-of-use asset 998 832 Interest on lease liabilities 129 119 Short-term lease cost 62 69 Total lease cost $ 5,603 $ 4,714
Summary of Other Information Related to Leases	Other information related to leases was as follows: Year ended March 31, 2021 2020 Cash paid for amounts included in the measurement of lease liabilities Operating leases - operating cash flows $ 3,793 $ 3,043 Finance leases - financing cash flows $ 633 $ 524 Finance leases - operating cash flows $ 129 $ 119 Non-cash leases activity Right-of-use assets obtained in exchange for new operating lease liabilities $ 332 $ 5,160 Right-of-use assets obtained in exchange for new finance lease liabilities $ 130 $ 969 As of March 31, 2021 As of March 31, 2020 Weighted average remaining lease terms (in years) Operating leases 29.5 30 Finance leases 1.6 2.3 Weighted average discount rate Operating leases 10.9 % 10.8 % Finance leases 9.1 % 4.5 %
Schedule of Future Lease Payments Required Under Non-Cancellable Operating Leases	Future lease payments required under non-cancellable operating leases in effect as of March 31, 2021 were as follows: March 31, 2021 March 31, 2020 2022 $ 3,819 $ 3,335 2023 3,295 3,319 2024 3,285 3,050 2025 3,334 3,055 2026 2,237 3,105 Thereafter 71,347 66,138 Total lease payments $ 87,317 $ 82,002 Less : imputed interest (62,963 ) (59,055 ) Total operating lease liabilities $ 24,354 $ 22,947
Schedule of Future Lease Payments Required Under Finance Leases	Future lease payments required under finance leases in effect as of March 31, 2021 were as follows: March 31, 2021 March 31, 2020 2022 $ 935 $ 720 2023 422 838 2024 42 349 2025 12 7 2026 — — Total lease payments 1,411 1,914 Less : imputed interest (131 ) (199 ) Total finance lease liabilities $ 1,280 $ 1,715

Restatement of Previously Iss_2

Restatement of Previously Issued Unaudited Condensed Consolidated Financial Statements (Tables)	12 Months Ended
	Mar. 31, 2021
Prior Period Adjustment [Abstract]
Schedule of Restatement of Previously Reported Consolidated Financial Statements	March 31, 2021 As previously Reported Restatement Impacts Restatement Reference As Restated ASSETS Current assets: Cash and cash equivalents $ 45,673 $ — $ 45,673 Short-term investments 65,999 — 65,999 Trade accounts receivable, net 5,323 — 5,323 Inventories 22,011 — 22,011 Prepaid expenses and other current assets 4,870 — 4,870 Total current assets 143,876 — 143,876 Restricted cash 9,024 — 9,024 Property and equipment, net 38,530 541 (B) 39,071 Operating lease right-of-use assets 22,011 — 22,011 Intangible assets, net 619 — 619 Deferred income taxes 255 — 255 Other non-current assets 4,956 — 4,956 Total assets $ 219,271 $ 541 $ 219,812 LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIT) Current liabilities: Accounts payable $ 4,659 $ — $ 4,659 Accrued compensation and benefits 11,833 510 (C) 12,343 Accrued expenses and other current liabilities 13,889 120 (F) 14,009 Current portion of long-term debt 24,167 — 24,167 Current portion of operating lease liability 3,446 — 3,446 Current portion of finance lease obligation 835 — 835 Total current liabilities 58,829 630 59,459 Long-term debt, less current portion 137,936 7,123 (A) 145,059 Operating lease liability, less current portion 20,907 — 20,907 Finance lease obligation, less current portion 445 — 445 Deferred income taxes 1,824 (672 ) (E) 1,152 Defined benefit pension plan obligation 6,896 — 6,896 7% Cumulative redeemable preference shares 21,475 — 21,475 Total liabilities 248,312 7,081 255,393 Commitments and contingencies — — — Shareholders' equity (deficit): Ordinary shares ( nil 540,813 — 540,813 Additional paid in capital 38,116 — 38,116 Accumulated other comprehensive loss (16,065 ) 1,467 (D) (14,598 ) Accumulated deficit (591,905 ) (8,007 ) (A)(B)(C)(D)(E)(F) (599,912 ) Total shareholders' equity (deficit) (29,041 ) (6,540 ) (35,581 ) Total liabilities and shareholders' equity (deficit) $ 219,271 $ 541 $ 219,812 March 31, 2020 As previously Reported Restatement Impacts Restatement Reference As Restated ASSETS Current assets: Cash and cash equivalents $ 3,923 $ — $ 3,923 Short-term investments 116,871 — 116,871 Trade accounts receivable, net 5,402 — 5,402 Inventories 20,501 — 20,501 Prepaid expenses and other current assets 3,775 — 3,775 Total current assets 150,472 — 150,472 Restricted cash 9,017 — 9,017 Property and equipment, net 40,165 275 (B) 40,440 Operating lease right-of-use assets 21,493 — 21,493 Intangible assets, net 625 — 625 Deferred income taxes 237 — 237 Other non-current assets 4,454 — 4,454 Total assets $ 226,463 $ 275 $ 226,738 LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIT) Current liabilities: Accounts payable $ 4,826 $ — $ 4,826 Accrued compensation and benefits 7,210 — 7,210 Accrued expenses and other current liabilities 15,490 — 15,490 Current portion of long-term debt — — — Current portion of operating lease liability 3,033 — 3,033 Current portion of finance lease obligation 598 — 598 Total current liabilities 31,157 — 31,157 Long-term debt, less current portion 153,024 3,237 (A) 156,261 Operating lease liability, less current portion 19,914 — 19,914 Finance lease obligation, less current portion 1,117 — 1,117 Deferred income taxes — — — Defined benefit pension plan obligation 6,353 — 6,353 7% Cumulative redeemable preference shares 20,425 — 20,425 Total liabilities 231,990 3,237 235,227 Commitments and contingencies — — — Shareholders' equity (deficit): Ordinary shares ( nil 459,931 — 459,931 Additional paid in capital 33,132 — 33,132 Accumulated other comprehensive loss (15,155 ) 2,483 (D) (12,672 ) Accumulated deficit (483,435 ) (5,445 ) (A)(B)(D) (488,880 ) Total shareholders' equity (deficit) (5,527 ) (2,962 ) (8,489 ) Total liabilities and shareholders' equity (deficit) $ 226,463 $ 275 $ 226,738 Year ended March 31, 2021 As previously Reported Restatement Impacts Restatement Reference As Restated Revenue: Product sales $ 35,787 $ — $ 35,787 Other revenues 7,592 — 7,592 Total revenue 43,379 — 43,379 Cost of revenue (20,074 ) — (20,074 ) Gross profit 23,305 — 23,305 Operating expenses: Sales and marketing (9,849 ) — (9,849 ) Research and development, net of government grants (54,168 ) 441 (B)(F) (53,727 ) General and administrative expense: Compensation expense in respect of share options and management equity incentives (4,984 ) — (4,984 ) Other general and administrative expenses (36,812 ) (630 ) (C)(F) (37,442 ) Total general and administrative expense (41,796 ) (630 ) (42,426 ) Total operating expense (105,813 ) (189 ) (106,002 ) Operating loss (82,508 ) (189 ) (82,697 ) Other income (expense): Interest expense, net (25,918 ) (3,886 ) (A) (29,804 ) Other, net 1,882 841 (D) 2,723 Other income (expense), net (24,036 ) (3,045 ) (27,081 ) Loss before income taxes (106,544 ) (3,234 ) (109,778 ) Provision for income taxes (1,926 ) 672 (E) (1,254 ) Net loss $ (108,470 ) $ (2,562 ) $ (111,032 ) Other comprehensive income (loss): Change in fair value of effective portion of foreign currency cash flow hedges $ 582 $ — $ 582 Unrealized gain (loss) on short-term investments (898 ) — (898 ) Foreign currency gain (loss) (1,216 ) (841 ) (D) (2,057 ) Provision for pension benefit obligation 622 (175 ) (F) 447 Other comprehensive loss, net (910 ) (1,016 ) (1,926 ) Comprehensive loss $ (109,380 ) $ (3,578 ) $ (112,958 ) Net loss available to ordinary shareholders - basic and diluted $ (108,470 ) $ (2,562 ) $ (111,032 ) Loss per share - basic and diluted $ (1.18 ) $ (0.03 ) $ (1.21 ) Weighted-average shares outstanding - basic and diluted 91,637,966 — 91,637,966 Year ended March 31, 2020 As previously Reported Restatement Impacts Restatement Reference As Restated Revenue: Product sales $ 31,601 $ — $ 31,601 Other revenues 1,055 — 1,055 Total revenue 32,656 — 32,656 Cost of revenue (17,800 ) — (17,800 ) Gross profit 14,856 — 14,856 Operating expenses: Sales and marketing (9,853 ) — (9,853 ) Research and development, net of government grants (53,744 ) 306 (B)(F) (53,438 ) General and administrative expense: Compensation expense in respect of share options and management equity incentives (4,467 ) — (4,467 ) Other general and administrative expenses (27,483 ) — (27,483 ) Total general and administrative expense (31,950 ) — (31,950 ) Total operating expense (95,547 ) 306 (95,241 ) Operating loss (80,691 ) 306 (80,385 ) Other income (expense): Interest expense, net (23,859 ) (3,041 ) (A) (26,900 ) Other, net 2,438 (233 ) (D) 2,205 Other income (expense), net (21,421 ) (3,274 ) (24,695 ) Loss before income taxes (102,112 ) (2,968 ) (105,080 ) Provision for income taxes (661 ) 603 (E) (58 ) Net loss $ (102,773 ) $ (2,365 ) $ (105,138 ) Other comprehensive income (loss): Change in fair value of effective portion of foreign currency cash flow hedges $ (157 ) $ — $ (157 ) Unrealized gain (loss) on short-term investments 554 — 554 Foreign currency gain (loss) (2,702 ) 233 (D) (2,469 ) Provision for pension benefit obligation 2,034 175 (F) 2,209 Other comprehensive loss, net (271 ) 408 137 Comprehensive loss $ (103,044 ) $ (1,957 ) $ (105,001 ) Net loss available to ordinary shareholders - basic and diluted $ (102,773 ) $ (2,365 ) $ (105,138 ) Loss per share - basic and diluted $ (1.44 ) $ (0.03 ) $ (1.47 ) Weighted-average shares outstanding - basic and diluted 71,610,035 — 71,610,035 Year ended March 31, 2019 As previously Reported Restatement Impacts Restatement Reference As Restated Revenue: Product sales $ 28,665 $ — $ 28,665 Other revenues 469 — 469 Total revenue 29,134 — 29,134 Cost of revenue (17,230 ) — (17,230 ) Gross profit 11,904 — 11,904 Operating expenses: Sales and marketing (8,637 ) — (8,637 ) Research and development, net of government grants (50,677 ) (206 ) (B) (50,883 ) General and administrative expense: Compensation expense in respect of share options and management equity incentives (4,957 ) — (4,957 ) Other general and administrative expenses (26,588 ) — (26,588 ) Total general and administrative expense (31,545 ) — (31,545 ) Total operating expense (90,859 ) (206 ) (91,065 ) Operating loss (78,955 ) (206 ) (79,161 ) Other income (expense): Interest expense, net (20,018 ) (259 ) (A) (20,277 ) Other, net (6,369 ) (574 ) (D) (6,943 ) Other income (expense), net (26,387 ) (833 ) (27,220 ) Loss before income taxes (105,342 ) (1,039 ) (106,381 ) Provision for income taxes (44 ) 14 (E) (30 ) Net loss $ (105,386 ) $ (1,025 ) $ (106,411 ) Other comprehensive income (loss): Change in fair value of effective portion of foreign currency cash flow hedges $ (123 ) $ — $ (123 ) Unrealized gain (loss) on short-term investments 796 — 796 Foreign currency gain (loss) 1,964 574 (D) 2,538 Provision for pension benefit obligation (887 ) — (887 ) Other comprehensive loss, net 1,750 574 2,324 Comprehensive loss $ (103,636 ) $ (451 ) $ (104,087 ) Net loss available to ordinary shareholders - basic and diluted $ (105,386 ) $ (1,025 ) $ (106,411 ) Loss per share - basic and diluted $ (1.92 ) $ (0.02 ) $ (1.94 ) Weighted-average shares outstanding - basic and diluted 54,874,391 — 54,874,391 Ordinary shares Shares Amount Additional paid in Capital Accumulated Other Comprehensive Loss Accumulated Deficit Total Shareholders' Equity (Deficit) As Previously Reported March 31, 2018 45,646,424 253,934 23,708 (16,634 ) (275,639 ) (14,631 ) Issue of shares, net of issue costs of $4,052 19,635,068 113,724 — — — 113,724 Issue of shares upon exercise of incentive share options and vesting of RSUS 618,955 1,300 — — — 1,300 Net loss — — — — (105,386 ) (105,386 ) Change in fair value of the effective portion of foreign currency cash flow hedges — — — (123 ) — (123 ) Change in unrealized gain in short-term investments — — — 796 — 796 Foreign currency gain (loss) on: Long-term investment nature intra-entity balances — — — 5,074 — 5,074 Retranslation of foreign entities — — — (3,110 ) — (3,110 ) Provision for pension benefit obligation — — — (887 ) — (887 ) Other comprehensive loss 1,750 1,750 Stock-based compensation — — 4,957 — — 4,957 March 31, 2019 65,900,447 368,958 28,665 (14,884 ) (381,025 ) 1,714 Restatement Impacts March 31, 2018 — — — 1,501 (2,055 ) (554 ) Issue of shares, net of issue costs of $4,052 — — — — — — Issue of shares upon exercise of incentive share options and vesting of RSUS — — — — — — Net loss — — — — (1,025 ) (1,025 ) Change in fair value of the effective portion of foreign currency cash flow hedges — — — — — — Change in unrealized gain in short-term investments — — — — — — Foreign currency gain (loss) on: Long-term investment nature intra-entity balances — — — — — — Retranslation of foreign entities — — — 574 — 574 Provision for pension benefit obligation — — — — — — Other comprehensive loss 574 574 Stock-based compensation — — — — — — March 31, 2019 — — — 2,075 (3,080 ) (1,005 ) As Restated March 31, 2018 45,646,424 253,934 23,708 (15,133 ) (277,694 ) (15,185 ) Issue of shares, net of issue costs of $4,052 19,635,068 113,724 — — — 113,724 Issue of shares upon exercise of incentive share options and vesting of RSUS 618,955 1,300 — — — 1,300 Net loss — — — — (106,411 ) (106,411 ) Change in fair value of the effective portion of foreign currency cash flow hedges — — — (123 ) — (123 ) Change in unrealized gain in short-term investments — — — 796 — 796 Foreign currency gain (loss) on: — Long-term investment nature intra-entity balances — — — 5,074 — 5,074 Retranslation of foreign entities — — — (2,536 ) — (2,536 ) Provision for pension benefit obligation — — — (887 ) — (887 ) Other comprehensive loss 2,324 2,324 Stock-based compensation — — 4,957 — — 4,957 March 31, 2019 65,900,447 368,958 28,665 (12,809 ) (384,105 ) 709 Ordinary shares Shares Amount Additional paid in Capital Accumulated Other Comprehensive Loss Accumulated Deficit Total Shareholders' Equity (Deficit) As Previously Reported March 31, 2019 65,900,447 $ 368,958 $ 28,665 $ (14,884 ) $ (381,025 ) $ 1,714 Issue of shares, net of issue costs of $6,072 13,800,000 90,528 — — — 90,528 Issue of shares upon exercise of incentive share options and vesting of RSUS 697,879 445 — — — 445 Net loss — — — — (102,773 ) (102,773 ) Change in fair value of the effective portion of foreign currency cash flow hedges — — — (157 ) — (157 ) Change in unrealized gain in short-term investments — — — 554 — 554 Foreign currency gain (loss) on: Long-term investment nature intra-entity balances — — — 18,394 — 18,394 Retranslation of foreign entities — — — (21,096 ) — (21,096 ) Provision for pension benefit obligation — — — 2,034 — 2,034 Other comprehensive loss (271 ) (271 ) Stock-based compensation — — 4,467 — — 4,467 Cumulative effect of accounting changes — — — 363 363 March 31, 2020 80,398,326 459,931 33,132 (15,155 ) (483,435 ) (5,527 ) Restatement Impacts March 31, 2019 — $ — $ — $ 2,075 $ (3,080 ) $ (1,005 ) Issue of shares, net of issue costs of $6,072 — — — — — — Issue of shares upon exercise of incentive share options and vesting of RSUS — — — — — — Net loss — — — — (2,365 ) (2,365 ) Change in fair value of the effective portion of foreign currency cash flow hedges — — — — — — Change in unrealized gain in short-term investments — — — — — — Foreign currency gain (loss) on: Long-term investment nature intra-entity balances — — — — — — Retranslation of foreign entities — — — 233 — 233 Provision for pension benefit obligation — — — 175 — 175 Other comprehensive loss 408 408 Stock-based compensation — — — — — — Cumulative effect of accounting changes — — — — — — March 31, 2020 — — — 2,483 (5,445 ) (2,962 ) As Restated March 31, 2019 65,900,447 $ 368,958 $ 28,665 $ (12,809 ) $ (384,105 ) $ 709 Issue of shares, net of issue costs of $6,072 13,800,000 90,528 — — — 90,528 Issue of shares upon exercise of incentive share options and vesting of RSUS 697,879 445 — — — 445 Net loss — — — — (105,138 ) (105,138 ) Change in fair value of the effective portion of foreign currency cash flow hedges — — — (157 ) — (157 ) Change in unrealized gain in short-term investments — — — 554 — 554 Foreign currency gain (loss) on: Long-term investment nature intra-entity balances — — — 18,394 — 18,394 Retranslation of foreign entities — — — (20,863 ) — (20,863 ) Provision for pension benefit obligation — — — 2,209 — 2,209 Other comprehensive loss 137 137 Stock-based compensation — — 4,467 — — 4,467 Cumulative effect of accounting changes — — — — 363 363 March 31, 2020 80,398,326 459,931 33,132 (12,672 ) (488,880 ) (8,489 ) Ordinary shares Shares Amount Additional paid in Capital Accumulated Other Comprehensive Loss Accumulated Deficit Total Shareholders' Equity (Deficit) As Previously Reported March 31, 2020 80,398,326 459,931 33,132 (15,155 ) (483,435 ) (5,527 ) Issue of shares, net of issue costs of $5,565 20,294,117 80,685 — — — 80,685 Issue of shares upon exercise of incentive share options and vesting of RSUS 571,969 197 — — — 197 Net loss — — — — (108,470 ) (108,470 ) Change in fair value of the effective portion of foreign currency cash flow hedges — — — 582 — 582 Change in unrealized gain in short-term investments — — — (898 ) — (898 ) Foreign currency gain (loss) on: Long-term investment nature intra-entity balances — — — (27,251 ) — (27,251 ) Retranslation of foreign entities — — — 26,035 — 26,035 Provision for pension benefit obligation — — — 622 — 622 Other comprehensive loss (910 ) (910 ) Stock-based compensation — — 4,984 — — 4,984 March 31, 2021 101,264,412 540,813 38,116 (16,065 ) (591,905 ) (29,041 ) Restatement Impacts March 31, 2020 — — — 2,483 (5,445 ) (2,962 ) Issue of shares, net of issue costs of $5,565 — — — — — — Issue of shares upon exercise of incentive share options and vesting of RSUS — — — — — — Net loss — — — — (2,562 ) (2,562 ) Change in fair value of the effective portion of foreign currency cash flow hedges — — — — — — Change in unrealized gain in short-term investments — — — — — — Foreign currency gain (loss) on: Long-term investment nature intra-entity balances — — — — — — Retranslation of foreign entities — — — (841 ) — (841 ) Provision for pension benefit obligation — — — (175 ) — (175 ) Other comprehensive loss (1,016 ) (1,016 ) Stock-based compensation — — — — — — March 31, 2021 — — — (1,016 ) (8,007 ) (6,540 ) As Restated March 31, 2020 80,398,326 459,931 33,132 (12,672 ) (488,880 ) (8,489 ) Issue of shares, net of issue costs of $5,565 20,294,117 80,685 — — — 80,685 Issue of shares upon exercise of incentive share options and vesting of RSUS 571,969 197 — — — 197 Net loss — — — — (111,032 ) (111,032 ) Change in fair value of the effective portion of foreign currency cash flow hedges — — — 582 — 582 Change in unrealized gain in short-term investments — — — (898 ) — (898 ) Foreign currency gain (loss) on: Long-term investment nature intra-entity balances — — — (27,251 ) — (27,251 ) Retranslation of foreign entities — — — 25,194 — 25,194 Provision for pension benefit obligation — — — 447 — 447 Other comprehensive loss (1,926 ) (1,926 ) Stock-based compensation — — 4,984 — — 4,984 March 31, 2021 101,264,412 540,813 38,116 (14,598 ) (599,912 ) (35,581 ) Year ended March 31, 2021 As previously Reported Restatement Impacts As Restated OPERATING ACTIVITIES: Net loss $ (108,470 ) $ (2,562 ) $ (111,032 ) Adjustments to reconcile net loss to net cash provided by operating activities: Depreciation, amortization and loss on disposal of fixed assets 8,620 (266 ) 8,354 Share-based compensation 4,984 — 4,984 Increase in deferred lease rentals 726 — 726 Swiss pension obligation 1,054 — 1,054 Amortization of deferred debt issue costs 9,079 3,886 12,965 Impairment of short term investments 2,285 — 2,285 Accrued preference share dividends 1,050 — 1,050 Income taxes 1,926 (672 ) 1,254 Net change in assets and liabilities: Trade accounts receivable, net 568 — 568 Inventories (475 ) — (475 ) Accounts payable and accrued liabilities (2,514 ) (896 ) (3,410 ) Accrued compensation and benefits 4,039 510 4,549 Other assets (454 ) — (454 ) Net cash used in operating activities (77,582 ) — (77,582 ) INVESTING ACTIVITIES: Increase in short-term investments (87,247 ) — (87,247 ) Realization of short-term investments 134,936 — 134,936 Purchase of property and equipment (4,240 ) — (4,240 ) Purchase of intangible assets — — — Net cash from (used in) investing activities 43,449 — 43,449 FINANCING ACTIVITIES: Repayment of finance leases (633 ) — (633 ) Proceeds from drawdown of new debt — — — Debt issue costs — — — Fee paid to noteholders — — — Proceeds from issuance of ordinary shares and warrants 80,881 — 80,881 Net cash generated from financing activities 80,248 — 80,248 Effect of exchange rate fluctuations on cash and cash equivalents (4,358 ) — (4,358 ) Change in cash and cash equivalents 41,757 — 41,757 Beginning cash and cash equivalents 12,940 — 12,940 Ending cash and cash equivalents $ 54,697 $ — $ 54,697 Supplemental cash flow disclosures: Income taxes paid $ — $ — $ — Interest paid $ 17,529 $ — $ 17,529 Reconciliation of cash, cash equivalents and restricted cash: Cash and cash equivalents $ 45,673 $ — $ 45,673 Restricted cash $ 9,024 $ — $ 9,024 Total cash, cash equivalents and restricted cash $ 54,697 $ — $ 54,697 Year ended March 31, 2020 As previously Reported Restatement Impacts As Restated OPERATING ACTIVITIES: Net loss $ (102,773 ) $ (2,365 ) $ (105,138 ) Adjustments to reconcile net loss to net cash provided by operating activities: Depreciation, amortization and loss on disposal of fixed assets 12,276 (275 ) 12,001 Share-based compensation 4,467 — 4,467 Increase in deferred lease rentals 293 — 293 Swiss pension obligation 756 — 756 Amortization of deferred debt issue costs 7,043 3,041 10,084 Impairment of short term investments — — — Accrued preference share dividends 1,050 — 1,050 Income taxes 368 (537 ) (169 ) Net change in assets and liabilities: Trade accounts receivable, net (2,177 ) — (2,177 ) Inventories (4,967 ) (206 ) (5,173 ) Accounts payable and accrued liabilities 2,456 342 2,798 Accrued compensation and benefits 1,218 — 1,218 Other assets (656 ) — (656 ) Net cash used in operating activities (80,646 ) — (80,646 ) INVESTING ACTIVITIES: Increase in short-term investments (95,000 ) — (95,000 ) Realization of short-term investments 69,412 — 69,412 Purchase of property and equipment (4,598 ) — (4,598 ) Purchase of intangible assets (2 ) — (2 ) Net cash from (used in) investing activities (30,188 ) — (30,188 ) FINANCING ACTIVITIES: Repayment of finance leases (524 ) — (524 ) Proceeds from drawdown of new debt 25,000 — 25,000 Debt issue costs (874 ) — (874 ) Fee paid to noteholders — — — Proceeds from issuance of ordinary shares and warrants 90,973 — 90,973 Net cash generated from financing activities 114,575 — 114,575 Effect of exchange rate fluctuations on cash and cash equivalents (2,404 ) — (2,404 ) Change in cash and cash equivalents 1,337 — 1,337 Beginning cash and cash equivalents 11,603 — 11,603 Ending cash and cash equivalents $ 12,940 $ — $ 12,940 Supplemental cash flow disclosures: Income taxes paid $ — $ — $ — Interest paid $ 15,776 $ — $ 15,776 Reconciliation of cash, cash equivalents and restricted cash: Cash and cash equivalents $ 3,923 $ — $ 3,923 Restricted cash $ 9,017 $ — $ 9,017 Total cash, cash equivalents and restricted cash $ 12,940 $ — $ 12,940 Year ended March 31, 2019 As previously Reported Restatement Impacts As Restated OPERATING ACTIVITIES: Net loss $ (105,386 ) $ (1,025 ) $ (106,411 ) Adjustments to reconcile net loss to net cash provided by operating activities: Depreciation, amortization and loss on disposal of fixed assets 12,767 — 12,767 Share-based compensation 4,957 — 4,957 Increase in deferred lease rentals 372 — 372 Swiss pension obligation 575 — 575 Amortization of deferred debt issue costs 5,908 259 6,167 Impairment of short term investments — — — Accrued preference share dividends 1,050 — 1,050 Income taxes 44 (105 ) (61 ) Net change in assets and liabilities: Trade accounts receivable, net (637 ) — (637 ) Inventories (93 ) 206 113 Accounts payable and accrued liabilities 370 665 1,035 Accrued compensation and benefits 1,121 — 1,121 Other assets 3,297 — 3,297 Net cash used in operating activities (75,655 ) — (75,655 ) INVESTING ACTIVITIES: Increase in short-term investments (119,000 ) — (119,000 ) Realization of short-term investments 34,735 — 34,735 Purchase of property and equipment (4,791 ) — (4,791 ) Purchase of intangible assets (3 ) — (3 ) Net cash from (used in) investing activities (89,059 ) — (89,059 ) FINANCING ACTIVITIES: Repayment of finance leases (486 ) — (486 ) Proceeds from drawdown of new debt 36,000 — 36,000 Debt issue costs (1,216 ) — (1,216 ) Fee paid to noteholders (3,900 ) — (3,900 ) Proceeds from issuance of ordinary shares and warrants 115,024 — 115,024 Net cash generated from financing activities 145,422 — 145,422 Effect of exchange rate fluctuations on cash and cash equivalents 5,690 — 5,690 Change in cash and cash equivalents (13,602 ) — (13,602 ) Beginning cash and cash equivalents 25,205 — 25,205 Ending cash and cash equivalents $ 11,603 $ — $ 11,603 Supplemental cash flow disclosures: Income taxes paid $ — $ — $ — Interest paid $ 11,838 $ — $ 11,838 Reconciliation of cash, cash equivalents and restricted cash: Cash and cash equivalents $ 4,096 $ — $ 4,096 Restricted cash $ 7,507 $ — $ 7,507 Total cash, cash equivalents and restricted cash $ 11,603 $ — $ 11,603 (unaudited) December 31, 2020 September 30, 2020 June 30, 2020 ASSETS As Restated As Restated As Restated Current assets: Cash and cash equivalents $ 3,401 $ 18,125 $ 7,325 Short-term investments 131,062 144,618 87,152 Trade accounts receivable, net 4,539 4,518 5,972 Inventories 23,709 22,798 21,291 Prepaid expenses and other current assets 4,928 5,851 4,091 Total current assets 167,639 195,910 125,831 Restricted cash 9,046 9,031 9,021 Property and equipment, net 41,299 40,182 39,563 Operating lease right-of-use assets 22,364 21,557 21,124 Intangible assets, net 632 614 606 Deferred income taxes 741 573 405 Other non-current assets 4,914 4,634 4,438 Total assets $ 246,635 $ 272,501 $ 200,988 LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIT) Current liabilities: Accounts payable $ 5,860 $ 5,138 $ 5,621 Accrued compensation and benefits 4,844 5,191 5,190 Accrued expenses and other current liabilities 11,351 17,410 13,317 Current portion of long-term debt 24,167 12,083 12,083 Current portion of operating lease liability 3,309 3,138 3,045 Current portion of finance lease obligation 878 577 573 Total current liabilities 50,409 43,537 39,829 Long-term debt, less current portion 141,822 149,007 147,260 Operating lease liability, less current portion 21,203 20,282 19,695 Finance lease obligation, less current portion 582 921 1,017 Deferred income taxes 1,455 — — Defined benefit pension plan obligation 7,707 7,169 6,623 7% Cumulative redeemable preference shares 21,213 20,950 20,688 Total liabilities 244,391 241,866 235,112 Commitments and contingencies — — — Shareholders' equity (deficit): Ordinary shares ( nil 540,819 540,769 459,990 Additional paid in capital 36,630 35,416 34,092 Accumulated other comprehensive loss (14,634 ) (16,659 ) (13,070 ) Accumulated deficit (560,571 ) (528,891 ) (515,136 ) Total shareholders' equity (deficit) 2,244 30,635 (34,124 ) Total liabilities and shareholders' equity (deficit) $ 246,635 $ 272,501 $ 200,988 (unaudited) December 31, 2020 September 30, 2020 June 30, 2020 December 31 2020 September 30, 2020 Quarter ended Quarter ended Quarter ended Nine months ended Six months ended As Restated As Restated As Restated As Restated As Restated Revenue: Product sales $ 8,740 $ 8,543 $ 8,924 $ 26,207 $ 17,467 Other revenues 11 7,523 — 7,534 7,523 Total revenue 8,751 16,066 8,924 33,741 24,990 Cost of revenue (4,970 ) (4,499 ) (5,414 ) (14,883 ) (9,913 ) Gross profit 3,781 11,567 3,510 18,858 15,077 Operating expenses: Sales and marketing (2,283 ) (2,231 ) (2,243 ) (6,757 ) (4,474 ) Research and development, net of government grants (14,350 ) (12,743 ) (11,415 ) (38,508 ) (24,158 ) General and administrative expense: Compensation expense in respect of share options and management equity incentives (1,214 ) (1,324 ) (960 ) (3,498 ) (2,284 ) Other general and administrative expenses (7,524 ) (8,232 ) (8,578 ) (24,334 ) (16,810 ) Total general and administrative expense (8,738 ) (9,556 ) (9,538 ) (27,832 ) (19,094 ) Total operating expense (25,371 ) (24,530 ) (23,196 ) (73,097 ) (47,726 ) Operating loss (21,590 ) (12,963 ) (19,686 ) (54,239 ) (32,649 ) Other income (expense): Interest expense, net (9,404 ) (6,297 ) (6,931 ) (22,632 ) (13,228 ) Other, net 617 5,354 208 6,179 5,562 Other income (expense), net (8,787 ) (943 ) (6,723 ) (16,453 ) (7,666 ) Loss before income taxes (30,377 ) (13,906 ) (26,409 ) (70,692 ) (40,315 ) Provision for income taxes (1,303 ) 151 153 (999 ) 304 Net loss $ (31,680 ) $ (13,755 ) $ (26,256 ) $ (71,691 ) $ (40,011 ) Other comprehensive income (loss): Change in fair value of effective portion of foreign currency cash flow hedges $ 295 $ 279 $ (3 ) $ 571 $ 276 Unrealized gain (loss) on short-term investments 111 (79 ) (404 ) (372 ) (483 ) Foreign currency gain (loss) 1,606 (3,803 ) 171 (2,026 ) (3,632 ) Provision for pension benefit obligation 13 14 (162 ) (135 ) (148 ) Other comprehensive loss, net 2,025 (3,589 ) (398 ) (1,962 ) (3,987 ) Comprehensive loss $ (29,655 ) $ (17,344 ) $ (26,654 ) $ (73,652 ) $ (43,998 ) Net loss available to ordinary shareholders - basic and diluted $ (31,680 ) $ (13,755 ) $ (26,256 ) $ (71,691 ) $ (40,011 ) Loss per share - basic and diluted $ (0.31 ) $ (0.16 ) $ (0.33 ) $ (0.81 ) $ (0.49 ) Weighted-average shares outstanding - basic and diluted 101,016,040 83,949,195 80,485,985 88,512,823 82,227,052 (unaudited) Ordinary shares Shares Amount Additional paid in Capital Accumulated Other Comprehensive Loss Accumulated Deficit Total Shareholders' Equity (Deficit) March 31, 2020 As Restated 80,398,326 $ 459,931 $ 33,132 $ (12,672 ) $ (488,880 ) $ (8,489 ) Issue of shares upon exercise of incentive share options and vesting of RSUS 195,114 59 — — — 59 Net loss — — — — (26,256 ) (26,256 ) Change in fair value of the effective portion of foreign currency cash flow hedges — — — (3 ) — (3 ) Change in unrealized gain in short-term investments — — — (404 ) — (404 ) Foreign currency gain (loss) on: — — Long-term investment nature intra-entity balances — — — 4,685 — 4,685 Retranslation of foreign entities — — — (4,514 ) — (4,514 ) Provision for pension benefit obligation — — — (162 ) — (162 ) Other comprehensive loss (398 ) (398 ) Stock-based compensation — — 960 — — 960 June 30, 2020 As Restated 80,593,440 459,990 34,092 (13,070 ) (515,136 ) (34,124 ) Issue of shares, net of issue costs of $5,565 20,294,117 80,685 — — — 80,685 Issue of shares upon exercise of incentive share options and vesting of RSUS 77,894 94 — — — 94 Net loss — — — — (13,755 ) (13,755 ) Change in fair value of the effective portion of foreign currency cash flow hedges — — — 279 — 279 Change in unrealized gain in short-term investments — — — (79 ) — (79 ) Foreign currency gain (loss) on: Long-term investment nature intra-entity balances — — — (3,841 ) — (3,841 ) Retranslation of foreign entities — — — 38 — 38 Provision for pension benefit obligation — — — 14 — 14 Other comprehensive loss (3,589 ) (3,589 ) Stock-based compensation — — 1,324 — — 1,324 September 30, 2020 As Restated 100,965,451 540,769 35,416 (16,659 ) (528,891 ) 30,635 Issue of shares — — — — — — Issue of shares upon exercise of incentive share options and vesting of RSUS 110,394 50 — — — 50 Net loss — — — — (31,680 ) (31,680 ) Change in fair value of the effective portion of foreign currency cash flow hedges — — — 295 — 295 Change in unrealized gain in short-term investments — — — 111 — 111 Foreign currency gain (loss) on: Long-term investment nature intra-entity balances — — — (4,692 ) — (4,692 ) Retranslation of foreign entities — — — 6,298 — 6,298 Provision for pension benefit obligation — — — 13 — 13 Other comprehensive loss 2,025 2,025 Stock-based compensation — — 1,214 — — 1,214 December 31, 2020 As Restated 101,075,845 540,819 36,630 (14,634 ) (560,571 ) 2,244 (unaudited) December 31 2020 September 30, 2020 June 30, 2020 OPERATING ACTIVITIES: Nine Months Ended Six Months Ended 3 Months Ended As Restated As Restated As Restated Net loss $ (71,691 ) $ (40,011 ) $ (26,256 ) Adjustments to reconcile net loss to net cash provided by operating activities: Depreciation, amortization and loss on disposal of fixed assets 6,354 4,131 2,093 Share-based compensation 3,498 2,284 960 Increase in deferred lease rentals 512 346 169 Swiss pension obligation 776 516 253 Amortization of deferred debt issue costs 9,728 4,830 3,083 Change in fair value of convertible loan derivatives — — — Impairment of short term investments — — — Accrued preference share dividends 788 525 263 Income taxes 999 (304 ) (153 ) Net change in assets and liabilities: — — — Trade accounts receivable, net 1,268 1,093 (587 ) Inventories (1,218 ) (1,411 ) (638 ) Accounts payable and accrued liabilities (4,601 ) 1,390 (1,664 ) Accrued compensation and benefits (2,825 ) (2,215 ) (2,025 ) Other assets (330 ) (1,807 ) (306 ) Net cash used in operating activities (56,742 ) (30,633 ) (24,808 ) INVESTING ACTIVITIES: Increase in short-term investments (72,247 ) (72,247 ) — Realization of short-term investments 57,683 44,016 29,314 Purchase of property and equipment (3,602 ) (2,069 ) (830 ) Purchase of intangible assets — — — Net cash from (used in) investing activities (18,166 ) (30,300 ) 28,484 FINANCING ACTIVITIES: Repayment of finance leases (491 ) (356 ) (171 ) Proceeds from drawdown of new debt — — — Debt issue costs — — — Fee paid to noteholders — — — Proceeds from issuance of ordinary shares and warrants 80,888 80,838 59 Net cash generated from financing activities 80,397 80,482 (112 ) Effect of exchange rate fluctuations on cash and cash equivalents (5,982 ) (5,333 ) (158 ) Change in cash and cash equivalents (493 ) 14,216 3,406 Beginning cash and cash equivalents 12,940 12,940 12,940 Ending cash and cash equivalents $ 12,447 $ 27,156 $ 16,346 Supplemental cash flow disclosures: Income taxes paid — $ — $ — Interest paid $ 17,499 $ 8,765 $ 8,731 Reconciliation of cash, cash equivalents and restricted cash: Cash and cash equivalents $ 3,401 $ 18,125 $ 7,325 Restricted cash $ 9,046 $ 9,031 $ 9,021 Total cash, cash equivalents and restricted cash $ 12,447 $ 27,156 $ 16,346 (unaudited) December 31, 2020 As previously Reported Restatement Impacts Restatement Reference As Restated ASSETS Current assets: Cash and cash equivalents $ 3,401 $ — $ 3,401 Short-term investments 131,062 — 131,062 Trade accounts receivable, net 4,539 — 4,539 Inventories 23,709 — 23,709 Prepaid expenses and other current assets 4,928 — 4,928 Total current assets 167,639 — 167,639 Rest

Organization and Summary of S_3

Organization and Summary of Significant Accounting Policies - Additional Information (Detail)

May 26, 2021USD ($)

Mar. 12, 2021USD ($)Investment

Jun. 29, 2018USD ($)

Oct. 14, 2016USD ($)

Apr. 30, 2021USD ($)

Mar. 31, 2021USD ($)InvestmentCustomer

Mar. 31, 2020USD ($)Customer

Mar. 31, 2019USD ($)Customer

Dec. 31, 2020USD ($)

Sep. 30, 2020USD ($)

Jun. 30, 2020USD ($)

Jan. 31, 2015USD ($)

Significant Accounting Policies [Line Items]

Accumulated deficit

$ (599,912,000)

$ (488,880,000)

$ (560,571,000)

$ (528,891,000)

$ (515,136,000)

Cash holdings and short-term investments

111,700,000

Aggregate principal amount of notes

25,000,000

$ 36,000,000

Restricted cash

9,024,000

9,017,000

$ 7,507,000

$ 9,046,000

$ 9,031,000

$ 9,021,000

Allowance for doubtful accounts

$ 48,000

$ 111,000

Number of customer represent 10% or more of accounts receivable | Customer

1

1

Number of customer represent 10% or more of product sales | Customer

1

1

1

Stock-based compensation cost included in inventory

$ 0

$ 0

Property and equipment impairment losses

0

0

$ 0

Impairment losses

$ 0

$ 0

$ 0

Class of warrants description

As of March 31, 2021, the Company had one class of warrants to purchase ordinary shares outstanding which comprised warrants that were issued in December 2013 and August 2015 in connection with the establishment and subsequent increase of the Company’s then existing secured term loan facility.

Accounting Standards Update 2016-13 [Member]

Significant Accounting Policies [Line Items]

Change in accounting principle, adopted

true

Change in accounting principle, adoption date

Apr. 1, 2020

Change in accounting principle, immaterial effect

true

Accounting Standards Update 2018-14 [Member]

Significant Accounting Policies [Line Items]

Change in accounting principle, adopted

true

Change in accounting principle, adoption date

Apr. 1, 2020

Change in accounting principle, immaterial effect

true

Customer Relationships [Member]

Significant Accounting Policies [Line Items]

Intangible assets amortization over estimated useful life

5 years

Brands Associated with Acquired Cell Lines [Member]

Significant Accounting Policies [Line Items]

Intangible assets amortization over estimated useful life

40 years

Product Licenses [Member]

Significant Accounting Policies [Line Items]

Intangible assets amortization over estimated useful life

10 years

Other Intangibles [Member]

Significant Accounting Policies [Line Items]

Intangible assets amortization over estimated useful life

7 years

Distribution and Supply Agreement [Member]

Significant Accounting Policies [Line Items]

Milestone amount receivable upon fulfillment of achievement

$ 59,000,000

Minimum [Member]

Significant Accounting Policies [Line Items]

Plant, machinery and equipment useful life

4 years

Maximum [Member]

Significant Accounting Policies [Line Items]

Plant, machinery and equipment useful life

6 years

Plant, Machinery and Equipment [Member] | Minimum [Member]

Significant Accounting Policies [Line Items]

Plant, machinery and equipment useful life

4 years

Plant, Machinery and Equipment [Member] | Maximum [Member]

Significant Accounting Policies [Line Items]

Plant, machinery and equipment useful life

25 years

Credit Concentration Risk [Member] | Accounts Receivable [Member] | Customer [Member]

Significant Accounting Policies [Line Items]

Concentration risk percentage

74.00%

70.00%

Security For Property Rental Obligations of Subsidiary [Member]

Significant Accounting Policies [Line Items]

Restricted cash

$ 324,000

$ 317,000

Senior Secured Notes Due 2023 [Member] | Cash Reserve Account Held by Collateral Agent [Member]

Significant Accounting Policies [Line Items]

Restricted cash

$ 8,700,000

$ 8,700,000

4.75% Convertible Notes due 2026 [Member] | Subsequent Event [Member]

Significant Accounting Policies [Line Items]

Aggregate principal amount of notes

$ 95,000,000

Debt instrument, interest rate

4.75%

Secured Notes [Member]

Significant Accounting Policies [Line Items]

Aggregate principal amount of notes

$ 36,000,000

$ 84,000,000

Debt instrument, interest rate

12.00%

12.00%

CSAM [Member]

Significant Accounting Policies [Line Items]

Number of short-term funds invested | Investment

2

2

Short-term investment held-to-maturity, current

$ 53,200,000

Impairment recognized, related to one of the short term funds invested

$ 2,300,000

Payments for (proceeds from) short-term investments

$ 75,600,000

Aggregate investment in suspend redemptions

$ 110,350,000

CSAM [Member] | Subsequent Event [Member]

Significant Accounting Policies [Line Items]

Payments for (proceeds from) short-term investments

$ (18,500,000)

Product [Member] | Customer Concentration Risk [Member] | Sales [Member]

Significant Accounting Policies [Line Items]

Concentration risk percentage

60.00%

61.00%

60.00%

Ortho's [Member]

Significant Accounting Policies [Line Items]

Milestone revenue recognized

$ 1,050,000

Non-refundable milestone payment

$ 7,500,000

Ortho's [Member] | Letter Agreement [Member]

Significant Accounting Policies [Line Items]

Non-refundable milestone payment

$ 7,500,000

Commencing on receipt of specified regulatory approvals period

10 years

Ortho's [Member] | Maximum [Member]

Significant Accounting Policies [Line Items]

Additional milestone payments receivable upon achievement of regulatory milestones and commercial sales benchmarks

$ 60,000,000

Milestone payments receivable upon achievement of cumulative gross revenue hurdles

25,000,000

MosaiQ [Member]

Significant Accounting Policies [Line Items]

Revenue recognized for milestone represents payment in respect of development work

7,500,000

Revenue remaining performance obligation

$ 0

MosaiQ [Member] | Secured Notes [Member]

Significant Accounting Policies [Line Items]

Debt instrument subscribers rights to receive payment as percentage of net MosaiQ sales

3.40%

Restatement of Previously Rep_3

Restatement of Previously Reported Consolidated Financial Statements - Additional Information (Detail) $ in Millions	12 Months Ended
	Mar. 31, 2022USD ($)
Prior Period Adjustment [Abstract]
Non cash interest expense	$ 7.1

Restatement of Previously Rep_4

Restatement of Previously Reported Consolidated Financial Statements - CONSOLIDATED BALANCE SHEETS (Detail) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2018
Current assets:
Cash and cash equivalents	$ 45,673	$ 3,401	$ 18,125	$ 7,325	$ 3,923	$ 4,096
Short-term investments	65,999	131,062	144,618	87,152	116,871
Trade accounts receivable, net	5,323	4,539	4,518	5,972	5,402
Inventories	22,011	23,709	22,798	21,291	20,501
Prepaid expenses and other current assets	4,870	4,928	5,851	4,091	3,775
Total current assets	143,876	167,639	195,910	125,831	150,472
Restricted cash	9,024	9,046	9,031	9,021	9,017	7,507
Property and equipment, net	39,071	41,299	40,182	39,563	40,440
Operating lease right-of-use assets	22,011	22,364	21,557	21,124	21,493
Intangible assets, net	619	632	614	606	625
Deferred income taxes	255	741	573	405	237
Other non-current assets	4,956	4,914	4,634	4,438	4,454
Total assets	219,812	246,635	272,501	200,988	226,738
Current liabilities:
Accounts payable	4,659	5,860	5,138	5,621	4,826
Accrued compensation and benefits	12,343	4,844	5,191	5,190	7,210
Accrued expenses and other current liabilities	14,009	11,351	17,410	13,317	15,490
Current portion of long-term debt	24,167	24,167	12,083	12,083
Current portion of operating lease liability	3,446	3,309	3,138	3,045	3,033
Current portion of finance lease obligation	835	878	577	573	598
Total current liabilities	59,459	50,409	43,537	39,829	31,157
Long-term debt, less current portion	145,059	141,822	149,007	147,260	156,261
Operating lease liability, less current portion	20,907	21,203	20,282	19,695	19,914
Finance lease obligation, less current portion	445	582	921	1,017	1,117
Deferred income taxes	1,152	1,455
Defined benefit pension plan obligation	6,896	7,707	7,169	6,623	6,353
7% Cumulative redeemable preference shares	21,475	21,213	20,950	20,688	20,425
Total liabilities	255,393	244,391	241,866	235,112	235,227
Commitments and contingencies
Shareholders' equity (deficit):
Ordinary shares (nil par value) 101,264,412 and 80,398,326 issued and outstanding at March 31, 2021 and March 31, 2020 respectively	540,813	540,819	540,769	459,990	459,931
Additional paid in capital	38,116	36,630	35,416	34,092	33,132
Accumulated other comprehensive loss	(14,598)	(14,634)	(16,659)	(13,070)	(12,672)
Accumulated deficit	(599,912)	(560,571)	(528,891)	(515,136)	(488,880)
Total shareholders' equity (deficit)	(35,581)	2,244	30,635	(34,124)	(8,489)	709	$ (15,185)
Total liabilities and shareholders' equity (deficit)	219,812	246,635	272,501	200,988	226,738
As previously Reported [Member]
Current assets:
Cash and cash equivalents	45,673	3,401	18,125	7,325	3,923	4,096
Short-term investments	65,999	131,062	144,618	87,152	116,871
Trade accounts receivable, net	5,323	4,539	4,518	5,972	5,402
Inventories	22,011	23,709	22,798	21,291	20,501
Prepaid expenses and other current assets	4,870	4,928	5,851	4,091	3,775
Total current assets	143,876	167,639	195,910	125,831	150,472
Restricted cash	9,024	9,046	9,031	9,021	9,017	7,507
Property and equipment, net	38,530	40,894	39,912	39,428	40,165
Operating lease right-of-use assets	22,011	22,364	21,557	21,124	21,493
Intangible assets, net	619	632	614	606	625
Deferred income taxes	255	237	237	237	237
Other non-current assets	4,956	4,914	4,634	4,438	4,454
Total assets	219,271	245,726	271,895	200,685	226,463
Current liabilities:
Accounts payable	4,659	5,860	5,138	5,621	4,826
Accrued compensation and benefits	11,833	4,844	5,191	5,190	7,210
Accrued expenses and other current liabilities	13,889	11,351	17,410	13,317	15,490
Current portion of long-term debt	24,167	24,167	12,083
Current portion of operating lease liability	3,446	3,309	3,138	3,045	3,033
Current portion of finance lease obligation	835	878	577	573	598
Total current liabilities	58,829	50,409	43,537	27,746	31,157
Long-term debt, less current portion	137,936	135,490	145,326	155,101	153,024
Operating lease liability, less current portion	20,907	21,203	20,282	19,695	19,914
Finance lease obligation, less current portion	445	582	921	1,017	1,117
Deferred income taxes	1,824	1,455
Defined benefit pension plan obligation	6,896	7,707	7,169	6,623	6,353
7% Cumulative redeemable preference shares	21,475	21,213	20,950	20,688	20,425
Total liabilities	248,312	238,059	238,185	230,870	231,990
Commitments and contingencies
Shareholders' equity (deficit):
Ordinary shares (nil par value) 101,264,412 and 80,398,326 issued and outstanding at March 31, 2021 and March 31, 2020 respectively	540,813	540,819	540,769	459,990	459,931
Additional paid in capital	38,116	36,630	35,416	34,092	33,132
Accumulated other comprehensive loss	(16,065)	(16,186)	(18,636)	(15,403)	(15,155)
Accumulated deficit	(591,905)	(553,596)	(523,839)	(508,864)	(483,435)
Total shareholders' equity (deficit)	(29,041)	7,667	33,710	(30,185)	(5,527)	1,714	(14,631)
Total liabilities and shareholders' equity (deficit)	219,271	245,726	271,895	200,685	226,463
Restatement Impacts [Member]
Current assets:
Property and equipment, net	541	405	270	135	275
Deferred income taxes		504	336	168
Total assets	541	909	606	303	275
Current liabilities:
Accrued compensation and benefits	510
Accrued expenses and other current liabilities	120
Current portion of long-term debt				12,083
Total current liabilities	630			12,083
Long-term debt, less current portion	7,123	6,332	3,681	(7,841)	3,237
Deferred income taxes	(672)
Total liabilities	7,081	6,332	3,681	4,242	3,237
Commitments and contingencies
Shareholders' equity (deficit):
Accumulated other comprehensive loss	1,467	1,552	1,977	2,333	2,483
Accumulated deficit	(8,007)	(6,975)	(5,052)	(6,272)	(5,445)
Total shareholders' equity (deficit)	(6,540)	(5,423)	(3,075)	(3,939)	(2,962)	$ (1,005)	$ (554)
Total liabilities and shareholders' equity (deficit)	$ 541	$ 909	$ 606	$ 303	$ 275

Restatement of Previously Rep_5

Restatement of Previously Reported Consolidated Financial Statements - CONSOLIDATED BALANCE SHEETS (Parenthetical) (Detail) - $ / shares	3 Months Ended	6 Months Ended	9 Months Ended	12 Months Ended
	Jun. 30, 2020	Sep. 30, 2020	Dec. 31, 2020	Mar. 31, 2021	Mar. 31, 2020
Prior Period Adjustment [Abstract]
Preference share dividend percentage	7.00%	7.00%	7.00%	7.00%	7.00%
Common stock, par value
Common stock, shares issued	80,593,440	100,965,451	101,075,845	101,264,412	80,398,326
Common stock, shares outstanding	80,593,440	100,965,451	101,075,845	101,264,412	80,398,326

Restatement of Previously Rep_6

Restatement of Previously Reported Consolidated Financial Statements - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended			6 Months Ended	9 Months Ended	12 Months Ended
	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Sep. 30, 2020	Dec. 31, 2020	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Revenue:
Total revenue	$ 8,751	$ 16,066	$ 8,924	$ 24,990	$ 33,741	$ 43,379	$ 32,656	$ 29,134
Cost of revenue	(4,970)	(4,499)	(5,414)	(9,913)	(14,883)	(20,074)	(17,800)	(17,230)
Gross profit	3,781	11,567	3,510	15,077	18,858	23,305	14,856	11,904
Operating expenses:
Sales and marketing	(2,283)	(2,231)	(2,243)	(4,474)	(6,757)	(9,849)	(9,853)	(8,637)
Research and development, net of government grants	(14,350)	(12,743)	(11,415)	(24,158)	(38,508)	(53,727)	(53,438)	(50,883)
General and administrative expense:
Compensation expense in respect of share options and management equity incentives	(1,214)	(1,324)	(960)	(2,284)	(3,498)	(4,984)	(4,467)	(4,957)
Other general and administrative expenses	(7,524)	(8,232)	(8,578)	(16,810)	(24,334)	(37,442)	(27,483)	(26,588)
Total general and administrative expense	(8,738)	(9,556)	(9,538)	(19,094)	(27,832)	(42,426)	(31,950)	(31,545)
Total operating expense	(25,371)	(24,530)	(23,196)	(47,726)	(73,097)	(106,002)	(95,241)	(91,065)
Operating loss	(21,590)	(12,963)	(19,686)	(32,649)	(54,239)	(82,697)	(80,385)	(79,161)
Other income (expense):
Interest expense, net	(9,404)	(6,297)	(6,931)	(13,228)	(22,632)	(29,804)	(26,900)	(20,277)
Other, net	617	5,354	208	5,562	6,179	2,723	2,205	(6,943)
Other income (expense), net	(8,787)	(943)	(6,723)	(7,666)	(16,453)	(27,081)	(24,695)	(27,220)
Loss before income taxes	(30,377)	(13,906)	(26,409)	(40,315)	(70,692)	(109,778)	(105,080)	(106,381)
Provision for income taxes	(1,303)	151	153	304	(999)	(1,254)	(58)	(30)
Net loss	(31,680)	(13,755)	(26,256)	(40,011)	(71,691)	(111,032)	(105,138)	(106,411)
Other comprehensive income (loss):
Change in fair value of effective portion of foreign currency cash flow hedges	295	279	(3)	276	571	582	(157)	(123)
Unrealized gain (loss) on short-term investments	111	(79)	(404)	(483)	(372)	(898)	554	796
Foreign currency gain (loss)	1,606	(3,803)	171	(3,632)	(2,026)	(2,057)	(2,469)	2,538
Provision for pension benefit obligation	13	14	(162)	(148)	(135)	447	2,209	(887)
Other comprehensive loss, net	2,025	(3,589)	(398)	(3,987)	(1,962)	(1,926)	137	2,324
Comprehensive loss	(29,655)	(17,344)	(26,654)	(43,998)	(73,652)	(112,958)	(105,001)	(104,087)
Net loss available to ordinary shareholders - basic and diluted	$ (31,680)	$ (13,755)	$ (26,256)	$ (40,011)	$ (71,691)	$ (111,032)	$ (105,138)	$ (106,411)
Loss per share - basic and diluted	$ (0.31)	$ (0.16)	$ (0.33)	$ (0.49)	$ (0.81)	$ (1.21)	$ (1.47)	$ (1.94)
Weighted-average shares outstanding - basic and diluted	101,016,040	83,949,195	80,485,985	82,227,052	88,512,823	91,637,966	71,610,035	54,874,391
As previously Reported [Member]
Revenue:
Total revenue	$ 8,751	$ 16,066	$ 8,924	$ 24,990	$ 33,741	$ 43,379	$ 32,656	$ 29,134
Cost of revenue	(4,970)	(4,499)	(5,414)	(9,913)	(14,883)	(20,074)	(17,800)	(17,230)
Gross profit	3,781	11,567	3,510	15,077	18,858	23,305	14,856	11,904
Operating expenses:
Sales and marketing	(2,283)	(2,231)	(2,243)	(4,474)	(6,757)	(9,849)	(9,853)	(8,637)
Research and development, net of government grants	(14,485)	(12,878)	(11,450)	(24,328)	(38,813)	(54,168)	(53,744)	(50,677)
General and administrative expense:
Compensation expense in respect of share options and management equity incentives	(1,214)	(1,324)	(960)	(2,284)	(3,498)	(4,984)	(4,467)	(4,957)
Other general and administrative expenses	(7,524)	(8,232)	(8,578)	(16,810)	(24,334)	(36,812)	(27,483)	(26,588)
Total general and administrative expense	(8,738)	(9,556)	(9,538)	(19,094)	(27,832)	(41,796)	(31,950)	(31,545)
Total operating expense	(25,506)	(24,665)	(23,231)	(47,896)	(73,402)	(105,813)	(95,547)	(90,859)
Operating loss	(21,725)	(13,098)	(19,721)	(32,819)	(54,544)	(82,508)	(80,691)	(78,955)
Other income (expense):
Interest expense, net	(6,753)	(6,858)	(5,926)	(12,784)	(19,537)	(25,918)	(23,859)	(20,018)
Other, net	192	4,998	233	5,231	5,423	1,882	2,438	(6,369)
Other income (expense), net	(6,561)	(1,860)	(5,693)	(7,553)	(14,114)	(24,036)	(21,421)	(26,387)
Loss before income taxes	(28,286)	(14,958)	(25,414)	(40,372)	(68,658)	(106,544)	(102,112)	(105,342)
Provision for income taxes	(1,471)	(17)	(15)	(32)	(1,503)	(1,926)	(661)	(44)
Net loss	(29,757)	(14,975)	(25,429)	(40,404)	(70,161)	(108,470)	(102,773)	(105,386)
Other comprehensive income (loss):
Change in fair value of effective portion of foreign currency cash flow hedges	295	279	(3)	276	571	582	(157)	(123)
Unrealized gain (loss) on short-term investments	111	(79)	(404)	(483)	(372)	(898)	554	796
Foreign currency gain (loss)	2,031	(3,447)	146	(3,301)	(1,270)	(1,216)	(2,702)	1,964
Provision for pension benefit obligation	13	14	13	27	40	622	2,034	(887)
Other comprehensive loss, net	2,450	(3,233)	(248)	(3,481)	(1,031)	(910)	(271)	1,750
Comprehensive loss	(27,307)	(18,208)	(25,677)	(43,885)	(71,192)	(109,380)	(103,044)	(103,636)
Net loss available to ordinary shareholders - basic and diluted	$ (29,757)	$ (14,975)	$ (25,429)	$ (40,404)	$ (70,161)	$ (108,470)	$ (102,773)	$ (105,386)
Loss per share - basic and diluted	$ (0.29)	$ (0.18)	$ (0.32)	$ (0.49)	$ (0.79)	$ (1.18)	$ (1.44)	$ (1.92)
Weighted-average shares outstanding - basic and diluted	101,016,040	83,949,195	80,485,985	82,227,052	88,512,823	91,637,966	71,610,035	54,874,391
Restatement Impacts [Member]
Operating expenses:
Research and development, net of government grants	$ 135	$ 135	$ 35	$ 170	$ 305	$ 441	$ 306	$ (206)
General and administrative expense:
Other general and administrative expenses						(630)
Total general and administrative expense						(630)
Total operating expense	135	135	35	170	305	(189)	306	(206)
Operating loss	135	135	35	170	305	(189)	306	(206)
Other income (expense):
Interest expense, net	(2,651)	561	(1,005)	(444)	(3,095)	(3,886)	(3,041)	(259)
Other, net	425	356	(25)	331	756	841	(233)	(574)
Other income (expense), net	(2,226)	917	(1,030)	(113)	(2,339)	(3,045)	(3,274)	(833)
Loss before income taxes	(2,091)	1,052	(995)	57	(2,034)	(3,234)	(2,968)	(1,039)
Provision for income taxes	168	168	168	336	504	672	603	14
Net loss	(1,923)	1,220	(827)	393	(1,530)	(2,562)	(2,365)	(1,025)
Other comprehensive income (loss):
Foreign currency gain (loss)	(425)	(356)	25	(331)	(756)	(841)	233	574
Provision for pension benefit obligation			(175)	(175)	(175)	(175)	175
Other comprehensive loss, net	(425)	(356)	(150)	(506)	(931)	(1,016)	408	574
Comprehensive loss	(2,348)	864	(977)	(113)	(2,461)	(3,578)	(1,957)	(451)
Net loss available to ordinary shareholders - basic and diluted	$ (1,923)	$ 1,220	$ (827)	$ 393	$ (1,530)	$ (2,562)	$ (2,365)	$ (1,025)
Loss per share - basic and diluted	$ (0.02)	$ 0.01	$ (0.01)	$ 0	$ (0.02)	$ (0.03)	$ (0.03)	$ (0.02)
Product Sales [Member]
Revenue:
Total revenue	$ 8,740	$ 8,543	$ 8,924	$ 17,467	$ 26,207	$ 35,787	$ 31,601	$ 28,665
Product Sales [Member] | As previously Reported [Member]
Revenue:
Total revenue	8,740	8,543	$ 8,924	17,467	26,207	35,787	31,601	28,665
Other Revenues [Member]
Revenue:
Total revenue	11	7,523		7,523	7,534	7,592	1,055	469
Other Revenues [Member] | As previously Reported [Member]
Revenue:
Total revenue	$ 11	$ 7,523		$ 7,523	$ 7,534	$ 7,592	$ 1,055	$ 469

Restatement of Previously Rep_7

Restatement of Previously Reported Consolidated Financial Statements - CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (DEFICIT) (Detail) - USD ($) $ in Thousands	Sep. 15, 2020	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Sep. 30, 2020	Dec. 31, 2020	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Error Corrections And Prior Period Adjustments Restatement [Line Items]
Beginning balance		$ 30,635	$ (34,124)	$ (8,489)	$ (8,489)	$ (8,489)	$ (8,489)	$ 709	$ (15,185)
Beginning balance, Shares		100,965,451	80,593,440	80,398,326	80,398,326	80,398,326	80,398,326
Issue of shares, net of issue costs, Amount			$ 80,685		$ 80,685	$ 80,685	$ 80,685	90,528	113,724
Issue of shares upon exercise of incentive share options and vesting of RSU's, Amount		$ 50	94	$ 59	153	203	197	445	1,300
Net loss		(31,680)	(13,755)	(26,256)	(40,011)	(71,691)	(111,032)	(105,138)	(106,411)
Change in the fair value of the effective portion of foreign currency cash flow hedges		295	279	(3)	276	571	582	(157)	(123)
Change in unrealized gain on short-term investments		111	(79)	(404)	(483)	(372)	(898)	554	796
Foreign currency gain (loss) on:
Long-term investment nature intra-entity balances		(4,692)	(3,841)	4,685	844	(3,848)	(27,251)	18,394	5,074
Retranslation of foreign entities		6,298	38	(4,514)	(4,476)	1,822	25,194	(20,863)	(2,536)
Provision for pension benefit obligation		13	14	(162)	(148)	(135)	447	2,209	(887)
Other comprehensive loss		2,025	(3,589)	(398)	(3,987)	(1,962)	(1,926)	137	2,324
Stock-based compensation		1,214	1,324	960	2,284	3,498	4,984	4,467	4,957
Ending balance		$ 2,244	$ 30,635	$ (34,124)	$ 30,635	$ 2,244	$ (35,581)	$ (8,489)	709
Ending balance, Shares		101,075,845	100,965,451	80,593,440	100,965,451	101,075,845	101,264,412	80,398,326
Cumulative Effect of Accounting Changes [Member]
Error Corrections And Prior Period Adjustments Restatement [Line Items]
Beginning balance				$ 363	$ 363	$ 363	$ 363
Foreign currency gain (loss) on:
Ending balance								$ 363
As previously Reported [Member]
Error Corrections And Prior Period Adjustments Restatement [Line Items]
Beginning balance		$ 33,710	$ (30,185)	(5,527)	(5,527)	(5,527)	(5,527)	1,714	(14,631)
Issue of shares, net of issue costs, Amount			80,685		80,685	80,685	80,685	90,528	113,724
Issue of shares upon exercise of incentive share options and vesting of RSU's, Amount		50	94	59	153	203	197	445	1,300
Net loss		(29,757)	(14,975)	(25,429)	(40,404)	(70,161)	(108,470)	(102,773)	(105,386)
Change in the fair value of the effective portion of foreign currency cash flow hedges		295	279	(3)	276	571	582	(157)	(123)
Change in unrealized gain on short-term investments		111	(79)	(404)	(483)	(372)	(898)	554	796
Foreign currency gain (loss) on:
Long-term investment nature intra-entity balances		(4,692)	(3,841)	4,685	844	(3,848)	(27,251)	18,394	5,074
Retranslation of foreign entities		6,723	394	(4,539)	(4,145)	2,578	26,035	(21,096)	(3,110)
Provision for pension benefit obligation		13	14	13	27	40	622	2,034	(887)
Other comprehensive loss		2,450	(3,233)	(248)	(3,481)	(1,031)	(910)	(271)	1,750
Stock-based compensation		1,214	1,324	960	2,284	3,498	4,984	4,467	4,957
Ending balance		7,667	33,710	(30,185)	33,710	7,667	(29,041)	(5,527)	1,714
As previously Reported [Member] | Cumulative Effect of Accounting Changes [Member]
Error Corrections And Prior Period Adjustments Restatement [Line Items]
Beginning balance				363	363	363	363
Foreign currency gain (loss) on:
Ending balance								363
Restatement Impacts [Member]
Error Corrections And Prior Period Adjustments Restatement [Line Items]
Beginning balance		(3,075)	(3,939)	(2,962)	(2,962)	(2,962)	(2,962)	(1,005)	(554)
Net loss		(1,923)	1,220	(827)	393	(1,530)	(2,562)	(2,365)	(1,025)
Foreign currency gain (loss) on:
Retranslation of foreign entities		(425)	(356)	25	(331)	(756)	(841)	233	574
Provision for pension benefit obligation				(175)	(175)	(175)	(175)	175
Other comprehensive loss		(425)	(356)	(150)	(506)	(931)	(1,016)	408	574
Ending balance		(5,423)	(3,075)	(3,939)	(3,075)	(5,423)	(6,540)	(2,962)	(1,005)
Ordinary Shares [Member]
Error Corrections And Prior Period Adjustments Restatement [Line Items]
Beginning balance		$ 540,769	$ 459,990	$ 459,931	$ 459,931	$ 459,931	$ 459,931	$ 368,958	$ 253,934
Beginning balance, Shares		100,965,451	80,593,440	80,398,326	80,398,326	80,398,326	80,398,326	65,900,447	45,646,424
Issue of shares, net of issue costs, Amount			$ 80,685		$ 80,685	$ 80,685	$ 80,685	$ 90,528	$ 113,724
Issue of shares, net of issue costs, Shares	20,294,117		20,294,117		20,294,117	20,294,117	20,294,117	13,800,000	19,635,068
Issue of shares upon exercise of incentive share options and vesting of RSU's, Amount		$ 50	$ 94	$ 59	$ 153	$ 203	$ 197	$ 445	$ 1,300
Issue of shares upon exercise of incentive share options and vesting of RSU's, Shares		110,394	77,894	195,114	273,008	383,402	571,969	697,879	618,955
Foreign currency gain (loss) on:
Ending balance		$ 540,819	$ 540,769	$ 459,990	$ 540,769	$ 540,819	$ 540,813	$ 459,931	$ 368,958
Ending balance, Shares		101,075,845	100,965,451	80,593,440	100,965,451	101,075,845	101,264,412	80,398,326	65,900,447
Ordinary Shares [Member] | As previously Reported [Member]
Error Corrections And Prior Period Adjustments Restatement [Line Items]
Beginning balance		$ 540,769	$ 459,990	$ 459,931	$ 459,931	$ 459,931	$ 459,931	$ 368,958	$ 253,934
Beginning balance, Shares		100,965,451	80,593,440	80,398,326	80,398,326	80,398,326	80,398,326	65,900,447	45,646,424
Issue of shares, net of issue costs, Amount			$ 80,685		$ 80,685	$ 80,685	$ 80,685	$ 90,528	$ 113,724
Issue of shares, net of issue costs, Shares			20,294,117		20,294,117	20,294,117	20,294,117	13,800,000	19,635,068
Issue of shares upon exercise of incentive share options and vesting of RSU's, Amount		$ 50	$ 94	$ 59	$ 153	$ 203	$ 197	$ 445	$ 1,300
Issue of shares upon exercise of incentive share options and vesting of RSU's, Shares		110,394	77,894	195,114	273,008	383,402	571,969	697,879	618,955
Foreign currency gain (loss) on:
Ending balance		$ 540,819	$ 540,769	$ 459,990	$ 540,769	$ 540,819	$ 540,813	$ 459,931	$ 368,958
Ending balance, Shares		101,075,845	100,965,451	80,593,440	100,965,451	101,075,845	101,264,412	80,398,326	65,900,447
Additional paid in Capital [Member]
Error Corrections And Prior Period Adjustments Restatement [Line Items]
Beginning balance		$ 35,416	$ 34,092	$ 33,132	$ 33,132	$ 33,132	$ 33,132	$ 28,665	$ 23,708
Foreign currency gain (loss) on:
Stock-based compensation		1,214	1,324	960	2,284	3,498	4,984	4,467	4,957
Ending balance		36,630	35,416	34,092	35,416	36,630	38,116	33,132	28,665
Additional paid in Capital [Member] | As previously Reported [Member]
Error Corrections And Prior Period Adjustments Restatement [Line Items]
Beginning balance		35,416	34,092	33,132	33,132	33,132	33,132	28,665	23,708
Foreign currency gain (loss) on:
Stock-based compensation		1,214	1,324	960	2,284	3,498	4,984	4,467	4,957
Ending balance		36,630	35,416	34,092	35,416	36,630	38,116	33,132	28,665
Accumulated Other Comprehensive Loss [Member]
Error Corrections And Prior Period Adjustments Restatement [Line Items]
Beginning balance		(16,659)	(13,070)	(12,672)	(12,672)	(12,672)	(12,672)	(12,809)	(15,133)
Change in the fair value of the effective portion of foreign currency cash flow hedges		295	279	(3)	276	571	582	(157)	(123)
Change in unrealized gain on short-term investments		111	(79)	(404)	(483)	(372)	(898)	554	796
Foreign currency gain (loss) on:
Long-term investment nature intra-entity balances		(4,692)	(3,841)	4,685	844	(3,848)	(27,251)	18,394	5,074
Retranslation of foreign entities		6,298	38	(4,514)	(4,476)	1,822	25,194	(20,863)	(2,536)
Provision for pension benefit obligation		13	14	(162)	(148)	(135)	447	2,209	(887)
Other comprehensive loss		2,025	(3,589)	(398)	(3,987)	(1,962)	(1,926)	137	2,324
Ending balance		(14,634)	(16,659)	(13,070)	(16,659)	(14,634)	(14,598)	(12,672)	(12,809)
Accumulated Other Comprehensive Loss [Member] | As previously Reported [Member]
Error Corrections And Prior Period Adjustments Restatement [Line Items]
Beginning balance		(18,636)	(15,403)	(15,155)	(15,155)	(15,155)	(15,155)	(14,884)	(16,634)
Change in the fair value of the effective portion of foreign currency cash flow hedges		295	279	(3)	276	571	582	(157)	(123)
Change in unrealized gain on short-term investments		111	(79)	(404)	(483)	(372)	(898)	554	796
Foreign currency gain (loss) on:
Long-term investment nature intra-entity balances		(4,692)	(3,841)	4,685	844	(3,848)	(27,251)	18,394	5,074
Retranslation of foreign entities		6,723	394	(4,539)	(4,145)	2,578	26,035	(21,096)	(3,110)
Provision for pension benefit obligation		13	14	13	27	40	622	2,034	(887)
Other comprehensive loss		2,450	(3,233)	(248)	(3,481)	(1,031)	(910)	(271)	1,750
Ending balance		(16,186)	(18,636)	(15,403)	(18,636)	(16,186)	(16,065)	(15,155)	(14,884)
Accumulated Other Comprehensive Loss [Member] | Restatement Impacts [Member]
Error Corrections And Prior Period Adjustments Restatement [Line Items]
Beginning balance		1,977	2,333	2,483	2,483	2,483	2,483	2,075	1,501
Foreign currency gain (loss) on:
Retranslation of foreign entities		(425)	(356)	25	(331)	(756)	(841)	233	574
Provision for pension benefit obligation				(175)	(175)	(175)	(175)	175
Other comprehensive loss		(425)	(356)	(150)	(506)	(931)	(1,016)	408	574
Ending balance		1,552	1,977	2,333	1,977	1,552	(1,016)	2,483	2,075
Accumulated Deficit [Member]
Error Corrections And Prior Period Adjustments Restatement [Line Items]
Beginning balance		(528,891)	(515,136)	(488,880)	(488,880)	(488,880)	(488,880)	(384,105)	(277,694)
Net loss		(31,680)	(13,755)	(26,256)	(40,011)	(71,691)	(111,032)	(105,138)	(106,411)
Foreign currency gain (loss) on:
Ending balance		(560,571)	(528,891)	(515,136)	(528,891)	(560,571)	(599,912)	(488,880)	(384,105)
Accumulated Deficit [Member] | Cumulative Effect of Accounting Changes [Member]
Error Corrections And Prior Period Adjustments Restatement [Line Items]
Beginning balance				363	363	363	363
Foreign currency gain (loss) on:
Ending balance								363
Accumulated Deficit [Member] | As previously Reported [Member]
Error Corrections And Prior Period Adjustments Restatement [Line Items]
Beginning balance		(523,839)	(508,864)	(483,435)	(483,435)	(483,435)	(483,435)	(381,025)	(275,639)
Net loss		(29,757)	(14,975)	(25,429)	(40,404)	(70,161)	(108,470)	(102,773)	(105,386)
Foreign currency gain (loss) on:
Ending balance		(553,596)	(523,839)	(508,864)	(523,839)	(553,596)	(591,905)	(483,435)	(381,025)
Accumulated Deficit [Member] | As previously Reported [Member] | Cumulative Effect of Accounting Changes [Member]
Error Corrections And Prior Period Adjustments Restatement [Line Items]
Beginning balance				363	363	363	363
Foreign currency gain (loss) on:
Ending balance								363
Accumulated Deficit [Member] | Restatement Impacts [Member]
Error Corrections And Prior Period Adjustments Restatement [Line Items]
Beginning balance		(5,052)	(6,272)	(5,445)	(5,445)	(5,445)	(5,445)	(3,080)	(2,055)
Net loss		(1,923)	1,220	(827)	393	(1,530)	(2,562)	(2,365)	(1,025)
Foreign currency gain (loss) on:
Ending balance		$ (6,975)	$ (5,052)	$ (6,272)	$ (5,052)	$ (6,975)	$ (8,007)	$ (5,445)	$ (3,080)

Restatement of Previously Rep_8

Restatement of Previously Reported Consolidated Financial Statements - CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (DEFICIT) (Parenthetical) (Detail) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended	9 Months Ended	12 Months Ended
	Sep. 30, 2020	Sep. 30, 2020	Dec. 31, 2020	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Error Corrections And Prior Period Adjustments Restatement [Line Items]
Issue of shares, issue costs	$ 5,565	$ 5,565	$ 5,565	$ 5,565	$ 6,072	$ 4,052
As previously Reported [Member]
Error Corrections And Prior Period Adjustments Restatement [Line Items]
Issue of shares, issue costs	5,565	5,565	5,565	5,565	6,072	4,052
Restatement Impacts [Member]
Error Corrections And Prior Period Adjustments Restatement [Line Items]
Issue of shares, issue costs	$ 5,565	$ 5,565	$ 5,565	$ 5,565	$ 6,072	$ 4,052

Restatement of Previously Rep_9

Restatement of Previously Reported Consolidated Financial Statements - CONSOLIDATED STATEMENTS OF CASH FLOWS (Detail) - USD ($) $ in Thousands	3 Months Ended			6 Months Ended	9 Months Ended	12 Months Ended
	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Sep. 30, 2020	Dec. 31, 2020	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
OPERATING ACTIVITIES:
Net loss			$ (26,256)	$ (40,011)	$ (71,691)	$ (111,032)	$ (105,138)	$ (106,411)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation, amortization and loss on disposal of fixed assets			2,093	4,131	6,354	8,354	12,001	12,767
Share-based compensation	$ 1,214	$ 1,324	960	2,284	3,498	4,984	4,467	4,957
Increase in deferred lease rentals			169	346	512	726	293	372
Swiss pension obligation			253	516	776	1,054	756	575
Amortization of deferred debt issue costs			3,083	4,830	9,728	12,965	10,084	6,167
Impairment of short term investments						2,285
Accrued preference share dividends			263	525	788	1,050	1,050	1,050
Income taxes			(153)	(304)	999	1,254	(169)	(61)
Net change in assets and liabilities:
Trade accounts receivable, net			(587)	1,093	1,268	568	(2,177)	(637)
Inventories			(638)	(1,411)	(1,218)	(475)	(5,173)	113
Accounts payable and accrued liabilities			(1,664)	1,390	(4,601)	(3,410)	2,798	1,035
Accrued compensation and benefits			(2,025)	(2,215)	(2,825)	4,549	1,218	1,121
Other assets			(306)	(1,807)	(330)	(454)	(656)	3,297
Net cash used in operating activities			(24,808)	(30,633)	(56,742)	(77,582)	(80,646)	(75,655)
INVESTING ACTIVITIES:
Increase in short-term investments				(72,247)	(72,247)	(87,247)	(95,000)	(119,000)
Realization of short-term investments			29,314	44,016	57,683	134,936	69,412	34,735
Purchase of property and equipment			(830)	(2,069)	(3,602)	(4,240)	(4,598)	(4,791)
Purchase of intangible assets							(2)	(3)
Net cash from (used in) investing activities			28,484	(30,300)	(18,166)	43,449	(30,188)	(89,059)
FINANCING ACTIVITIES:
Repayment of finance leases			(171)	(356)	(491)	(633)	(524)	(486)
Proceeds from drawdown of new debt							25,000	36,000
Debt issue costs							(874)	(1,216)
Fee paid to noteholders								(3,900)
Proceeds from issuance of ordinary shares and warrants			59	80,838	80,888	80,881	90,973	115,024
Net cash generated from financing activities			(112)	80,482	80,397	80,248	114,575	145,422
Effect of exchange rate fluctuations on cash and cash equivalents			(158)	(5,333)	(5,982)	(4,358)	(2,404)	5,690
Change in cash and cash equivalents			3,406	14,216	(493)	41,757	1,337	(13,602)
Beginning cash and cash equivalents	27,156	16,346	12,940	12,940	12,940	12,940	11,603	25,205
Ending cash and cash equivalents	12,447	27,156	16,346	27,156	12,447	54,697	12,940	11,603
Supplemental cash flow disclosures:
Interest paid			8,731	8,765	17,499	17,529	15,776	11,838
Reconciliation of cash, cash equivalents and restricted cash:
Cash and cash equivalents	3,401	18,125	7,325	18,125	3,401	45,673	3,923	4,096
Restricted cash	9,046	9,031	9,021	9,031	9,046	9,024	9,017	7,507
Total cash, cash equivalents and restricted cash	12,447	27,156	16,346	27,156	12,447	54,697	12,940	11,603
As previously Reported [Member]
OPERATING ACTIVITIES:
Net loss			(25,429)	(40,404)	(70,161)	(108,470)	(102,773)	(105,386)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation, amortization and loss on disposal of fixed assets			1,953	4,126	6,484	8,620	12,276	12,767
Share-based compensation	1,214	1,324	960	2,284	3,498	4,984	4,467	4,957
Increase in deferred lease rentals			169	346	512	726	293	372
Swiss pension obligation			253	516	776	1,054	756	575
Amortization of deferred debt issue costs			2,078	4,386	6,633	9,079	7,043	5,908
Impairment of short term investments						2,285
Accrued preference share dividends			263	525	788	1,050	1,050	1,050
Income taxes			15	32	1,503	1,926	368	44
Net change in assets and liabilities:
Trade accounts receivable, net			(587)	1,093	1,268	568	(2,177)	(637)
Inventories			(638)	(1,411)	(1,218)	(475)	(4,967)	(93)
Accounts payable and accrued liabilities			(1,514)	1,896	(3,670)	(2,514)	2,456	370
Accrued compensation and benefits			(2,025)	(2,215)	(2,825)	4,039	1,218	1,121
Other assets			(306)	(1,807)	(330)	(454)	(656)	3,297
Net cash used in operating activities			(24,808)	(30,633)	(56,742)	(77,582)	(80,646)	(75,655)
INVESTING ACTIVITIES:
Increase in short-term investments				(72,247)	(72,247)	(87,247)	(95,000)	(119,000)
Realization of short-term investments			29,314	44,016	57,683	134,936	69,412	34,735
Purchase of property and equipment			(830)	(2,069)	(3,602)	(4,240)	(4,598)	(4,791)
Purchase of intangible assets							(2)	(3)
Net cash from (used in) investing activities			28,484	(30,300)	(18,166)	43,449	(30,188)	(89,059)
FINANCING ACTIVITIES:
Repayment of finance leases			(171)	(356)	(491)	(633)	(524)	(486)
Proceeds from drawdown of new debt							25,000	36,000
Debt issue costs							(874)	(1,216)
Fee paid to noteholders								(3,900)
Proceeds from issuance of ordinary shares and warrants			59	80,838	80,888	80,881	90,973	115,024
Net cash generated from financing activities			(112)	80,482	80,397	80,248	114,575	145,422
Effect of exchange rate fluctuations on cash and cash equivalents			(158)	(5,333)	(5,982)	(4,358)	(2,404)	5,690
Change in cash and cash equivalents			3,406	14,216	(493)	41,757	1,337	(13,602)
Beginning cash and cash equivalents	27,156	16,346	12,940	12,940	12,940	12,940	11,603	25,205
Ending cash and cash equivalents	12,447	27,156	16,346	27,156	12,447	54,697	12,940	11,603
Supplemental cash flow disclosures:
Interest paid			8,731	8,765	17,499	17,529	15,776	11,838
Reconciliation of cash, cash equivalents and restricted cash:
Cash and cash equivalents	3,401	18,125	7,325	18,125	3,401	45,673	3,923	4,096
Restricted cash	9,046	9,031	9,021	9,031	9,046	9,024	9,017	7,507
Total cash, cash equivalents and restricted cash	$ 12,447	$ 27,156	16,346	27,156	12,447	54,697	12,940	11,603
Restatement Impacts [Member]
OPERATING ACTIVITIES:
Net loss			(827)	393	(1,530)	(2,562)	(2,365)	(1,025)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation, amortization and loss on disposal of fixed assets			140	5	(130)	(266)	(275)
Amortization of deferred debt issue costs			1,005	444	3,095	3,886	3,041	259
Income taxes			(168)	(336)	(504)	(672)	(537)	(105)
Net change in assets and liabilities:
Inventories							(206)	206
Accounts payable and accrued liabilities			$ (150)	$ (506)	$ (931)	(896)	$ 342	$ 665
Accrued compensation and benefits						$ 510

Intangible Assets - Schedule of

Intangible Assets - Schedule of Intangible Assets (Detail) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020
Finite Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 4,390	$ 3,945
Accumulated Amortization	(3,771)	(3,320)
Net Carrying Amount	$ 619	$ 625	$ 632	$ 614	$ 606
Weighted Average Remaining Useful Life	16 years 9 months 18 days	16 years 3 months 18 days
Customer Relationships [Member]
Finite Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 2,711	$ 2,436
Accumulated Amortization	(2,711)	(2,436)
Brands Associated with Acquired Cell Lines [Member]
Finite Lived Intangible Assets [Line Items]
Gross Carrying Amount	559	502
Accumulated Amortization	(190)	(158)
Net Carrying Amount	$ 369	$ 344
Weighted Average Remaining Useful Life	26 years 4 months 24 days	27 years 4 months 24 days
Product Licenses [Member]
Finite Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 944	$ 849
Accumulated Amortization	(694)	(568)
Net Carrying Amount	$ 250	$ 281
Weighted Average Remaining Useful Life	2 years 7 months 6 days	3 years 6 months
Other Intangibles [Member]
Finite Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 176	$ 158
Accumulated Amortization	$ (176)	$ (158)

Intangible Assets - Additional

Intangible Assets - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Goodwill And Intangible Assets Disclosure [Abstract]
Amortization expense	$ 73	$ 94	$ 104

Intangible Assets - Schedule _2

Intangible Assets - Schedule of Future Amortization Expense (Detail) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020
Goodwill And Intangible Assets Disclosure [Abstract]
2022	$ 76
2023	76
2024	76
2025	77
2026	14
Thereafter	300
Net Carrying Amount	$ 619	$ 632	$ 614	$ 606	$ 625

Debt - Schedule of Long-Term De

Debt - Schedule of Long-Term Debt (Detail) - USD ($) $ in Thousands	Mar. 31, 2021	Mar. 31, 2020
Debt Disclosure [Abstract]
Secured Notes	$ 145,000	$ 145,000
Debt discount, net of amortization	(11,127)	(16,261)
Deferred debt costs, net of amortization	(4,261)	(6,375)
Carrying value Secured Notes	129,612	122,364
Royalty liability	39,614	33,897
Total Debt	$ 169,226	$ 156,261

Debt - Additional Information (

Debt - Additional Information (Detail) - USD ($)	Jun. 29, 2018	Oct. 14, 2016	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019	Apr. 15, 2021	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	May 15, 2019	Dec. 18, 2018
Debt Instrument [Line Items]
Current portion of long-term debt			$ 24,167,000				$ 24,167,000	$ 12,083,000	$ 12,083,000
Aggregate principal amount of notes issued				$ 25,000,000	$ 36,000,000
Secured Notes [Member]
Debt Instrument [Line Items]
Debt instrument, issuance date			Oct. 14, 2016
Aggregate principal amount of notes available for issue			$ 120,000,000
Aggregate principal amount of notes issued	$ 36,000,000	$ 84,000,000
Debt instrument, unused/additional borrowing capacity			The Company issued $84 million aggregate principal amount of the Secured Notes on October 14, 2016 and an additional $36 million aggregate principal amount of the Secured Notes on June 29, 2018.
Debt instrument, restrictive covenants			The Company and its subsidiaries must also comply with certain customary affirmative and negative covenants, including a requirement to maintain six-months of interest in a cash reserve account maintained with the collateral agent. Upon the occurrence of a Change of Control, subject to certain conditions, or certain Asset Sales (each, as defined in the indenture), holders of the Secured Notes may require the Company to repurchase for cash all or part of their Secured Notes at a repurchase price equal to 101% or 100%, respectively, of the principal amount of the Secured Notes to be repurchased, plus accrued and unpaid interest to the date of repurchase.
Debt instrument, percentage of repurchase price on change of control			101.00%
Debt instrument, percentage of repurchase price on certain asset sales			100.00%
Payment to cash reserve account held by collateral agent				$ 8,700,000						$ 1,500,000
Debt instrument date of first required payment, interest		Apr. 15, 2017
Debt instrument date of first required payment, principal		Apr. 15, 2021
Debt instrument, interest rate			12.00%	12.00%
Debt instrument principal payment		$ 12,100,000
Secured Notes [Member] | Subsequent Event [Member]
Debt Instrument [Line Items]
Payment to cash reserve account held by collateral agent						$ 8,000,000
Secured Notes [Member] | MosaiQ [Member]
Debt Instrument [Line Items]
Aggregate principal additional amount of notes agreed to be issued										$ 25,000,000
Debt instrument subscribers rights to receive payment as percentage of net MosaiQ sales			3.40%
Estimated amount under royalty agreement			$ 106,500,000	$ 87,000,000
Secured Notes [Member] | Maximum [Member]
Debt Instrument [Line Items]
Aggregate principal amount of notes available for issue		$ 120,000,000									$ 145,000,000

Debt - Schedule of Outstanding

Debt - Schedule of Outstanding Debt (Detail) $ in Thousands	Mar. 31, 2021USD ($)
Long-term Debt, Rolling Maturity [Abstract]
Within 1 year	$ 24,167
Between 1 and 2 years	42,291
Between 2 and 3 years	48,334
Between 3 and 4 years	30,208
Total debt	$ 145,000

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - USD ($) $ in Thousands		Mar. 31, 2021	Mar. 31, 2020
Assets:
Total assets measured at fair value		$ 355
Liabilities:
Total liabilities measured at fair value			$ 227
Recurring [Member]
Assets:
Total assets measured at fair value		31,106	129,307
Liabilities:
Total liabilities measured at fair value			227
Recurring [Member] | Pension plan assets [Member]
Assets:
Total assets measured at fair value	[1]	15,751	12,436
Recurring [Member] | Short-term Investments [Member]
Assets:
Total assets measured at fair value	[2]	15,000	116,871
Recurring [Member] | Foreign currency forward contracts [Member]
Assets:
Total assets measured at fair value	[3]	355
Liabilities:
Total liabilities measured at fair value	[3]		227
Recurring [Member] | Level 1 [Member]
Assets:
Total assets measured at fair value			116,871
Recurring [Member] | Level 1 [Member] | Short-term Investments [Member]
Assets:
Total assets measured at fair value	[2]		116,871
Recurring [Member] | Level 2 [Member]
Assets:
Total assets measured at fair value		31,106	12,436
Liabilities:
Total liabilities measured at fair value			227
Recurring [Member] | Level 2 [Member] | Pension plan assets [Member]
Assets:
Total assets measured at fair value	[1]	15,751	12,436
Recurring [Member] | Level 2 [Member] | Short-term Investments [Member]
Assets:
Total assets measured at fair value	[2]	15,000
Recurring [Member] | Level 2 [Member] | Foreign currency forward contracts [Member]
Assets:
Total assets measured at fair value	[3]	$ 355
Liabilities:
Total liabilities measured at fair value	[3]		$ 227
[1]	The fair value of pension plan assets has been determined as the surrender value of the portfolio of active insured employees held within the AXA LLP Foundation Suisse Romande collective investment fund.
[2]	The fair value of short-term investments has been determined based on the quoted value of the units held in the money market fund at the balance sheet date. The short-term investments as of March 31, 2021, relate to new investments made in a Treasury Money Market Fund. See Note 1, “Summary of Significant Accounting Policies – Short-term Investments”.
[3]	The fair value of foreign currency forward contracts has been determined by calculating the present value of future cash flows, estimated using market-based observable inputs including forward and spot exchange rates and interest rate curves obtained from third party market price quotations.

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail) $ in Thousands	Mar. 12, 2021USD ($)Investment	Mar. 31, 2021USD ($)Investment	Mar. 31, 2020USD ($)	Mar. 31, 2019USD ($)	Dec. 31, 2020USD ($)	Sep. 30, 2020USD ($)	Jun. 30, 2020USD ($)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Short-term investments		$ 65,999	$ 116,871		$ 131,062	$ 144,618	$ 87,152
Impairment of short term investments		2,285
Unrealized gains on short-term investments		734	1,881	$ 1,127
Unrealized gains reclassified to earnings		$ 1,632	$ 1,327	$ 331
CSAM [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Number of short-term funds invested | Investment	2	2
Aggregate investment in suspend redemptions	$ 110,350
Payments for (proceeds from) short-term investments	$ 75,600
Short-term investments		$ 110,300
Short-term investment, Estimated fair value		108,000
Impairment of short term investments		2,300
Carrying value of investments		$ 51,000

Consolidated Balance Sheet De_3

Consolidated Balance Sheet Detail - Summary of Inventory (Detail) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020
Inventory Disclosure [Abstract]
Raw materials	$ 9,189				$ 9,737
Work in progress	9,105				8,522
Finished goods	3,717				2,242
Total inventories	$ 22,011	$ 23,709	$ 22,798	$ 21,291	$ 20,501

Consolidated Balance Sheet De_4

Consolidated Balance Sheet Detail - Additional Information (Detail) - USD ($) $ in Thousands	Feb. 28, 2021	Mar. 31, 2021	Mar. 31, 2020
Raw materials		$ 9,189	$ 9,737
Work in progress		9,105	8,522
Finished goods		3,717	2,242
Transition benefit costs			807
Termination benefit costs			1,323
New Chief Executive Officer [Member]
Transition benefit costs		3,825
Payments for transition arrangements	$ 1,800
Transition arrangements payments expected to be paid		2,025
Former Chief Executive Officer [Member]
Transition benefit costs		1,193
Former Chief Operating Officer [Member]
Transition benefit costs		371
MosaiQ Project [Member]
Raw materials		6,829	8,093
Work in progress		4,321	4,395
Finished goods		1,465	$ 368
Inventory provisions		$ 2,015

Consolidated Balance Sheet De_5

Consolidated Balance Sheet Detail - Summary of Property and Equipment (Detail) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020
Property Plant And Equipment [Line Items]
Total property and equipment	$ 96,309				$ 89,121
Less: accumulated depreciation	(57,238)				(48,681)
Total property and equipment, net	39,071	$ 41,299	$ 40,182	$ 39,563	40,440
Plant and Equipment [Member]
Property Plant And Equipment [Line Items]
Total property and equipment	62,940				57,726
Leasehold Improvements [Member]
Property Plant And Equipment [Line Items]
Total property and equipment	$ 33,369				$ 31,395

Consolidated Balance Sheet De_6

Consolidated Balance Sheet Detail - Summary of Property and Equipment (Parenthetical) (Detail) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Depreciation expenses	$ 8,813	$ 12,457	$ 12,663
Reduction in depreciation expenses	$ 1,164
Minimum [Member]
Plant, machinery and equipment useful life	4 years
Maximum [Member]
Plant, machinery and equipment useful life	6 years

Consolidated Balance Sheet De_7

Consolidated Balance Sheet Detail - Summary of Accrued Compensation and Benefits (Detail) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020
Compensation Related Costs [Abstract]
Salary and related benefits	$ 666				$ 635
Accrued vacation	931				521
Accrued payroll taxes	1,765				1,200
Accrued incentive payments	5,392				3,700
Accrued termination and transition payments	3,589				1,154
Total accrued compensation and benefits	$ 12,343	$ 4,844	$ 5,191	$ 5,190	$ 7,210

Consolidated Balance Sheet De_8

Consolidated Balance Sheet Detail - Summary of Accrued Expenses and Other Current Liabilities (Detail) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020
Payables And Accruals [Abstract]
Accrued legal and professional fees	$ 1,005				$ 829
Accrued interest	8,009				8,056
Goods received not invoiced	1,722				1,724
Accrued capital expenditure	1,201				1,287
Other accrued expenses	2,072				3,594
Total accrued expenses and other current liabilities	$ 14,009	$ 11,351	$ 17,410	$ 13,317	$ 15,490

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) $ in Thousands	3 Months Ended	6 Months Ended	9 Months Ended	12 Months Ended
	Jun. 30, 2020	Sep. 30, 2020	Dec. 31, 2020	Mar. 31, 2021USD ($)Contracts$ / shares$ / £	Mar. 31, 2020USD ($)
Commitments And Contingencies [Line Items]
Total assets measured at fair value				$ 355
Total liabilities measured at fair value					$ 227
Preference share dividend percentage	7.00%	7.00%	7.00%	7.00%	7.00%
Subscriptions price of stock				$ 25,000
Certain MosaiQ Products [Member] | TTP plc [Member]
Commitments And Contingencies [Line Items]
Royalty term				20 years
MosaiQ Microarrays [Member] | Catalloid Products, Inc. [Member]
Commitments And Contingencies [Line Items]
Royalty term				10 years
7% Cumulative Redeemable Preference Shares [Member]
Commitments And Contingencies [Line Items]
Preference share dividend percentage				7.00%	7.00%
Preferred stock, no par value | $ / shares
April 2021 through June 2021 [Member]
Commitments And Contingencies [Line Items]
Number of forward exchange contracts | Contracts				3
Forward exchange contracts sold				$ 500
Forward exchange contracts exchange rate pounds sterling to US dollar | $ / £				1.2630
July 2021 through September 2021 [Member]
Commitments And Contingencies [Line Items]
Number of forward exchange contracts | Contracts				3
Forward exchange contracts sold				$ 500
Forward exchange contracts exchange rate pounds sterling to US dollar | $ / £				1.26
October 2021 through December 2021 [Member]
Commitments And Contingencies [Line Items]
Number of forward exchange contracts | Contracts				3
Forward exchange contracts sold				$ 500
Forward exchange contracts exchange rate pounds sterling to US dollar | $ / £				1.3090
January 2022 through March 2022
Commitments And Contingencies [Line Items]
Number of forward exchange contracts | Contracts				3
Forward exchange contracts sold				$ 500
Forward exchange contracts exchange rate pounds sterling to US dollar | $ / £				1.3735

Commitments and Contingencies_2

Commitments and Contingencies - Schedule of Purchase Obligations (Detail) $ in Thousands	Mar. 31, 2021USD ($)
Commitments And Contingencies Disclosure [Abstract]
2022	$ 19,142
2023	13,480
2024	15,878
2025	17,301
2026	23,642
Total minimum future purchase obligations	$ 89,443

Geographic Information - Additi

Geographic Information - Additional Information (Detail) $ in Thousands	12 Months Ended
	Mar. 31, 2021USD ($)Segment	Mar. 31, 2020USD ($)	Mar. 31, 2019USD ($)
Geographic Areas Long Lived Assets [Abstract]
Number of business segments | Segment	1
Foreign exchange gains (losses) | $	$ 4,998	$ 2,205	$ (5,984)

Geographic Information - Schedu

Geographic Information - Schedule of Revenue From Customer By Geographic Area (Detail) - USD ($) $ in Thousands		12 Months Ended
		Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Revenues From External Customers And Long Lived Assets [Line Items]
Revenue		$ 43,379	$ 32,656	$ 29,134
United States [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Revenue		28,135	17,831	14,754
France [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Revenue		7,406	7,105	6,501
Japan [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Revenue		4,506	4,333	3,846
Other foreign countries [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Revenue	[1]	$ 3,332	$ 3,387	$ 4,033
[1]	No individual country represented more than 10% of the respective totals.

Geographic Information - Consol

Geographic Information - Consolidated Property and Equipment, Net by Country (Detail) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020
Property, Plant and Equipment [Line Items]
Property and equipment, net	$ 39,071	$ 41,299	$ 40,182	$ 39,563	$ 40,440
United Kingdom [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, net	16,890				17,388
Switzerland [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, net	$ 22,181				$ 23,052

Ordinary and Preference Share_2

Ordinary and Preference Shares - Summary of Shares Issued and Outstanding (Detail) - $ / shares	Mar. 31, 2021	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2018
Class Of Stock [Line Items]
Ordinary shares, shares issued	101,264,412	101,075,845	100,965,451	80,593,440	80,398,326
Common stock, par value
Ordinary shares, shares outstanding	101,264,412	101,075,845	100,965,451	80,593,440	80,398,326
Ordinary shares, par value
Preference shares, shares issued	666,665				666,665
Preference shares, shares outstanding	666,665				666,665
7% Cumulative Redeemable Preference Shares [Member]
Class Of Stock [Line Items]
Preference shares, shares issued	666,665				666,665
Liquidation amount per share	$ 32.21				$ 30.64
Preference shares, shares outstanding	666,665				666,665
Ordinary Shares [Member]
Class Of Stock [Line Items]
Ordinary shares, shares issued	101,264,412				80,398,326
Common stock, par value
Ordinary shares, shares outstanding	101,264,412	101,075,845	100,965,451	80,593,440	80,398,326	65,900,447	45,646,424
Ordinary shares, par value

Ordinary and Preference Share_3

Ordinary and Preference Shares - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions	Sep. 15, 2020	Sep. 30, 2020	Sep. 30, 2020	Dec. 31, 2020	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019	Jan. 29, 2015
7% Cumulative Redeemable Preference Shares [Member]
Class Of Stock [Line Items]
Subscriptions price, per share								$ 22.50
Ordinary Shares [Member]
Class Of Stock [Line Items]
Newly issued ordinary shares Issues	20,294,117	20,294,117	20,294,117	20,294,117	20,294,117	13,800,000	19,635,068
Newly issued ordinary price per share	$ 4.25
Proceeds from issuance of ordinary shares	$ 86.3
Underwriting discounts and other offering expenses	$ 5.6

Ordinary and Preference Share_4

Ordinary and Preference Shares - Summary of Shares Issued and Outstanding (Parenthetical) (Detail)	3 Months Ended	6 Months Ended	9 Months Ended	12 Months Ended
	Jun. 30, 2020	Sep. 30, 2020	Dec. 31, 2020	Mar. 31, 2021	Mar. 31, 2020
Class Of Stock [Line Items]
Preference share dividend percentage	7.00%	7.00%	7.00%	7.00%	7.00%
7% Cumulative Redeemable Preference Shares [Member]
Class Of Stock [Line Items]
Preference share dividend percentage				7.00%	7.00%

Share-Based Compensation - Addi

Share-Based Compensation - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019	Oct. 29, 2020	Oct. 31, 2018	Oct. 28, 2016
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation expense	$ 4,984	$ 4,467	$ 4,957
Number of Options Granted	258,026	110,623	189,552
Total fair value of stock options granted	$ 889	$ 588	$ 676
Risk-free interest rate, Description	Risk-Free Interest Rate. The risk-free interest rate is based on the UK Government 10 year bond yield curve in effect at the time of grant prior to the initial public offering and 10 year U.S. Treasury Stock for awards from April 2014 onwards.
Total compensation cost not yet recognized related to share options and RSUs	$ 4,608
Total compensation cost not yet recognized related to share options, RSUs, weighted average remaining amortization period	18 months
Ordinary Shares [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Fair value of ordinary shares per share	$ 3.68
Restricted Stock Units (RSUs) [Member] | Time Based Vesting [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of restricted stock units outstanding	783,759
Weighted average remaining vesting period	10 months
Restricted Stock Units (RSUs) [Member] | Milestone Vesting [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of restricted stock units outstanding	118,650
Employee Stock Option [Member] | Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period	1 year
Employee Stock Option [Member] | Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period	3 years
2012 Option Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares upon each option exercised	1
Maximum number of shares authorized for grant	839,509
Vesting period	3 years
Contractual life	10 years
Options exercisable percentage description	Options were not exercisable before the Company became a public company and all outstanding options become exercisable in the event of an acquisition of 75% or more of the share capital of the Company by a third party. No further awards will be granted under the 2012 Option Plan.
Number of Options Granted	0
2014 Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Ordinary shares reserved for issuance	1,500,000
Percentage of automatic increase in ordinary shares	0.75%
Increase in number of shares reserved for future issuance				750,000	550,000	750,000

Share-Based Compensation - Summ

Share-Based Compensation - Summary of Share Option Activity (Detail) - $ / shares	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2018
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Number of Share Options Outstanding, Beginning Balance	1,848,052	1,936,397	2,096,283
Number of Share Options Outstanding, Granted	258,026	110,623	189,552
Number of Share Options Outstanding, Exercised	(147,264)	(103,264)	(253,066)
Number of Share Options Outstanding, Forfeited	(148,029)	(95,704)	(96,372)
Number of Share Options Outstanding, Ending Balance	1,810,785	1,848,052	1,936,397	2,096,283
Number of Share Options Outstanding, Exercisable	1,497,464
Weighted-Average Exercise Price, Beginning Balance	$ 7.73	$ 7.77	$ 7.79
Weighted-Average Exercise Price, Granted	5.38	8.44	6.59
Weighted-Average Exercise Price, Exercised	1.18	4.77	5.14
Weighted-Average Exercise Price, Forfeited	10.76	12.53	12.69
Weighted-Average Exercise Price, Ending Balance	7.69	$ 7.73	$ 7.77	$ 7.79
Weighted-Average Exercise Price, Exercisable	$ 8.11
Weighted-Average Remaining Contractual Life, Outstanding	68 months	70 months	78 months	84 months
Weighted-Average Remaining Contractual Life, Granted	120 months	120 months	120 months
Weighted-Average Remaining Contractual Life, Exercisable	59 months

Share-Based Compensation - Su_2

Share-Based Compensation - Summary of Share Option Granted, Exercise Price, Fair Value, Intrinsic Value (Detail) - $ / shares	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Options Granted	258,026	110,623	189,552
Exercise Price	$ 5.38	$ 8.44	$ 6.59
Ordinary Shares Fair Value Per Share at Grant Date	$ 5.38	$ 8.44	$ 6.14
May 24, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Grant Date	May 24, 2020
Number of Options Granted	60,438
Exercise Price	$ 7.69
Ordinary Shares Fair Value Per Share at Grant Date	7.69
Per Share Intrinsic Value of Options	$ 4.96
September 1, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Grant Date	Sep. 1, 2020
Number of Options Granted	45,922
Exercise Price	$ 4.81
Ordinary Shares Fair Value Per Share at Grant Date	4.81
Per Share Intrinsic Value of Options	$ 3.07
October 29, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Grant Date	Oct. 29, 2020
Number of Options Granted	81,666
Exercise Price	$ 4.55
Ordinary Shares Fair Value Per Share at Grant Date	4.55
Per Share Intrinsic Value of Options	$ 2.93
October 31, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Grant Date	Oct. 31, 2020
Number of Options Granted	70,000
Exercise Price	$ 4.72
Ordinary Shares Fair Value Per Share at Grant Date	4.72
Per Share Intrinsic Value of Options	$ 3.05

Share-Based Compensation - Su_3

Share-Based Compensation - Summary of Share Option Granted, Exercise Price, Fair Value, Intrinsic Value (Parenthetical) (Detail) - $ / shares	Sep. 01, 2020	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Options Granted		258,026	110,623	189,552
Exercise Price		$ 5.38	$ 8.44	$ 6.59
Dr Larue and Dr Buckle [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Options Granted	20,790
Exercise Price	$ 4.81
Share options, term of years	10 years

Share-Based Compensation - Su_4

Share-Based Compensation - Summary of Weighted-Average Assumptions to Share Options Issued (Detail) - $ / shares	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Risk-free interest rate	0.77%	1.84%	3.08%
Expected lives (years)	6 years	6 years	6 years
Volatility	73.70%	69.43%	67.19%
Grant date fair value (per share)	$ 5.38	$ 8.44	$ 6.14
Number granted	258,026	110,623	189,552

Share-Based Compensation - Su_5

Share-Based Compensation - Summary of RSUs (Detail) - Restricted Stock Units (RSUs) [Member]	12 Months Ended
	Mar. 31, 2021shares
Time Based Vesting [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of RSUs Outstanding	783,759
Weighted Average Remaining Vesting Period (Months)	10 months
Milestone Vesting [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of RSUs Outstanding	118,650

Income Taxes - Schedule of Comp

Income Taxes - Schedule of Components of Provision for Income Taxes (Detail) - USD ($) $ in Thousands	3 Months Ended			6 Months Ended	9 Months Ended	12 Months Ended
	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Sep. 30, 2020	Dec. 31, 2020	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Income Tax Disclosure [Abstract]
Current - Federal						$ (126)
Deferred - Federal						(1,128)	$ (58)	$ (30)
Income tax (provision) benefit	$ (1,303)	$ 151	$ 153	$ 304	$ (999)	$ (1,254)	$ (58)	$ (30)

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	3 Months Ended			6 Months Ended	9 Months Ended	12 Months Ended
	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Sep. 30, 2020	Dec. 31, 2020	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2018
Income Taxes [Line items]
Statutory standard corporate income tax rate						25.00%
Reduction or reversal of deferred tax assets								$ (30,000)
Provision for income taxes	$ 1,303,000	$ (151,000)	$ (153,000)	$ (304,000)	$ 999,000	$ 1,254,000	$ 58,000	30,000
Additional deferred tax expense						1,200,000
Net operating loss carry forwards						286,595,000
Net operating loss carry forwards, subject to expiration						$ 22,354,000
Net operating loss carry forwards expiration year, beginning						2022
Net operating loss carry forwards expiration year, ending						2028
Corporate income tax rate						25.00%
Deferred tax expense						$ 576,000
Unrecognized benefit						1,216,000	1,216,000	603,000	$ 617,000
Interest expense carryforward, disqualified as interest expense						613,000
Impact of reassessment of transfer pricing policies						603,000
Unrecognized tax benefits, Income tax penalties and interest accrued						0	$ 0	$ 0
Tax charge on other comprehensive loss						$ 0
Jersey Taxing Authority [Member]
Income Taxes [Line items]
Statutory standard corporate income tax rate						0.00%
Corporate income tax rate						0.00%

Income Taxes - Reconciliation o

Income Taxes - Reconciliation of the Income Tax Expenses at the Statutory Rate (Detail) - USD ($) $ in Thousands	3 Months Ended			6 Months Ended	9 Months Ended	12 Months Ended
	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Sep. 30, 2020	Dec. 31, 2020	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Income Tax Disclosure [Abstract]
Impact of tax uncertainties						$ (1,200)		$ 14
Foreign tax rate differential						2,362	$ 2,255	5,287
(Increase) decrease in valuation allowance against deferred tax assets						(2,416)	(2,313)	(5,331)
Income tax (provision) benefit	$ (1,303)	$ 151	$ 153	$ 304	$ (999)	$ (1,254)	$ (58)	$ (30)

Income Taxes - Components of De

Income Taxes - Components of Deferred Tax Assets (Detail) - USD ($) $ in Thousands	Mar. 31, 2021	Mar. 31, 2020
Income Tax Disclosure [Abstract]
Provisions and reserves	$ 1,022	$ 1,315
Operating lease liability	4,100	3,409
Research and development	672
Net operating loss carry forwards	22,628	19,526
Gross deferred tax assets	28,422	24,250
Fixed asset basis difference	(2,289)	(90)
Operating lease right-of-use assets	(4,100)	(3,409)
Gross deferred tax liabilities	6,389	3,499
Net deferred tax asset	22,033	20,751
Valuation allowance	22,930	20,514
Net deferred taxes	$ (897)
Net deferred taxes		$ 237

Income Taxes - Classification o

Income Taxes - Classification of Net Deferred Tax Assets (Detail) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020	Mar. 31, 2020
Income Tax Disclosure [Abstract]
Net noncurrent deferred tax assets	$ 255		$ 237
Net noncurrent deferred tax liabilities	(1,152)	$ (1,455)
Net deferred taxes	$ (897)
Net deferred taxes			$ 237

Income Taxes - Summary of Activ

Income Taxes - Summary of Activity Related to Uncertain Tax Positions (Detail) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Income Tax Uncertainties [Abstract]
Balance at beginning of period	$ 1,216	$ 603	$ 617
Increases related to current year tax positions	0	613	(14)
Increases related to prior years tax positions	0
Balance at end of period	$ 1,216	$ 1,216	$ 603

Pension Plans - Additional Info

Pension Plans - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Defined Contribution Plan Disclosure [Line Items]
Defined contribution pension cost		$ 581	$ 963	$ 750
Accumulated pension obligation		22,648	18,789	17,784
Plan assets		15,751	12,436	$ 10,416
Net funded status		6,897	6,353
Contributions paid by plan participants		2,704	2,180
Cumulative amounts recognized in other comprehensive income		3,035	3,482
Cumulative amounts recognized in other comprehensive income, net loss		2,431	2,819
Cumulative amounts recognized in other comprehensive income, prior service cost		605	663
Contributions paid or to be paid by employer		1,333	1,280
Scenario, Forecast [Member]
Defined Contribution Plan Disclosure [Line Items]
Contributions paid or to be paid by employer	$ 1,436
New Employees [Member]
Defined Contribution Plan Disclosure [Line Items]
Contributions paid by plan participants		$ 1,768	$ 1,375

Pension Plans - Reconciliation

Pension Plans - Reconciliation of Benefit Obligations (Detail) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Defined Benefit Plan Net Periodic Benefit Cost [Abstract]
Pension benefit obligation, beginning of year	$ 18,789	$ 17,784
Service cost	2,272	2,003	$ 1,574
Contributions paid by plan participants	2,704	2,180
Interest cost	126	131	153
Benefits paid	(2,207)	(2,841)
Prior service cost		836
Actuarial loss / (gain)	648	(1,915)
Foreign currency translation	316	611
Pension benefit obligation, end of year	$ 22,648	$ 18,789	$ 17,784

Pension Plans - Reconciliatio_2

Pension Plans - Reconciliation of Plan Assets (Detail) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Defined Benefit Plan Net Periodic Benefit Cost [Abstract]
Fair value of plan assets, beginning of year	$ 12,436	$ 10,416
Actual return on plan assets	1,293	1,008
Contributions paid by employer	1,333	1,280
Contributions paid by plan participants	2,704	2,180
Benefits paid	(2,207)	(2,841)
Foreign currency translation	192	393
Fair value of plan assets, end of year	$ 15,751	$ 12,436

Pension Plans - Reconciliatio_3

Pension Plans - Reconciliation of Funded Status (Detail) - USD ($) $ in Thousands	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Defined Benefit Plan Net Periodic Benefit Cost [Abstract]
Pension benefit obligation, end of year	$ 22,648	$ 18,789	$ 17,784
Fair value of plan assets, end of year	15,751	12,436	$ 10,416
Net funding obligation, end of year	$ 6,897	$ 6,353

Pension Plans - Assumptions Use

Pension Plans - Assumptions Used to Determine Pension Benefit Obligation (Detail)	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Defined Benefit Plan Net Periodic Benefit Cost [Abstract]
Price inflation	1.00%	1.00%	1.00%
Discount rate	0.35%	0.60%	0.70%
Interest rate on retirement savings capital	0.60%	0.60%	1.20%
Expected return on plan assets	1.75%	1.75%	1.20%
Average rate of salary increase	1.00%	1.00%	1.00%

Pension Plans - Schedule of Net

Pension Plans - Schedule of Net Pension Costs (Detail) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Defined Benefit Plan Net Periodic Benefit Cost [Abstract]
Employer service cost	$ 2,272	$ 2,003	$ 1,574
Interest cost	126	131	153
Expected return on plan assets	(243)	(130)	(131)
Amortization of prior service credit	58	(23)	(14)
Amortization of net loss		216	154
Net pension cost	$ 2,213	$ 2,197	$ 1,736

Pension Plans - Schedule of Pro

Pension Plans - Schedule of Provision for Pension Benefit Obligation Recognized in Other Comprehensive Income (Detail) - USD ($) $ in Thousands	3 Months Ended			6 Months Ended	9 Months Ended	12 Months Ended
	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Sep. 30, 2020	Dec. 31, 2020	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Defined Benefit Plan Net Periodic Benefit Cost [Abstract]
Net actuarial (gain) / loss						$ (389)	$ (2,016)	$ 1,027
Amortization of prior service credit						(58)	23	14
Amortization of net loss							(216)	(154)
Provision for pension benefit obligation	$ (13)	$ (14)	$ 162	$ 148	$ 135	$ (447)	$ (2,209)	$ 887

Pension Plans - Schedule of Ben

Pension Plans - Schedule of Benefit Payments Expected to be Paid (Detail) $ in Thousands	Mar. 31, 2021USD ($)
Defined Benefit Plan Net Periodic Benefit Cost [Abstract]
2022	$ 1,122
2023	1,161
2024	1,178
2025	1,199
2026	1,215
2027 to 2030	$ 6,397

Net Loss Per Share - Computatio

Net Loss Per Share - Computation of Earnings Per Share Basic and Diluted (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended			6 Months Ended	9 Months Ended	12 Months Ended
	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Sep. 30, 2020	Dec. 31, 2020	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Numerator:
Net loss	$ (31,680)	$ (13,755)	$ (26,256)	$ (40,011)	$ (71,691)	$ (111,032)	$ (105,138)	$ (106,411)
Net loss available to ordinary shareholders - basic and diluted	$ (31,680)	$ (13,755)	$ (26,256)	$ (40,011)	$ (71,691)	$ (111,032)	$ (105,138)	$ (106,411)
Denominator:
Weighted-average shares outstanding - basic and diluted	101,016,040	83,949,195	80,485,985	82,227,052	88,512,823	91,637,966	71,610,035	54,874,391
Loss per share - basic and diluted	$ (0.31)	$ (0.16)	$ (0.33)	$ (0.49)	$ (0.81)	$ (1.21)	$ (1.47)	$ (1.94)

Net Loss Per Share - Summary of

Net Loss Per Share - Summary of Number of Ordinary Shares Excluded from Computation of Earnings Per Share (Detail) - shares	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2019
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Ordinary shares issuable excluded from computation of earnings per share	2,888,719	2,717,924	3,078,611
Exercise Of Options To Purchase Ordinary Shares [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Ordinary shares issuable excluded from computation of earnings per share	1,810,785	1,848,052	1,936,397
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Ordinary shares issuable excluded from computation of earnings per share	902,409	694,347	966,689
Exercise Of Warrants At $16.14 Per Share [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Ordinary shares issuable excluded from computation of earnings per share	111,525	111,525	111,525
Exercise Of Warrants At $9.375 Per Share [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Ordinary shares issuable excluded from computation of earnings per share	64,000	64,000	64,000

Net Loss Per Share - Summary _2

Net Loss Per Share - Summary of Number of Ordinary Shares Excluded from Computation of Earnings Per Share (Detail) (Parenthetical) - $ / shares	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Exercise Of Warrants At $16.14 Per Share [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Exercise price of warrants per share	$ 16.14	$ 16.14	$ 16.14
Exercise Of Warrants At $9.375 Per Share [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Exercise price of warrants per share	$ 9.375	$ 9.375	$ 9.375

Lease Commitments - Additional

Lease Commitments - Additional Information (Detail) £ in Thousands, $ in Thousands	12 Months Ended
	Mar. 31, 2021USD ($)ft²Sublease	Mar. 31, 2021GBP (£)ft²	Dec. 31, 2020USD ($)	Sep. 30, 2020USD ($)	Jun. 30, 2020USD ($)	Mar. 31, 2020USD ($)
Lessee Lease Description [Line Items]
Number of sublease agreements | Sublease	0
Area of conventional reagents manufacturing facility | ft²	87,200	87,200
Lease commencement period	2018-03
Lease expiration period	2052-09
Lease term	5 years	5 years
Lessee, operating lease, extended term	5 years	5 years
Lessee, operating lease, option to extend, description	This lease was extended for a further five-year period to March 14, 2025.
Lessee, operating lease, existence of option to extend	true
Lessee, operating lease, expiration date	Mar. 14, 2025
Operating lease right-of-use assets	$ 22,011		$ 22,364	$ 21,557	$ 21,124	$ 21,493
Operating lease liability	24,354					22,947
Operating lease liability, current	3,446		3,309	3,138	3,045	3,033
Finance lease right of use asset	1,384					2,126
Finance lease liability	1,280					1,715
Finance lease liability, current	835		$ 878	$ 577	$ 573	598
Other Non-current Assets [Member]
Lessee Lease Description [Line Items]
Rent deposit	$ 5,000	£ 3,600				$ 4,500
Minimum [Member]
Lessee Lease Description [Line Items]
Lease term	1 year	1 year
Maximum [Member]
Lessee Lease Description [Line Items]
Lease term	3 years	3 years

Lease Commitments - Schedule of

Lease Commitments - Schedule of Elements of Lease Expense (Detail) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Lease Cost [Abstract]
Operating lease cost	$ 4,414	$ 3,694
Finance lease cost
Amortization of right-of-use asset	998	832
Interest on lease liabilities	129	119
Short-term lease cost	62	69
Total lease cost	$ 5,603	$ 4,714

Lease Commitments - Summary of

Lease Commitments - Summary of Other Information Related to Leases (Detail) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Cash paid for amounts included in the measurement of lease liabilities
Operating leases - operating cash flows	$ 3,793	$ 3,043
Finance leases - financing cash flows	633	524
Finance leases - operating cash flows	129	119
Non-cash leases activity
Right-of-use assets obtained in exchange for new operating lease liabilities	332	5,160
Right-of-use assets obtained in exchange for new finance lease liabilities	$ 130	$ 969
Weighted average remaining lease terms (in years)
Operating leases	29 years 6 months	30 years
Finance leases	1 year 7 months 6 days	2 years 3 months 18 days
Weighted average discount rate
Operating leases	10.90%	10.80%
Finance leases	9.10%	4.50%

Lease Commitments - Schedule _2

Lease Commitments - Schedule of Future Lease Payments Required Under Non-Cancellable Operating Leases (Detail) - USD ($) $ in Thousands	Mar. 31, 2021	Mar. 31, 2020
Leases [Abstract]
2022	$ 3,819	$ 3,335
2023	3,295	3,319
2024	3,285	3,050
2025	3,334	3,055
2026	2,237	3,105
Thereafter	71,347	66,138
Total lease payments	87,317	82,002
Less : imputed interest	(62,963)	(59,055)
Total operating lease liabilities	$ 24,354	$ 22,947

Lease Commitments - Schedule _3

Lease Commitments - Schedule of Future Lease Payments Required Under Finance Leases (Detail) - USD ($) $ in Thousands	Mar. 31, 2021	Mar. 31, 2020
Leases [Abstract]
2022	$ 935	$ 720
2023	422	838
2024	42	349
2025	12	7
Total lease payments	1,411	1,914
Less : imputed interest	(131)	(199)
Total finance lease liabilities	$ 1,280	$ 1,715

Subsequent Events - Additional

Subsequent Events - Additional Information (Details) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	May 26, 2021	Mar. 31, 2020	Mar. 31, 2019
Subsequent Event [Line Items]
Aggregate principal amount of notes issued		$ 25,000	$ 36,000
Convertible Notes [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Aggregate principal amount of notes issued	$ 95,000

Restatement of Previously Iss_3

Restatement of Previously Issued Unaudited Condensed Consolidated Financial Statements - CONSOLIDATED BALANCE SHEETS (Detail) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2018
Current assets:
Cash and cash equivalents	$ 45,673	$ 3,401	$ 18,125	$ 7,325	$ 3,923	$ 4,096
Short-term investments	65,999	131,062	144,618	87,152	116,871
Trade accounts receivable, net	5,323	4,539	4,518	5,972	5,402
Inventories	22,011	23,709	22,798	21,291	20,501
Prepaid expenses and other current assets	4,870	4,928	5,851	4,091	3,775
Total current assets	143,876	167,639	195,910	125,831	150,472
Restricted cash	9,024	9,046	9,031	9,021	9,017	7,507
Property and equipment, net	39,071	41,299	40,182	39,563	40,440
Operating lease right-of-use assets	22,011	22,364	21,557	21,124	21,493
Intangible assets, net	619	632	614	606	625
Deferred income taxes	255	741	573	405	237
Other non-current assets	4,956	4,914	4,634	4,438	4,454
Total assets	219,812	246,635	272,501	200,988	226,738
Current liabilities:
Accounts payable	4,659	5,860	5,138	5,621	4,826
Accrued compensation and benefits	12,343	4,844	5,191	5,190	7,210
Accrued expenses and other current liabilities	14,009	11,351	17,410	13,317	15,490
Current portion of long-term debt	24,167	24,167	12,083	12,083
Current portion of operating lease liability	3,446	3,309	3,138	3,045	3,033
Current portion of finance lease obligation	835	878	577	573	598
Total current liabilities	59,459	50,409	43,537	39,829	31,157
Long-term debt, less current portion	145,059	141,822	149,007	147,260	156,261
Operating lease liability, less current portion	20,907	21,203	20,282	19,695	19,914
Finance lease obligation, less current portion	445	582	921	1,017	1,117
Deferred income taxes	1,152	1,455
Defined benefit pension plan obligation	6,896	7,707	7,169	6,623	6,353
7% Cumulative redeemable preference shares	21,475	21,213	20,950	20,688	20,425
Total liabilities	255,393	244,391	241,866	235,112	235,227
Commitments and contingencies
Shareholders' equity (deficit):
Ordinary shares	540,813	540,819	540,769	459,990	459,931
Additional paid in capital	38,116	36,630	35,416	34,092	33,132
Accumulated other comprehensive loss	(14,598)	(14,634)	(16,659)	(13,070)	(12,672)
Accumulated deficit	(599,912)	(560,571)	(528,891)	(515,136)	(488,880)
Total shareholders' equity (deficit)	(35,581)	2,244	30,635	(34,124)	(8,489)	709	$ (15,185)
Total liabilities and shareholders' equity (deficit)	219,812	246,635	272,501	200,988	226,738
As previously Reported [Member]
Current assets:
Cash and cash equivalents	45,673	3,401	18,125	7,325	3,923	4,096
Short-term investments	65,999	131,062	144,618	87,152	116,871
Trade accounts receivable, net	5,323	4,539	4,518	5,972	5,402
Inventories	22,011	23,709	22,798	21,291	20,501
Prepaid expenses and other current assets	4,870	4,928	5,851	4,091	3,775
Total current assets	143,876	167,639	195,910	125,831	150,472
Restricted cash	9,024	9,046	9,031	9,021	9,017	7,507
Property and equipment, net	38,530	40,894	39,912	39,428	40,165
Operating lease right-of-use assets	22,011	22,364	21,557	21,124	21,493
Intangible assets, net	619	632	614	606	625
Deferred income taxes	255	237	237	237	237
Other non-current assets	4,956	4,914	4,634	4,438	4,454
Total assets	219,271	245,726	271,895	200,685	226,463
Current liabilities:
Accounts payable	4,659	5,860	5,138	5,621	4,826
Accrued compensation and benefits	11,833	4,844	5,191	5,190	7,210
Accrued expenses and other current liabilities	13,889	11,351	17,410	13,317	15,490
Current portion of long-term debt	24,167	24,167	12,083
Current portion of operating lease liability	3,446	3,309	3,138	3,045	3,033
Current portion of finance lease obligation	835	878	577	573	598
Total current liabilities	58,829	50,409	43,537	27,746	31,157
Long-term debt, less current portion	137,936	135,490	145,326	155,101	153,024
Operating lease liability, less current portion	20,907	21,203	20,282	19,695	19,914
Finance lease obligation, less current portion	445	582	921	1,017	1,117
Deferred income taxes	1,824	1,455
Defined benefit pension plan obligation	6,896	7,707	7,169	6,623	6,353
7% Cumulative redeemable preference shares	21,475	21,213	20,950	20,688	20,425
Total liabilities	248,312	238,059	238,185	230,870	231,990
Commitments and contingencies
Shareholders' equity (deficit):
Ordinary shares	540,813	540,819	540,769	459,990	459,931
Additional paid in capital	38,116	36,630	35,416	34,092	33,132
Accumulated other comprehensive loss	(16,065)	(16,186)	(18,636)	(15,403)	(15,155)
Accumulated deficit	(591,905)	(553,596)	(523,839)	(508,864)	(483,435)
Total shareholders' equity (deficit)	(29,041)	7,667	33,710	(30,185)	(5,527)	1,714	(14,631)
Total liabilities and shareholders' equity (deficit)	219,271	245,726	271,895	200,685	226,463
Restatement Impacts [Member]
Current assets:
Property and equipment, net	541	405	270	135	275
Deferred income taxes		504	336	168
Total assets	541	909	606	303	275
Current liabilities:
Accrued compensation and benefits	510
Accrued expenses and other current liabilities	120
Current portion of long-term debt				12,083
Total current liabilities	630			12,083
Long-term debt, less current portion	7,123	6,332	3,681	(7,841)	3,237
Deferred income taxes	(672)
Total liabilities	7,081	6,332	3,681	4,242	3,237
Commitments and contingencies
Shareholders' equity (deficit):
Accumulated other comprehensive loss	1,467	1,552	1,977	2,333	2,483
Accumulated deficit	(8,007)	(6,975)	(5,052)	(6,272)	(5,445)
Total shareholders' equity (deficit)	(6,540)	(5,423)	(3,075)	(3,939)	(2,962)	$ (1,005)	$ (554)
Total liabilities and shareholders' equity (deficit)	$ 541	$ 909	$ 606	$ 303	$ 275

Restatement of Previously Iss_4

Restatement of Previously Issued Unaudited Condensed Consolidated Financial Statements - CONSOLIDATED BALANCE SHEETS (Parenthetical) (Detail) - $ / shares	3 Months Ended	6 Months Ended	9 Months Ended	12 Months Ended
	Jun. 30, 2020	Sep. 30, 2020	Dec. 31, 2020	Mar. 31, 2021	Mar. 31, 2020
Prior Period Adjustment [Abstract]
Preference share dividend percentage	7.00%	7.00%	7.00%	7.00%	7.00%
Common stock, par value
Common stock, shares issued	80,593,440	100,965,451	101,075,845	101,264,412	80,398,326
Common stock, shares outstanding	80,593,440	100,965,451	101,075,845	101,264,412	80,398,326

Restatement of Previously Iss_5

Restatement of Previously Issued Unaudited Condensed Consolidated Financial Statements - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended			6 Months Ended	9 Months Ended	12 Months Ended
	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Sep. 30, 2020	Dec. 31, 2020	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Revenue:
Total revenue	$ 8,751	$ 16,066	$ 8,924	$ 24,990	$ 33,741	$ 43,379	$ 32,656	$ 29,134
Cost of revenue	(4,970)	(4,499)	(5,414)	(9,913)	(14,883)	(20,074)	(17,800)	(17,230)
Gross profit	3,781	11,567	3,510	15,077	18,858	23,305	14,856	11,904
Operating expenses:
Sales and marketing	(2,283)	(2,231)	(2,243)	(4,474)	(6,757)	(9,849)	(9,853)	(8,637)
Research and development, net of government grants	(14,350)	(12,743)	(11,415)	(24,158)	(38,508)	(53,727)	(53,438)	(50,883)
General and administrative expense:
Compensation expense in respect of share options and management equity incentives	(1,214)	(1,324)	(960)	(2,284)	(3,498)	(4,984)	(4,467)	(4,957)
Other general and administrative expenses	(7,524)	(8,232)	(8,578)	(16,810)	(24,334)	(37,442)	(27,483)	(26,588)
Total general and administrative expense	(8,738)	(9,556)	(9,538)	(19,094)	(27,832)	(42,426)	(31,950)	(31,545)
Total operating expense	(25,371)	(24,530)	(23,196)	(47,726)	(73,097)	(106,002)	(95,241)	(91,065)
Operating loss	(21,590)	(12,963)	(19,686)	(32,649)	(54,239)	(82,697)	(80,385)	(79,161)
Other income (expense):
Interest expense, net	(9,404)	(6,297)	(6,931)	(13,228)	(22,632)	(29,804)	(26,900)	(20,277)
Other, net	617	5,354	208	5,562	6,179	2,723	2,205	(6,943)
Other income (expense), net	(8,787)	(943)	(6,723)	(7,666)	(16,453)	(27,081)	(24,695)	(27,220)
Loss before income taxes	(30,377)	(13,906)	(26,409)	(40,315)	(70,692)	(109,778)	(105,080)	(106,381)
Provision for income taxes	(1,303)	151	153	304	(999)	(1,254)	(58)	(30)
Net loss	(31,680)	(13,755)	(26,256)	(40,011)	(71,691)	(111,032)	(105,138)	(106,411)
Other comprehensive income (loss):
Change in fair value of effective portion of foreign currency cash flow hedges	295	279	(3)	276	571	582	(157)	(123)
Unrealized gain (loss) on short-term investments	111	(79)	(404)	(483)	(372)	(898)	554	796
Foreign currency gain (loss)	1,606	(3,803)	171	(3,632)	(2,026)	(2,057)	(2,469)	2,538
Provision for pension benefit obligation	13	14	(162)	(148)	(135)	447	2,209	(887)
Other comprehensive loss, net	2,025	(3,589)	(398)	(3,987)	(1,962)	(1,926)	137	2,324
Comprehensive loss	(29,655)	(17,344)	(26,654)	(43,998)	(73,652)	(112,958)	(105,001)	(104,087)
Net loss available to ordinary shareholders - basic and diluted	$ (31,680)	$ (13,755)	$ (26,256)	$ (40,011)	$ (71,691)	$ (111,032)	$ (105,138)	$ (106,411)
Loss per share - basic and diluted	$ (0.31)	$ (0.16)	$ (0.33)	$ (0.49)	$ (0.81)	$ (1.21)	$ (1.47)	$ (1.94)
Weighted-average shares outstanding - basic and diluted	101,016,040	83,949,195	80,485,985	82,227,052	88,512,823	91,637,966	71,610,035	54,874,391
As previously Reported [Member]
Revenue:
Total revenue	$ 8,751	$ 16,066	$ 8,924	$ 24,990	$ 33,741	$ 43,379	$ 32,656	$ 29,134
Cost of revenue	(4,970)	(4,499)	(5,414)	(9,913)	(14,883)	(20,074)	(17,800)	(17,230)
Gross profit	3,781	11,567	3,510	15,077	18,858	23,305	14,856	11,904
Operating expenses:
Sales and marketing	(2,283)	(2,231)	(2,243)	(4,474)	(6,757)	(9,849)	(9,853)	(8,637)
Research and development, net of government grants	(14,485)	(12,878)	(11,450)	(24,328)	(38,813)	(54,168)	(53,744)	(50,677)
General and administrative expense:
Compensation expense in respect of share options and management equity incentives	(1,214)	(1,324)	(960)	(2,284)	(3,498)	(4,984)	(4,467)	(4,957)
Other general and administrative expenses	(7,524)	(8,232)	(8,578)	(16,810)	(24,334)	(36,812)	(27,483)	(26,588)
Total general and administrative expense	(8,738)	(9,556)	(9,538)	(19,094)	(27,832)	(41,796)	(31,950)	(31,545)
Total operating expense	(25,506)	(24,665)	(23,231)	(47,896)	(73,402)	(105,813)	(95,547)	(90,859)
Operating loss	(21,725)	(13,098)	(19,721)	(32,819)	(54,544)	(82,508)	(80,691)	(78,955)
Other income (expense):
Interest expense, net	(6,753)	(6,858)	(5,926)	(12,784)	(19,537)	(25,918)	(23,859)	(20,018)
Other, net	192	4,998	233	5,231	5,423	1,882	2,438	(6,369)
Other income (expense), net	(6,561)	(1,860)	(5,693)	(7,553)	(14,114)	(24,036)	(21,421)	(26,387)
Loss before income taxes	(28,286)	(14,958)	(25,414)	(40,372)	(68,658)	(106,544)	(102,112)	(105,342)
Provision for income taxes	(1,471)	(17)	(15)	(32)	(1,503)	(1,926)	(661)	(44)
Net loss	(29,757)	(14,975)	(25,429)	(40,404)	(70,161)	(108,470)	(102,773)	(105,386)
Other comprehensive income (loss):
Change in fair value of effective portion of foreign currency cash flow hedges	295	279	(3)	276	571	582	(157)	(123)
Unrealized gain (loss) on short-term investments	111	(79)	(404)	(483)	(372)	(898)	554	796
Foreign currency gain (loss)	2,031	(3,447)	146	(3,301)	(1,270)	(1,216)	(2,702)	1,964
Provision for pension benefit obligation	13	14	13	27	40	622	2,034	(887)
Other comprehensive loss, net	2,450	(3,233)	(248)	(3,481)	(1,031)	(910)	(271)	1,750
Comprehensive loss	(27,307)	(18,208)	(25,677)	(43,885)	(71,192)	(109,380)	(103,044)	(103,636)
Net loss available to ordinary shareholders - basic and diluted	$ (29,757)	$ (14,975)	$ (25,429)	$ (40,404)	$ (70,161)	$ (108,470)	$ (102,773)	$ (105,386)
Loss per share - basic and diluted	$ (0.29)	$ (0.18)	$ (0.32)	$ (0.49)	$ (0.79)	$ (1.18)	$ (1.44)	$ (1.92)
Weighted-average shares outstanding - basic and diluted	101,016,040	83,949,195	80,485,985	82,227,052	88,512,823	91,637,966	71,610,035	54,874,391
Restatement Impacts [Member]
Operating expenses:
Research and development, net of government grants	$ 135	$ 135	$ 35	$ 170	$ 305	$ 441	$ 306	$ (206)
General and administrative expense:
Other general and administrative expenses						(630)
Total general and administrative expense						(630)
Total operating expense	135	135	35	170	305	(189)	306	(206)
Operating loss	135	135	35	170	305	(189)	306	(206)
Other income (expense):
Interest expense, net	(2,651)	561	(1,005)	(444)	(3,095)	(3,886)	(3,041)	(259)
Other, net	425	356	(25)	331	756	841	(233)	(574)
Other income (expense), net	(2,226)	917	(1,030)	(113)	(2,339)	(3,045)	(3,274)	(833)
Loss before income taxes	(2,091)	1,052	(995)	57	(2,034)	(3,234)	(2,968)	(1,039)
Provision for income taxes	168	168	168	336	504	672	603	14
Net loss	(1,923)	1,220	(827)	393	(1,530)	(2,562)	(2,365)	(1,025)
Other comprehensive income (loss):
Foreign currency gain (loss)	(425)	(356)	25	(331)	(756)	(841)	233	574
Provision for pension benefit obligation			(175)	(175)	(175)	(175)	175
Other comprehensive loss, net	(425)	(356)	(150)	(506)	(931)	(1,016)	408	574
Comprehensive loss	(2,348)	864	(977)	(113)	(2,461)	(3,578)	(1,957)	(451)
Net loss available to ordinary shareholders - basic and diluted	$ (1,923)	$ 1,220	$ (827)	$ 393	$ (1,530)	$ (2,562)	$ (2,365)	$ (1,025)
Loss per share - basic and diluted	$ (0.02)	$ 0.01	$ (0.01)	$ 0	$ (0.02)	$ (0.03)	$ (0.03)	$ (0.02)
Product Sales [Member]
Revenue:
Total revenue	$ 8,740	$ 8,543	$ 8,924	$ 17,467	$ 26,207	$ 35,787	$ 31,601	$ 28,665
Product Sales [Member] | As previously Reported [Member]
Revenue:
Total revenue	8,740	8,543	$ 8,924	17,467	26,207	35,787	31,601	28,665
Other Revenues [Member]
Revenue:
Total revenue	11	7,523		7,523	7,534	7,592	1,055	469
Other Revenues [Member] | As previously Reported [Member]
Revenue:
Total revenue	$ 11	$ 7,523		$ 7,523	$ 7,534	$ 7,592	$ 1,055	$ 469

Restatement of Previously Iss_6

Restatement of Previously Issued Unaudited Condensed Consolidated Financial Statements - CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (DEFICIT) (Detail) - USD ($) $ in Thousands	Sep. 15, 2020	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Sep. 30, 2020	Dec. 31, 2020	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Error Corrections And Prior Period Adjustments Restatement [Line Items]
Beginning balance		$ 30,635	$ (34,124)	$ (8,489)	$ (8,489)	$ (8,489)	$ (8,489)	$ 709	$ (15,185)
Beginning balance, Shares		100,965,451	80,593,440	80,398,326	80,398,326	80,398,326	80,398,326
Issue of shares upon exercise of incentive share options and vesting of RSU's, Amount		$ 50	$ 94	$ 59	$ 153	$ 203	$ 197	445	1,300
Net loss		(31,680)	(13,755)	(26,256)	(40,011)	(71,691)	(111,032)	(105,138)	(106,411)
Change in the fair value of the effective portion of foreign currency cash flow hedges		295	279	(3)	276	571	582	(157)	(123)
Change in unrealized gain on short-term investments		111	(79)	(404)	(483)	(372)	(898)	554	796
Foreign currency gain (loss) on:
Long-term investment nature intra-entity balances		(4,692)	(3,841)	4,685	844	(3,848)	(27,251)	18,394	5,074
Retranslation of foreign entities		6,298	38	(4,514)	(4,476)	1,822	25,194	(20,863)	(2,536)
Provision for pension benefit obligation		13	14	(162)	(148)	(135)	447	2,209	(887)
Other comprehensive loss		2,025	(3,589)	(398)	(3,987)	(1,962)	(1,926)	137	2,324
Stock-based compensation		1,214	1,324	960	2,284	3,498	4,984	4,467	4,957
Ending balance		$ 2,244	$ 30,635	$ (34,124)	$ 30,635	$ 2,244	$ (35,581)	$ (8,489)	709
Ending balance, Shares		101,075,845	100,965,451	80,593,440	100,965,451	101,075,845	101,264,412	80,398,326
Issue of shares, net of issue costs, Amount			$ 80,685		$ 80,685	$ 80,685	$ 80,685	$ 90,528	113,724
As previously Reported [Member]
Error Corrections And Prior Period Adjustments Restatement [Line Items]
Beginning balance		$ 33,710	(30,185)	$ (5,527)	(5,527)	(5,527)	(5,527)	1,714	(14,631)
Issue of shares upon exercise of incentive share options and vesting of RSU's, Amount		50	94	59	153	203	197	445	1,300
Net loss		(29,757)	(14,975)	(25,429)	(40,404)	(70,161)	(108,470)	(102,773)	(105,386)
Change in the fair value of the effective portion of foreign currency cash flow hedges		295	279	(3)	276	571	582	(157)	(123)
Change in unrealized gain on short-term investments		111	(79)	(404)	(483)	(372)	(898)	554	796
Foreign currency gain (loss) on:
Long-term investment nature intra-entity balances		(4,692)	(3,841)	4,685	844	(3,848)	(27,251)	18,394	5,074
Retranslation of foreign entities		6,723	394	(4,539)	(4,145)	2,578	26,035	(21,096)	(3,110)
Provision for pension benefit obligation		13	14	13	27	40	622	2,034	(887)
Other comprehensive loss		2,450	(3,233)	(248)	(3,481)	(1,031)	(910)	(271)	1,750
Stock-based compensation		1,214	1,324	960	2,284	3,498	4,984	4,467	4,957
Ending balance		7,667	33,710	(30,185)	33,710	7,667	(29,041)	(5,527)	1,714
Issue of shares, net of issue costs, Amount			80,685		80,685	80,685	80,685	90,528	113,724
Restatement Impacts [Member]
Error Corrections And Prior Period Adjustments Restatement [Line Items]
Beginning balance		(3,075)	(3,939)	(2,962)	(2,962)	(2,962)	(2,962)	(1,005)	(554)
Net loss		(1,923)	1,220	(827)	393	(1,530)	(2,562)	(2,365)	(1,025)
Foreign currency gain (loss) on:
Retranslation of foreign entities		(425)	(356)	25	(331)	(756)	(841)	233	574
Provision for pension benefit obligation				(175)	(175)	(175)	(175)	175
Other comprehensive loss		(425)	(356)	(150)	(506)	(931)	(1,016)	408	574
Ending balance		(5,423)	(3,075)	(3,939)	(3,075)	(5,423)	(6,540)	(2,962)	(1,005)
Cumulative Effect of Accounting Changes [Member]
Error Corrections And Prior Period Adjustments Restatement [Line Items]
Beginning balance				363	363	363	363
Foreign currency gain (loss) on:
Ending balance								363
Cumulative Effect of Accounting Changes [Member] | As previously Reported [Member]
Error Corrections And Prior Period Adjustments Restatement [Line Items]
Beginning balance				363	363	363	363
Foreign currency gain (loss) on:
Ending balance								363
Ordinary Shares [Member]
Error Corrections And Prior Period Adjustments Restatement [Line Items]
Beginning balance		$ 540,769	$ 459,990	$ 459,931	$ 459,931	$ 459,931	$ 459,931	$ 368,958	$ 253,934
Beginning balance, Shares		100,965,451	80,593,440	80,398,326	80,398,326	80,398,326	80,398,326	65,900,447	45,646,424
Issue of shares upon exercise of incentive share options and vesting of RSU's, Amount		$ 50	$ 94	$ 59	$ 153	$ 203	$ 197	$ 445	$ 1,300
Issue of shares upon exercise of incentive share options and vesting of RSU's, Shares		110,394	77,894	195,114	273,008	383,402	571,969	697,879	618,955
Foreign currency gain (loss) on:
Ending balance		$ 540,819	$ 540,769	$ 459,990	$ 540,769	$ 540,819	$ 540,813	$ 459,931	$ 368,958
Ending balance, Shares		101,075,845	100,965,451	80,593,440	100,965,451	101,075,845	101,264,412	80,398,326	65,900,447
Issue of shares, net of issue costs, Amount			$ 80,685		$ 80,685	$ 80,685	$ 80,685	$ 90,528	$ 113,724
Issue of shares, net of issue costs, Shares	20,294,117		20,294,117		20,294,117	20,294,117	20,294,117	13,800,000	19,635,068
Ordinary Shares [Member] | As previously Reported [Member]
Error Corrections And Prior Period Adjustments Restatement [Line Items]
Beginning balance		$ 540,769	$ 459,990	$ 459,931	$ 459,931	$ 459,931	$ 459,931	$ 368,958	$ 253,934
Beginning balance, Shares		100,965,451	80,593,440	80,398,326	80,398,326	80,398,326	80,398,326	65,900,447	45,646,424
Issue of shares upon exercise of incentive share options and vesting of RSU's, Amount		$ 50	$ 94	$ 59	$ 153	$ 203	$ 197	$ 445	$ 1,300
Issue of shares upon exercise of incentive share options and vesting of RSU's, Shares		110,394	77,894	195,114	273,008	383,402	571,969	697,879	618,955
Foreign currency gain (loss) on:
Ending balance		$ 540,819	$ 540,769	$ 459,990	$ 540,769	$ 540,819	$ 540,813	$ 459,931	$ 368,958
Ending balance, Shares		101,075,845	100,965,451	80,593,440	100,965,451	101,075,845	101,264,412	80,398,326	65,900,447
Issue of shares, net of issue costs, Amount			$ 80,685		$ 80,685	$ 80,685	$ 80,685	$ 90,528	$ 113,724
Issue of shares, net of issue costs, Shares			20,294,117		20,294,117	20,294,117	20,294,117	13,800,000	19,635,068
Additional paid in Capital [Member]
Error Corrections And Prior Period Adjustments Restatement [Line Items]
Beginning balance		$ 35,416	$ 34,092	$ 33,132	$ 33,132	$ 33,132	$ 33,132	$ 28,665	$ 23,708
Foreign currency gain (loss) on:
Stock-based compensation		1,214	1,324	960	2,284	3,498	4,984	4,467	4,957
Ending balance		36,630	35,416	34,092	35,416	36,630	38,116	33,132	28,665
Additional paid in Capital [Member] | As previously Reported [Member]
Error Corrections And Prior Period Adjustments Restatement [Line Items]
Beginning balance		35,416	34,092	33,132	33,132	33,132	33,132	28,665	23,708
Foreign currency gain (loss) on:
Stock-based compensation		1,214	1,324	960	2,284	3,498	4,984	4,467	4,957
Ending balance		36,630	35,416	34,092	35,416	36,630	38,116	33,132	28,665
Accumulated Other Comprehensive Loss [Member]
Error Corrections And Prior Period Adjustments Restatement [Line Items]
Beginning balance		(16,659)	(13,070)	(12,672)	(12,672)	(12,672)	(12,672)	(12,809)	(15,133)
Change in the fair value of the effective portion of foreign currency cash flow hedges		295	279	(3)	276	571	582	(157)	(123)
Change in unrealized gain on short-term investments		111	(79)	(404)	(483)	(372)	(898)	554	796
Foreign currency gain (loss) on:
Long-term investment nature intra-entity balances		(4,692)	(3,841)	4,685	844	(3,848)	(27,251)	18,394	5,074
Retranslation of foreign entities		6,298	38	(4,514)	(4,476)	1,822	25,194	(20,863)	(2,536)
Provision for pension benefit obligation		13	14	(162)	(148)	(135)	447	2,209	(887)
Other comprehensive loss		2,025	(3,589)	(398)	(3,987)	(1,962)	(1,926)	137	2,324
Ending balance		(14,634)	(16,659)	(13,070)	(16,659)	(14,634)	(14,598)	(12,672)	(12,809)
Accumulated Other Comprehensive Loss [Member] | As previously Reported [Member]
Error Corrections And Prior Period Adjustments Restatement [Line Items]
Beginning balance		(18,636)	(15,403)	(15,155)	(15,155)	(15,155)	(15,155)	(14,884)	(16,634)
Change in the fair value of the effective portion of foreign currency cash flow hedges		295	279	(3)	276	571	582	(157)	(123)
Change in unrealized gain on short-term investments		111	(79)	(404)	(483)	(372)	(898)	554	796
Foreign currency gain (loss) on:
Long-term investment nature intra-entity balances		(4,692)	(3,841)	4,685	844	(3,848)	(27,251)	18,394	5,074
Retranslation of foreign entities		6,723	394	(4,539)	(4,145)	2,578	26,035	(21,096)	(3,110)
Provision for pension benefit obligation		13	14	13	27	40	622	2,034	(887)
Other comprehensive loss		2,450	(3,233)	(248)	(3,481)	(1,031)	(910)	(271)	1,750
Ending balance		(16,186)	(18,636)	(15,403)	(18,636)	(16,186)	(16,065)	(15,155)	(14,884)
Accumulated Other Comprehensive Loss [Member] | Restatement Impacts [Member]
Error Corrections And Prior Period Adjustments Restatement [Line Items]
Beginning balance		1,977	2,333	2,483	2,483	2,483	2,483	2,075	1,501
Foreign currency gain (loss) on:
Retranslation of foreign entities		(425)	(356)	25	(331)	(756)	(841)	233	574
Provision for pension benefit obligation				(175)	(175)	(175)	(175)	175
Other comprehensive loss		(425)	(356)	(150)	(506)	(931)	(1,016)	408	574
Ending balance		1,552	1,977	2,333	1,977	1,552	(1,016)	2,483	2,075
Accumulated Deficit [Member]
Error Corrections And Prior Period Adjustments Restatement [Line Items]
Beginning balance		(528,891)	(515,136)	(488,880)	(488,880)	(488,880)	(488,880)	(384,105)	(277,694)
Net loss		(31,680)	(13,755)	(26,256)	(40,011)	(71,691)	(111,032)	(105,138)	(106,411)
Foreign currency gain (loss) on:
Ending balance		(560,571)	(528,891)	(515,136)	(528,891)	(560,571)	(599,912)	(488,880)	(384,105)
Accumulated Deficit [Member] | As previously Reported [Member]
Error Corrections And Prior Period Adjustments Restatement [Line Items]
Beginning balance		(523,839)	(508,864)	(483,435)	(483,435)	(483,435)	(483,435)	(381,025)	(275,639)
Net loss		(29,757)	(14,975)	(25,429)	(40,404)	(70,161)	(108,470)	(102,773)	(105,386)
Foreign currency gain (loss) on:
Ending balance		(553,596)	(523,839)	(508,864)	(523,839)	(553,596)	(591,905)	(483,435)	(381,025)
Accumulated Deficit [Member] | Restatement Impacts [Member]
Error Corrections And Prior Period Adjustments Restatement [Line Items]
Beginning balance		(5,052)	(6,272)	(5,445)	(5,445)	(5,445)	(5,445)	(3,080)	(2,055)
Net loss		(1,923)	1,220	(827)	393	(1,530)	(2,562)	(2,365)	(1,025)
Foreign currency gain (loss) on:
Ending balance		$ (6,975)	$ (5,052)	(6,272)	(5,052)	(6,975)	(8,007)	(5,445)	$ (3,080)
Accumulated Deficit [Member] | Cumulative Effect of Accounting Changes [Member]
Error Corrections And Prior Period Adjustments Restatement [Line Items]
Beginning balance				363	363	363	363
Foreign currency gain (loss) on:
Ending balance								363
Accumulated Deficit [Member] | Cumulative Effect of Accounting Changes [Member] | As previously Reported [Member]
Error Corrections And Prior Period Adjustments Restatement [Line Items]
Beginning balance				$ 363	$ 363	$ 363	$ 363
Foreign currency gain (loss) on:
Ending balance								$ 363

Restatement of Previously Iss_7

Restatement of Previously Issued Unaudited Condensed Consolidated Financial Statements - CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (DEFICIT) (Parenthetical) (Detail) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended	9 Months Ended	12 Months Ended
	Sep. 30, 2020	Sep. 30, 2020	Dec. 31, 2020	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Error Corrections And Prior Period Adjustments Restatement [Line Items]
Issue of shares, issue costs	$ 5,565	$ 5,565	$ 5,565	$ 5,565	$ 6,072	$ 4,052
As previously Reported [Member]
Error Corrections And Prior Period Adjustments Restatement [Line Items]
Issue of shares, issue costs	5,565	5,565	5,565	5,565	6,072	4,052
Restatement Impacts [Member]
Error Corrections And Prior Period Adjustments Restatement [Line Items]
Issue of shares, issue costs	$ 5,565	$ 5,565	$ 5,565	$ 5,565	$ 6,072	$ 4,052

Restatement of Previously Iss_8

Restatement of Previously Issued Unaudited Condensed Consolidated Financial Statements - CONSOLIDATED STATEMENTS OF CASH FLOWS (Detail) - USD ($) $ in Thousands	3 Months Ended			6 Months Ended	9 Months Ended	12 Months Ended
	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Sep. 30, 2020	Dec. 31, 2020	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
OPERATING ACTIVITIES:
Net loss			$ (26,256)	$ (40,011)	$ (71,691)	$ (111,032)	$ (105,138)	$ (106,411)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation, amortization and loss on disposal of fixed assets			2,093	4,131	6,354	8,354	12,001	12,767
Share-based compensation	$ 1,214	$ 1,324	960	2,284	3,498	4,984	4,467	4,957
Increase in deferred lease rentals			169	346	512	726	293	372
Swiss pension obligation			253	516	776	1,054	756	575
Amortization of deferred debt issue costs			3,083	4,830	9,728	12,965	10,084	6,167
Impairment of short term investments						2,285
Accrued preference share dividends			263	525	788	1,050	1,050	1,050
Income taxes			(153)	(304)	999	1,254	(169)	(61)
Net change in assets and liabilities:
Trade accounts receivable, net			(587)	1,093	1,268	568	(2,177)	(637)
Inventories			(638)	(1,411)	(1,218)	(475)	(5,173)	113
Accounts payable and accrued liabilities			(1,664)	1,390	(4,601)	(3,410)	2,798	1,035
Accrued compensation and benefits			(2,025)	(2,215)	(2,825)	4,549	1,218	1,121
Other assets			(306)	(1,807)	(330)	(454)	(656)	3,297
Net cash used in operating activities			(24,808)	(30,633)	(56,742)	(77,582)	(80,646)	(75,655)
INVESTING ACTIVITIES:
Increase in short-term investments				(72,247)	(72,247)	(87,247)	(95,000)	(119,000)
Realization of short-term investments			29,314	44,016	57,683	134,936	69,412	34,735
Purchase of property and equipment			(830)	(2,069)	(3,602)	(4,240)	(4,598)	(4,791)
Purchase of intangible assets							(2)	(3)
Net cash from (used in) investing activities			28,484	(30,300)	(18,166)	43,449	(30,188)	(89,059)
FINANCING ACTIVITIES:
Repayment of finance leases			(171)	(356)	(491)	(633)	(524)	(486)
Proceeds from drawdown of new debt							25,000	36,000
Debt issue costs							(874)	(1,216)
Fee paid to noteholders								(3,900)
Proceeds from issuance of ordinary shares and warrants			59	80,838	80,888	80,881	90,973	115,024
Net cash generated from financing activities			(112)	80,482	80,397	80,248	114,575	145,422
Effect of exchange rate fluctuations on cash and cash equivalents			(158)	(5,333)	(5,982)	(4,358)	(2,404)	5,690
Change in cash and cash equivalents			3,406	14,216	(493)	41,757	1,337	(13,602)
Beginning cash and cash equivalents	27,156	16,346	12,940	12,940	12,940	12,940	11,603	25,205
Ending cash and cash equivalents	12,447	27,156	16,346	27,156	12,447	54,697	12,940	11,603
Supplemental cash flow disclosures:
Interest paid			8,731	8,765	17,499	17,529	15,776	11,838
Reconciliation of cash, cash equivalents and restricted cash:
Cash and cash equivalents	3,401	18,125	7,325	18,125	3,401	45,673	3,923	4,096
Restricted cash	9,046	9,031	9,021	9,031	9,046	9,024	9,017	7,507
Total cash, cash equivalents and restricted cash	12,447	27,156	16,346	27,156	12,447	54,697	12,940	11,603
As previously Reported [Member]
OPERATING ACTIVITIES:
Net loss			(25,429)	(40,404)	(70,161)	(108,470)	(102,773)	(105,386)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation, amortization and loss on disposal of fixed assets			1,953	4,126	6,484	8,620	12,276	12,767
Share-based compensation	1,214	1,324	960	2,284	3,498	4,984	4,467	4,957
Increase in deferred lease rentals			169	346	512	726	293	372
Swiss pension obligation			253	516	776	1,054	756	575
Amortization of deferred debt issue costs			2,078	4,386	6,633	9,079	7,043	5,908
Impairment of short term investments						2,285
Accrued preference share dividends			263	525	788	1,050	1,050	1,050
Income taxes			15	32	1,503	1,926	368	44
Net change in assets and liabilities:
Trade accounts receivable, net			(587)	1,093	1,268	568	(2,177)	(637)
Inventories			(638)	(1,411)	(1,218)	(475)	(4,967)	(93)
Accounts payable and accrued liabilities			(1,514)	1,896	(3,670)	(2,514)	2,456	370
Accrued compensation and benefits			(2,025)	(2,215)	(2,825)	4,039	1,218	1,121
Other assets			(306)	(1,807)	(330)	(454)	(656)	3,297
Net cash used in operating activities			(24,808)	(30,633)	(56,742)	(77,582)	(80,646)	(75,655)
INVESTING ACTIVITIES:
Increase in short-term investments				(72,247)	(72,247)	(87,247)	(95,000)	(119,000)
Realization of short-term investments			29,314	44,016	57,683	134,936	69,412	34,735
Purchase of property and equipment			(830)	(2,069)	(3,602)	(4,240)	(4,598)	(4,791)
Purchase of intangible assets							(2)	(3)
Net cash from (used in) investing activities			28,484	(30,300)	(18,166)	43,449	(30,188)	(89,059)
FINANCING ACTIVITIES:
Repayment of finance leases			(171)	(356)	(491)	(633)	(524)	(486)
Proceeds from drawdown of new debt							25,000	36,000
Debt issue costs							(874)	(1,216)
Fee paid to noteholders								(3,900)
Proceeds from issuance of ordinary shares and warrants			59	80,838	80,888	80,881	90,973	115,024
Net cash generated from financing activities			(112)	80,482	80,397	80,248	114,575	145,422
Effect of exchange rate fluctuations on cash and cash equivalents			(158)	(5,333)	(5,982)	(4,358)	(2,404)	5,690
Change in cash and cash equivalents			3,406	14,216	(493)	41,757	1,337	(13,602)
Beginning cash and cash equivalents	27,156	16,346	12,940	12,940	12,940	12,940	11,603	25,205
Ending cash and cash equivalents	12,447	27,156	16,346	27,156	12,447	54,697	12,940	11,603
Supplemental cash flow disclosures:
Interest paid			8,731	8,765	17,499	17,529	15,776	11,838
Reconciliation of cash, cash equivalents and restricted cash:
Cash and cash equivalents	3,401	18,125	7,325	18,125	3,401	45,673	3,923	4,096
Restricted cash	9,046	9,031	9,021	9,031	9,046	9,024	9,017	7,507
Total cash, cash equivalents and restricted cash	$ 12,447	$ 27,156	16,346	27,156	12,447	54,697	12,940	11,603
Restatement Impacts [Member]
OPERATING ACTIVITIES:
Net loss			(827)	393	(1,530)	(2,562)	(2,365)	(1,025)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation, amortization and loss on disposal of fixed assets			140	5	(130)	(266)	(275)
Amortization of deferred debt issue costs			1,005	444	3,095	3,886	3,041	259
Income taxes			(168)	(336)	(504)	(672)	(537)	(105)
Net change in assets and liabilities:
Inventories							(206)	206
Accounts payable and accrued liabilities			$ (150)	$ (506)	$ (931)	(896)	$ 342	$ 665
Accrued compensation and benefits						$ 510